U.S. patent application number 17/347791 was filed with the patent office on 2021-12-16 for gene delivery carrier.
This patent application is currently assigned to Massachusetts Institute of Technology. The applicant listed for this patent is Massachusetts Institute of Technology, Politecnico di Milano. Invention is credited to Daniel Griffith Anderson, Umberto Capasso Palmiero, James C. Kaczmarek, Davide Moscatelli.
Application Number | 20210388196 17/347791 |
Document ID | / |
Family ID | 1000005795193 |
Filed Date | 2021-12-16 |
United States Patent
Application |
20210388196 |
Kind Code |
A1 |
Capasso Palmiero; Umberto ;
et al. |
December 16, 2021 |
GENE DELIVERY CARRIER
Abstract
Disclosed are methods, compositions, reagents, systems, and kits
to prepare and utilize poly (.beta.-amino ester) (PBAE) polymers,
which are synthesized via Michael addition reactions of diacrylates
and amines disclosed herein. Various embodiments utilize lactones
and lactone derivatives to generate the diacrylate compounds. The
PBAE polymers are shown to be effective biodegradable carriers for
the delivery of an agent such as an organic molecule, inorganic
molecule, nucleic acid, protein, peptide, polynucleotide, targeting
agent, an isotopically labeled chemical compound, vaccine, or an
immunological agent.
Inventors: |
Capasso Palmiero; Umberto;
(Zurich, CH) ; Kaczmarek; James C.; (Wakefield,
MA) ; Anderson; Daniel Griffith; (Framingham, MA)
; Moscatelli; Davide; (Arese, IT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Massachusetts Institute of Technology
Politecnico di Milano |
Cambridge
Milan |
MA |
US
IT |
|
|
Assignee: |
Massachusetts Institute of
Technology
Cambridge
MA
Politecnico di Milano
Milan
|
Family ID: |
1000005795193 |
Appl. No.: |
17/347791 |
Filed: |
June 15, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16179698 |
Nov 2, 2018 |
11041069 |
|
|
17347791 |
|
|
|
|
62661864 |
Apr 24, 2018 |
|
|
|
62581277 |
Nov 3, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C08L 2203/02 20130101;
C08L 33/14 20130101; C08L 2201/06 20130101; C08G 63/6852 20130101;
A61K 48/0041 20130101; C12N 2310/14 20130101; C12N 15/87 20130101;
C08F 20/34 20130101; C08G 73/02 20130101 |
International
Class: |
C08L 33/14 20060101
C08L033/14; C08G 73/02 20060101 C08G073/02; C08G 63/685 20060101
C08G063/685; A61K 48/00 20060101 A61K048/00; C08F 20/34 20060101
C08F020/34; C12N 15/87 20060101 C12N015/87 |
Claims
1. A polymer of Formula (I): ##STR00246## or a pharmaceutically
acceptable salt thereof, wherein: is a single bond or a double bond
A is hydrogen or --XR.sub.3; each B independently is a diradical of
the formula: ##STR00247## each D independently is: ##STR00248## E
is hydrogen or --XR.sub.4; each R, R', and R'' independently is
optionally substituted, cyclic or acyclic aliphatic; optionally
substituted, cyclic or acyclic heteroaliphatic; or a combination
thereof; each R.sub.a independently is hydrogen or optionally
substituted aliphatic; R.sub.1 and R.sub.2 independently are
selected from hydrogen, optionally substituted, cyclic or acyclic
aliphatic; optionally substituted, cyclic or acyclic
heteroaliphatic; optionally substituted aryl; optionally
substituted heteroaryl; and a nitrogen protecting group; or R.sub.1
and R.sub.2 are combined to form a ring; R.sub.3 and R.sub.4
independently are selected from hydrogen; optionally substituted,
cyclic or acyclic aliphatic; optionally substituted, cyclic or
acyclic heteroaliphatic; optionally substituted aryl; optionally
substituted heteroaryl; and a protecting group; X is O, S, NH, or
NR.sub.X, wherein R.sub.X is optionally substituted, aliphatic;
optionally substituted carbocyclyl; optionally substituted
heteroaliphatic; optionally substituted heterocyclyl; optionally
substituted aryl; or optionally substituted heteroaryl; X' is O or
NR.sub.y, wherein R.sub.y is hydrogen; optionally substituted,
aliphatic; optionally substituted carbocyclyl; optionally
substituted heteroaliphatic; optionally substituted heterocyclyl;
optionally substituted aryl; or optionally substituted heteroaryl;
each m independently is an integer between 1 and 100, inclusive;
and n is an integer between 1 and 10,000, inclusive.
2.-4. (canceled)
5. The polymer of claim 1, having the structure of Formula (III) or
Formula (V): ##STR00249##
6.-35. (canceled)
36. The polymer of claim 1, wherein B is of the formula:
##STR00250##
37. (canceled)
38. The polymer of claim 1, wherein m is an integer between 3 and
7, inclusive
39.-85. (canceled)
86. The polymer of claim 1, wherein the polymer is of the formula:
##STR00251## wherein: each D is ##STR00252##
87.-93. (canceled)
94. The polymer of claim 1, wherein the polymer has a molecular
weight between 1-100 kDa.
95.-113. (canceled)
114. A method of preparing a polymer of Formula (III), as defined
in claim 5, or a pharmaceutically acceptable salt thereof:
##STR00253## comprising reacting a polymer of Formula (V), as
defined in claim 1, or a pharmaceutically acceptable salt thereof:
##STR00254## with one or more nucleophiles selected from R.sub.3XH
and R.sub.4XH; to obtain the polymer of Formula (III).
115.-117. (canceled)
118. A composition comprising a polymer of claim 1 and an
excipient.
119.-123. (canceled)
124. The composition of claim 118, wherein the composition further
comprises an agent.
125. (canceled)
126. The composition of claim 124, wherein the agent is a
polynucleotide.
127. The composition of claim 126, wherein the polynucleotide is
DNA.
128. The composition of claim 126, wherein the polynucleotide is
RNA.
129. The composition of claim 128, wherein the RNA is dsRNA, siRNA,
shRNA, miRNA, mRNA, or antisense RNA.
130. The composition of claim 126, wherein the polynucleotide
carries out RNA interference.
131. (canceled)
132. The composition of claim 118, wherein the composition is in
the form of a particle.
133.-134. (canceled)
135. The composition of claim 132, wherein the particle
encapsulates an agent.
136. A method of treating a disease, disorder, or condition from
which a subject suffers, comprising administering to a subject in
need thereof an effective amount of a composition of claim 118.
137. (canceled)
138. A method of delivering a polynucleotide to a cell, comprising
contacting the cell with a composition of claim 126.
139.-140. (canceled)
141. The composition of claim 128, wherein the RNA is mRNA.
142. The composition of claim 141, wherein the mRNA encodes an
antigen.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 16/179,698, filed Nov. 2, 2018, which claims priority under 35
U.S.C. .sctn. 119(e) to U.S. Provisional Application Ser. No.
62/581,277, filed on Nov. 3, 2017, and to U.S. Provisional
Application Ser. No. 62/661,864, filed on Apr. 24, 2018, each of
which is incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] Chemical materials have been widely used in biological
research and medicine for the development of delivery systems for a
variety of payloads including organic molecules, inorganic
molecules, nucleic acids, proteins, peptides, polynucleotides,
targeting agents, isotopically labeled chemical compounds,
vaccines, and immunological agents..sup.1 In particular, chemical
delivery systems, such as lipids, polymers, and hydrogels, have
helped advance the field of gene delivery, in which efficacious
delivery of naked polynucleotides to the site of interest is a
challenge due to their clearance by the immune system, their
inability to cross the cell membrane, and their potential
degradation in lysosomes..sup.2
[0003] Gene delivery is a process by which foreign nucleic acids
(DNA and RNA) are transferred to host cells for applications such
as genetic research or gene therapy. Gene delivery methods can be
biological (e.g., viral or bacterial vectors), mechanical (e.g.,
microinjection, electroporation, or biolistics), or chemical (e.g.,
lipid or nanoparticle carriers)..sup.1 The ideal gene delivery and
transfection systems should have high transfection efficiency, high
cell specificity, and low cell toxicity.
[0004] Biological gene delivery systems exhibit well-known adverse
effects, such as immunogenicity and application limitations, such
as difficulties in handling, difficulties in large-scale
production, and limited length of the nucleic acid to be
delivered..sup.3,4 Mechanical gene delivery methods also present
several drawbacks. For example, mechanical methods cause damage to
cells, and involve difficulty in large-scale manipulation,
labor-intensive protocols, and/or the necessity of costly
instruments..sup.5 To overcome the drawbacks of biological and
mechanical systems, a variety of chemical gene delivery vehicles,
such as calcium phosphates, lipids, and cationic polymers,
including polyamidoamine dendrimers, polyethylenimine (PEI), poly
(.beta.-amino esters) (PBAEs), have been developed since the late
1960s..sup.6-8
[0005] Cationic polymers are among the most common materials that
have been used for gene delivery given their ability to
electrostatically bind and condense nucleic acids to form
nanoparticles.
[0006] Although many types of cationic polymers have been
synthesized and tested as possible chemical delivery systems for
gene delivery, such as polyethyleneimine (PEI), poly(amido-amine)
(PAMAM), and poly (.beta.-amino ester) (PBAE) polymers, only
CALAA-01, a cyclodextrin containing polymer, has entered the clinic
for siRNA delivery..sup.13 High net-positive charge and inability
to undergo degradation under physiological conditions or the
production of potentially toxic degradation products, which can
accumulate in the body at hazardous levels, are the main reasons
limiting clinical applications of known cationic polymers. Of the
known cationic polymers, PBAEs are particularly useful due to their
high transfection efficiency and biodegradability. As such, there
remains a need for new, improved PBAEs for gene delivery.
SUMMARY OF THE INVENTION
[0007] Described herein are novel PBAEs derived from polylactone
diacrylates. Poly-caprolactone (PCL) and poly-lactic acid (PLA)
based polymers are useful in biomedical applications due to their
biodegradability and biocompatibility..sup.14 Several PCL and PLA
derivatives are already approved by the FDA for human use. However,
existing PCL- and PLA-based polymers are not positively charged,
and therefore are unsuitable for applications related to gene
delivery. The use of polylactone-based diacrylates in the
preparation of PBAEs is expected to produce PBAEs with high
transfection efficiency and improved biocompatibility.
Polylactone-based diacrylates can be synthesized via a novel
two-step procedure that consists of (i) a ring opening
polymerization of a lactone initiated by a mono-acrylate-containing
nucleophile, and (ii) acylation of the polylactone mono-acrylate
with an acryloyl electrophile. See FIG. 4.
[0008] The ring opening polymerization depicted in the first step
in FIG. 4 is a so-called "living polymerization", a technique that
allows control over the number of units of lactone monomers, which
in turn allows for control over the polylactone's physical
properties, such as molecular weight and lipophilicity.
[0009] Methods, compositions, reagents, systems, and kits for the
preparation and utilization of polylactone-based PBAEs are also
disclosed herein. In certain embodiments, a polylactone diacrylate
is reacted with one or more amines in a step-growth polymerization
to yield acrylate-terminated PBAEs. The terminal acrylate groups
can be reacted with nucleophiles (e.g., amines) to form
end-functionalized PBAEs. See FIG. 5.
[0010] In one aspect, provided herein is a polymer of Formula
(I):
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein:
[0011] is a single bond or a double bond
[0012] A is hydrogen or --XR.sub.3;
[0013] each B independently is a diradical of the formula:
##STR00002##
[0014] each D independently is:
##STR00003##
[0015] E is hydrogen or --XR.sub.4;
[0016] each R, R', and R'' independently is optionally substituted,
cyclic or acyclic aliphatic; optionally substituted, cyclic or
acyclic heteroaliphatic; or a combination thereof;
[0017] each R.sub.a independently is hydrogen or optionally
substituted aliphatic;
[0018] R.sub.1 and R.sub.2 independently are selected from
hydrogen; optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic;
optionally substituted aryl; optionally substituted heteroaryl; and
a nitrogen protecting group; or R.sub.1 and R.sub.2 are combined to
form a ring;
[0019] R.sub.3 and R.sub.4 independently are selected from
hydrogen; optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic;
optionally substituted aryl; optionally substituted heteroaryl; and
a protecting group;
[0020] X is O, S, NH, or NR.sub.X, wherein R.sub.X is optionally
substituted, cyclic or acyclic aliphatic; optionally substituted,
cyclic or acyclic heteroaliphatic; optionally substituted aryl; or
optionally substituted heteroaryl;
[0021] X' is O or NR.sub.y, wherein R.sub.y is hydrogen or
optionally substituted aliphatic;
[0022] each m independently is an integer between 1 and 100,
inclusive;
[0023] n is an integer between 1 and 10,000, inclusive.
[0024] In certain embodiments, provided herein are polymers of
Formulae (II), (III), (IV), and (V), and pharmaceutically
acceptable salts thereof:
##STR00004##
[0025] In another aspect, provided herein is a polylactone
diacrylate compound of Formula (VI):
##STR00005##
wherein:
[0026] R is optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic; or a
combination thereof;
[0027] each R' independently is optionally substituted, cyclic or
acyclic aliphatic; optionally substituted, cyclic or acyclic
heteroaliphatic; or a combination thereof;
[0028] each R.sub.a independently is hydrogen or optionally
substituted aliphatic; and
[0029] m is an integer between 1 and 100, inclusive.
[0030] In another aspect, the present disclosure provides methods
of preparing polymers of Formulae (II), (III), (IV), and (V). In
another aspect, the present disclosure provides methods of
preparing compounds of Formula (VI).
[0031] In another aspect, the present disclosure provides
compositions comprising a polymer described herein. In certain
embodiments, the composition further comprises an agent, e.g., a
small organic molecule, inorganic molecule, nucleic acid, protein,
peptide, or polynucleotide.
[0032] In another aspect, provided herein are methods of treating a
disease, disorder, or condition from which a subject suffers
comprising administering to the subject in need thereof an
effective amount of a composition described herein.
[0033] In another aspect, provided herein are methods of delivering
a polynucleotide to a cell comprising contacting the cell with a
composition described herein.
[0034] In another aspect, the present disclosure provides a kit
comprising one or more components selected from the polymers and
compounds described herein.
[0035] The details of certain embodiments of the invention are set
forth in the Detailed Description of Certain Embodiments, as
described below. Other features, objects, and advantages of the
invention will be apparent from the Definitions, Figures, Examples,
and Claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1 shows the general synthesis of PBAE polymers.
[0037] FIG. 2 shows the biodegradation products generated by the
hydrolysis of the PBAE polymers.
[0038] FIG. 3 shows the structure of 1,4-butanediol diacrylate and
Bisphenol A glycerolate diacrylate (DD).
[0039] FIG. 4 shows the synthesis of poly-caprolactone-based
diacrylates.
[0040] FIG. 5 shows an embodiment of the synthesis of PBAE polymers
using exemplary amines and diacrylates.
[0041] FIG. 6 shows exemplary PCL-based diacrylates used in the
synthesis of PBAE polymers.
[0042] FIG. 7 shows exemplary amines used in the synthesis of PBAE
polymers.
[0043] FIGS. 8A to 8B show: (FIG. 8A) The characterization data for
diacrylates A, B, C, and D. (FIG. 8B) .sup.1H NMR spectrum and
proton peak assignments of diacrylate C.
[0044] FIG. 9 shows the gel permeation chromatography (GPC)
characterization of PBAE polymers prepared from amines (1, 2, 3, 4)
and diacrylates (A, B, C, D).
[0045] FIGS. 10A to 10D show: (FIG. 10A) M.sub.w of the custom
diacrylates and the PBAE polymers with different hydrophilic
amines. (FIG. 10B) Transfection in HeLA cells of a PBAE series
using direct mixing or pre-mixing protocol. (FIG. 10C) Transfection
in HeLA cells using only pre-mixing protocol. (FIG. 10D) HeLa cell
relative viability for all the synthesized PBAE polymers.
[0046] FIG. 11 shows NP PEG-lipid distributions of B2 for the
primary and secondary NPs obtained in the direct mixing protocol
and NP D.sub.n distribution of the same PBAE with the pre-mixing
protocol.
[0047] FIG. 12A shows the characterization data of selected
mRNA-containing PBAE nanoparticles containing 0% PEG. FIG. 12B
shows the characterization data of selected mRNA-containing PBAE
nanoparticles containing 15% PEG.
[0048] FIGS. 13A to 13F show: (FIG. 13A) Serum stability of PBAE
polymers with 5 CL unit (C) at 7 wt. % of PEG-lipid. (FIG. 13B)
Serum stability of C1 at different wt. % of PEG-lipid. (FIG. 13C)
Image of C1 24 hours after IV injection (0.5 mg/kg mRNA). (FIG.
13D) Liver enzyme activity of C1 and Jet PEI at a dose of 0.5
mg/kg. (FIG. 13E) Average radiance of C1 and JET PEI in the spleen
after 24 hours at different mRNA doses. (FIG. 13F) Average radiance
of C1 and JET PEI in the lungs after 24 hours at different mRNA
doses.
[0049] FIGS. 14A to 14B show: (FIG. 14A) Transfection efficiency of
PBAE 2 series with varying percentages of PEG-lipid. (FIG. 14B)
Transfection efficiency of all PBAEs with 15 wt. % PEG-lipid.
[0050] FIG. 15 shows percent weight gain for C1 nanoparticles. Data
are presented as mean.+-.SD, n=3.
DEFINITIONS
[0051] For convenience, certain terms employed herein, in the
specification, examples, and claims are collected herein.
[0052] Unless otherwise required by context, singular terms shall
include pluralities, and plural terms shall include the
singular.
[0053] The following definitions are more general terms used
throughout the present application:
[0054] The singular terms "a," "an," and "the" include plural
references unless the context clearly indicates otherwise.
Similarly, the word "or" is intended to include "and" unless the
context clearly indicates otherwise.
[0055] Other than in the examples, or where otherwise indicated,
all numbers expressing quantities of ingredients or reaction
conditions used herein should be understood as modified in all
instances by the term "about." "About" and "approximately" shall
generally mean an acceptable degree of error for the quantity
measured given the nature or precision of the measurements.
Exemplary degrees of error are within 20 percent (%), typically,
within 10%, or more typically, within 5%, 4%, 3%, 2%, or 1% of a
given value or range of values.
[0056] Definitions of specific functional groups and chemical terms
are described in more detail below. The chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed.,
inside cover, and specific functional groups are generally defined
as described therein. Additionally, general principles of organic
chemistry, as well as specific functional moieties and reactivity,
are described in Organic Chemistry, Thomas Sorrell, University
Science Books, Sausalito, 1999; Smith and March March's Advanced
Organic Chemistry, 5.sup.th Edition, John Wiley & Sons, Inc.,
New York, 2001; Larock, Comprehensive Organic Transformations, VCH
Publishers, Inc., New York, 1989; and Carruthers, Some Modern
Methods of Organic Synthesis, 3.sup.rd Edition, Cambridge
University Press, Cambridge, 1987.
[0057] Compounds described herein can include one or more
asymmetric centers, and thus can exist in various stereoisomeric
forms, e.g., enantiomers and/or diastereomers. For example, the
compounds described herein can be in the form of an individual
enantiomer, diastereomer or geometric isomer, or can be in the form
of a mixture of stereoisomers, including racemic mixtures and
mixtures enriched in one or more stereoisomer. Isomers can be
isolated from mixtures by methods known to those skilled in the
art, including chiral high pressure liquid chromatography (HPLC)
and the formation and crystallization of chiral salts; or preferred
isomers can be prepared by asymmetric syntheses. See, for example,
Jacques et al., Enantiomers, Racemates and Resolutions (Wiley
Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725
(1977); Eliel, E. L. Stereochemistry of Carbon Compounds
(McGraw-Hill, N Y, 1962); and Wilen, S. H. Tables of Resolving
Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of
Notre Dame Press, Notre Dame, Ind. 1972). The disclosure
additionally encompasses compounds as individual isomers
substantially free of other isomers, and alternatively, as mixtures
of various isomers.
[0058] In a chemical formula, represents a bond that is absent or a
single bond, and or each represent a single or double bond.
[0059] When a range of values is listed, it is intended to
encompass each value and sub-range within the range. For example
"C.sub.1-C.sub.6 alkyl" is intended to encompass, C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-C.sub.6,
C.sub.1-C.sub.5, C.sub.1-C.sub.4, C.sub.1-C.sub.3, C.sub.1-C.sub.2,
C.sub.2-C.sub.6, C.sub.2-C.sub.5, C.sub.2-C.sub.4, C.sub.2-C.sub.3,
C.sub.3-C.sub.6, C.sub.3-C.sub.5, C.sub.3-C.sub.4, C.sub.4-C.sub.6,
C.sub.4-C.sub.5, and C.sub.5-C.sub.6 alkyl.
[0060] The term "aliphatic" includes both saturated and
unsaturated, straight chain (i.e., unbranched), branched, acyclic,
cyclic, or polycyclic aliphatic hydrocarbons, which are optionally
substituted with one or more functional groups. Likewise, the term
"heteroaliphatic" refers to heteroalkyl, heteroalkenyl,
heteroalkynyl, and heterocyclic groups. As will be appreciated by
one of ordinary skill in the art, "aliphatic" is intended herein to
include, but is not limited to, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, and cycloalkynyl moieties. Thus, the term
"alkyl" includes straight, branched and cyclic alkyl groups. An
analogous convention applies to other generic terms such as
"alkenyl", "alkynyl", and the like. Furthermore, the terms "alkyl",
"alkenyl", "alkynyl", and the like encompass both substituted and
unsubstituted groups. In certain embodiments, "lower alkyl" is used
to indicate those alkyl groups (cyclic, acyclic, substituted,
unsubstituted, branched, or unbranched) having 1-6 carbon
atoms.
[0061] In certain embodiments, the alkyl, alkenyl, and alkynyl
groups employed in the disclosure contain 1-100 aliphatic carbon
atoms. In certain other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-50 aliphatic
carbon atoms. In certain other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-20 aliphatic
carbon atoms. In certain other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-10 aliphatic
carbon atoms. In yet other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-8 aliphatic
carbon atoms. In still other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-6 aliphatic
carbon atoms. In yet other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the disclosure contain 1-4 carbon atoms.
Illustrative aliphatic groups thus include, but are not limited to,
for example, methyl, ethyl, npropyl, isopropyl, cyclopropyl,
--CH.sub.2-cyclopropyl, vinyl, allyl, n-butyl, sec-butyl, isobutyl,
tertbutyl, cyclobutyl, --CH.sub.2-cyclobutyl, n-pentyl, sec-pentyl,
isopentyl, tert-pentyl, cyclopentyl, --CH.sub.2-cyclopentyl,
n-hexyl, sec-hexyl, cyclohexyl, --CH.sub.2-cyclohexyl, and the
like, which again may bear one or more substituents. Alkenyl groups
include, but are not limited to, for example, ethenyl, propenyl,
butenyl, 1-methyl-2-buten-1-yl, and the like. Representative
alkynyl groups include, but are not limited to, ethynyl, 2-propynyl
(propargyl), 1-propynyl, and the like.
[0062] The term "alkyl" refers to a radical of a straight-chain or
branched saturated hydrocarbon group. In some embodiments, an alkyl
group has 1 to 1000 carbon atoms ("C.sub.1-C.sub.1000 alkyl"), 1 to
900 carbon atoms ("C.sub.1-C.sub.900 alkyl"), 1 to 800 carbon atoms
("C.sub.1-C.sub.800 alkyl"), 1 to 700 carbon atoms
("C.sub.1-C.sub.700 alkyl"), 1 to 600 carbon atoms
("C.sub.1-C.sub.600 alkyl"), 1 to 500 carbon atoms
("C.sub.1-C.sub.500 alkyl"), 1 to 400 carbon atoms
("C.sub.1-C.sub.400 alkyl"), 1 to 300 carbon atoms
("C.sub.1-C.sub.300 alkyl"), 1 to 200 carbon atoms
("C.sub.1-C.sub.200 alkyl"), 1 to 100 carbon atom
("C.sub.1-C.sub.100 alkyl"). In some embodiments, an alkyl group
has 1 to 10 carbon atoms ("C.sub.1-C.sub.10 alkyl"), 1 to 9 carbon
atoms ("C.sub.1-C.sub.9 alkyl"), 1 to 8 carbon atoms
("C.sub.1-C.sub.8 alkyl"), 1 to 7 carbon atoms ("C.sub.1-C.sub.7
alkyl"), 1 to 6 carbon atoms ("C.sub.1-C.sub.6 alkyl"), 1 to 5
carbon atoms ("C.sub.1-C.sub.5 alkyl"), 1 to 4 carbon atoms
("C.sub.1-C.sub.4 alkyl"), 1 to 3 carbon atoms ("C.sub.1-C.sub.3
alkyl"), 1 to 2 carbon atoms ("C.sub.1-C.sub.2 alkyl"), or 1 carbon
atom ("C.sub.1 alkyl"). Examples of C.sub.1-C.sub.6 alkyl groups
include methyl (C.sub.1), ethyl (C.sub.2), n-propyl (C.sub.3),
isopropyl (C.sub.3), n-butyl (C.sub.4), tert-butyl (C.sub.4),
sec-butyl (C.sub.4), iso-butyl (C.sub.4), n-pentyl (C.sub.5),
3-pentanyl (C.sub.5), amyl (C.sub.5), neopentyl (C.sub.5),
3-methyl-2-butanyl (C.sub.5), tertiary amyl (C.sub.5), and n-hexyl
(C.sub.6). Additional examples of alkyl groups include n-heptyl
(C.sub.7), n-octyl (C.sub.8) and the like. Unless otherwise
specified, each instance of an alkyl group is independently
unsubstituted (an "unsubstituted alkyl") or substituted (a
"substituted alkyl") with one or more substituents.
[0063] The term "alkenyl" refers to a radical of a straight-chain
or branched hydrocarbon group having from 2 to 1000 carbon atoms
and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4
double bonds). In some embodiments, an alkenyl group has 2 to 1000
carbon atoms ("C.sub.2-C.sub.1000 alkenyl"), 2 to 900 carbon atoms
("C.sub.2-C.sub.900 alkenyl"), 2 to 800 carbon atoms
("C.sub.2-C.sub.800 alkenyl"), 2 to 700 carbon atoms
("C.sub.2-C.sub.700 alkenyl"), 2 to 600 carbon atoms
("C.sub.2-C.sub.600 alkenyl"), 2 to 500 carbon atoms
("C.sub.2-C.sub.500 alkenyl"), 2 to 400 carbon atoms
("C.sub.2-C.sub.400 alkenyl"), 2 to 300 carbon atoms
("C.sub.2-C.sub.300 alkenyl"), 2 to 200 carbon atoms
("C.sub.2-C.sub.200 alkenyl"), 2 to 100 carbon atom
("C.sub.2-C.sub.100 alkenyl"). In some embodiments, an alkenyl
group has 2 to 9 carbon atoms ("C.sub.2-9 alkenyl"). In some
embodiments, an alkenyl group has 2 to 8 carbon atoms ("C.sub.2-8
alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon
atoms ("C.sub.2-7 alkenyl"). In some embodiments, an alkenyl group
has 2 to 6 carbon atoms ("C.sub.2-6 alkenyl"). In some embodiments,
an alkenyl group has 2 to 5 carbon atoms ("C.sub.2-5 alkenyl"). In
some embodiments, an alkenyl group has 2 to 4 carbon atoms
("C.sub.2-4 alkenyl"). In some embodiments, an alkenyl group has 2
to 3 carbon atoms ("C.sub.2-3 alkenyl"). In some embodiments, an
alkenyl group has 2 carbon atoms ("C.sub.2 alkenyl"). The one or
more carbon-carbon double bonds can be internal (such as in
2-butenyl) or terminal (such as in 1-butenyl). Examples of
C.sub.2-4 alkenyl groups include ethenyl (C.sub.2), 1-propenyl
(C.sub.3), 2-propenyl (C.sub.3), 1-butenyl (C.sub.4), 2-butenyl
(C.sub.4), butadienyl (C.sub.4), and the like. Examples of
C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4
alkenyl groups as well as pentenyl (C.sub.5), pentadienyl
(C.sub.5), hexenyl (C.sub.6), and the like. Unless otherwise
specified, each instance of an alkenyl group is independently
unsubstituted (an "unsubstituted alkenyl") or substituted (a
"substituted alkenyl") with one or more substituents. In an alkenyl
group, a C.dbd.C double bond for which the stereochemistry is not
specified (e.g., --CH.dbd.CHCH.sub.3
##STR00006##
may be in the (E)- or (Z)-configuration.
[0064] The term "alkynyl" refers to a radical of a straight-chain
or branched hydrocarbon group having from 2 to 1000 carbon atoms
and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4
triple bonds). In some embodiments, an alkynyl group has 2 to 1000
carbon atoms ("C.sub.2-C.sub.1000 alkynyl"), 2 to 900 carbon atoms
("C.sub.2-C.sub.900 alkynyl"), 2 to 800 carbon atoms
("C.sub.2-C.sub.800 alkynyl"), 2 to 700 carbon atoms
("C.sub.2-C.sub.700 alkynyl"), 2 to 600 carbon atoms
("C.sub.2-C.sub.600 alkynyl"), 2 to 500 carbon atoms
("C.sub.2-C.sub.500 alkynyl"), 2 to 400 carbon atoms
("C.sub.2-C.sub.400 alkynyl"), 2 to 300 carbon atoms
("C.sub.2-C.sub.300 alkynyl"), 2 to 200 carbon atoms
("C.sub.2-C.sub.200 alkynyl"), 2 to 100 carbon atom
("C.sub.2-C.sub.100 alkynyl"). In some embodiments, an alkynyl
group has 2 to 9 carbon atoms ("C.sub.2-9 alkynyl"), 2 to 8 carbon
atoms ("C.sub.2-8 alkynyl"), 2 to 7 carbon atoms ("C.sub.2-7
alkynyl"), 2 to 6 carbon atoms ("C.sub.2-6 alkynyl"), 2 to 5 carbon
atoms ("C.sub.2-5 alkynyl"), 2 to 4 carbon atoms ("C.sub.2-4
alkynyl"), 2 to 3 carbon atoms ("C.sub.2-3 alkynyl"), or 2 carbon
atoms ("C.sub.2 alkynyl"). The one or more carbon-carbon triple
bonds can be internal (such as in 2-butynyl) or terminal (such as
in 1-butynyl). Examples of C.sub.2-4 alkynyl groups include,
without limitation, ethynyl (C.sub.2), 1-propynyl (C.sub.3),
2-propynyl (C.sub.3), 1-butynyl (C.sub.4), 2-butynyl (C.sub.4), and
the like. Examples of C.sub.2-6 alkenyl groups include the
aforementioned C.sub.2-4 alkynyl groups as well as pentynyl
(C.sub.5), hexynyl (C.sub.6), and the like. Unless otherwise
specified, each instance of an alkynyl group is independently
unsubstituted (an "unsubstituted alkynyl") or substituted (a
"substituted alkynyl") with one or more substituents.
[0065] The term "heteroalkyl" refers to an alkyl group which
further includes at least one heteroatom (e.g., 1, 2, 3, or 4
heteroatoms) selected from oxygen, nitrogen, phosphorus, or sulfur
within (i.e., inserted between adjacent carbon atoms of) and/or
placed at one or more terminal position(s) of the parent chain. In
certain embodiments, a heteroalkyl group refers to a saturated
group having from 1 to 1000 carbon atoms and 1 or more heteroatoms
within the parent chain ("C.sub.1-C.sub.1000 heteroalkyl"), 1 to
900 carbon atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.900 heteroalkyl"), 1 to 800 carbon atoms and 1 or
more heteroatoms within the parent chain ("C.sub.1-C.sub.800
heteroalkyl"), 1 to 700 carbon atoms and 1 or more heteroatoms
within the parent chain ("C.sub.1-C.sub.700 heteroalkyl"), 1 to 600
carbon atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.600 heteroalkyl"), 1 to 500 carbon atoms and 1 or
more heteroatoms within the parent chain ("C.sub.1-C.sub.500
heteroalkyl"), 1 to 400 carbon atoms and 1 or more heteroatoms
within the parent chain ("C.sub.1-C.sub.400 heteroalkyl"), 1 to 300
carbon atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.300 heteroalkyl"), 1 to 200 carbon atoms and 1 or
more heteroatoms within the parent chain ("C.sub.1-C.sub.200
heteroalkyl"), or 1 to 100 carbon atoms and 1 or more heteroatoms
within the parent chain ("C.sub.1-C.sub.100 heteroalkyl"). In
certain embodiments, a heteroalkyl group refers to a saturated
group having from 1 to 10 carbon atoms and 1 or more heteroatoms
within the parent chain ("C.sub.1-C.sub.10 heteroalkyl"), 1 to 9
carbon atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.9 heteroalkyl"), 1 to 8 carbon atoms and 1 or more
heteroatoms within the parent chain ("C.sub.1-C.sub.8
heteroalkyl"), 1 to 7 carbon atoms and 1 or more heteroatoms within
the parent chain ("C.sub.1-C.sub.7 heteroalkyl"), 1 to 6 carbon
atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.6 heteroalkyl"), 1 to 5 carbon atoms and 1 or more
heteroatoms within the parent chain ("C.sub.1-C.sub.5
heteroalkyl"), 1 to 4 carbon atoms and 1 or more heteroatoms within
the parent chain ("C.sub.1-C.sub.4 heteroalkyl"), 1 to 3 carbon
atoms and 1 or more heteroatoms within the parent chain
("C.sub.1-C.sub.3 heteroalkyl"), 1 to 2 carbon atoms and 1
heteroatom within the parent chain ("C.sub.1-C.sub.2 heteroalkyl"),
or 1 carbon atom and 1 heteroatom ("C.sub.1 heteroalkyl"). Unless
otherwise specified, each instance of a heteroalkyl group is
independently unsubstituted (an "unsubstituted heteroalkyl") or
substituted (a "substituted heteroalkyl") with one or more
substituents.
[0066] The term "heteroalkenyl" refers to an alkenyl group, which
further includes at least one heteroatom (e.g., 1, 2, 3, or 4
heteroatoms) selected from oxygen, nitrogen, or sulfur within
(i.e., inserted between adjacent carbon atoms of) and/or placed at
one or more terminal position(s) of the parent chain. In certain
embodiments, a heteroalkenyl group refers to a saturated group
having from 1 to 1000 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.1000 alkenyl"), 1 to 900
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.900 alkenyl"), 1 to 800 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.800
alkenyl"), 1 to 700 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.700 alkenyl"), 1 to 600
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.600 alkenyl"), 1 to 500 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.500
alkenyl"), 1 to 400 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.400 alkenyl"), 1 to 300
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.300 alkenyl"), 1 to 200 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.200
alkenyl"), or 1 to 100 carbon atoms and 1 or more heteroatoms
within the parent chain ("heteroC.sub.1-C.sub.100 alkenyl"). In
certain embodiments, a heteroalkenyl group refers to a group having
from 2 to 10 carbon atoms, at least one double bond, and 1 or more
heteroatoms within the parent chain ("heteroC.sub.2-10 alkenyl").
In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms
at least one double bond, and 1 or more heteroatoms within the
parent chain ("heteroC.sub.2-9 alkenyl"). In some embodiments, a
heteroalkenyl group has 2 to 8 carbon atoms, at least one double
bond, and 1 or more heteroatoms within the parent chain
("heteroC.sub.2-8 alkenyl"). In some embodiments, a heteroalkenyl
group has 2 to 7 carbon atoms, at least one double bond, and 1 or
more heteroatoms within the parent chain ("heteroC.sub.2-7
alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6
carbon atoms, at least one double bond, and 1 or more heteroatoms
within the parent chain ("heteroC.sub.2-6 alkenyl"). In some
embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at
least one double bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-5 alkenyl"). In some embodiments, a
heteroalkenyl group has 2 to 4 carbon atoms, at least one double
bond, and 1 or 2 heteroatoms within the parent chain
("heteroC.sub.2-4 alkenyl"). In some embodiments, a heteroalkenyl
group has 2 to 3 carbon atoms, at least one double bond, and 1
heteroatom within the parent chain ("heteroC.sub.2-3 alkenyl"). In
some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at
least one double bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-6 alkenyl"). Unless otherwise specified, each
instance of a heteroalkenyl group is independently unsubstituted
(an "unsubstituted heteroalkenyl") or substituted (a "substituted
heteroalkenyl") with one or more substituents. In certain
embodiments, the heteroalkenyl group is an unsubstituted
heteroC.sub.2-10 alkenyl. In certain embodiments, the heteroalkenyl
group is a substituted heteroC.sub.2-10 alkenyl.
[0067] The term "heteroalkynyl" refers to an alkynyl group, which
further includes at least one heteroatom (e.g., 1, 2, 3, or 4
heteroatoms) selected from oxygen, nitrogen, or sulfur within
(i.e., inserted between adjacent carbon atoms of) and/or placed at
one or more terminal position(s) of the parent chain. In certain
embodiments, a heteroalkynyl group refers to a saturated group
having from 1 to 1000 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.1000 alkynyl"), 1 to 900
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.900 alkynyl"), 1 to 800 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.800
alkynyl"), 1 to 700 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.700 alkynyl), 1 to 600
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.600 alkynyl"), 1 to 500 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.500
alkynyl"), 1 to 400 carbon atoms and 1 or more heteroatoms within
the parent chain ("heteroC.sub.1-C.sub.400 alkynyl"), 1 to 300
carbon atoms and 1 or more heteroatoms within the parent chain
("heteroC.sub.1-C.sub.300 alkynyl"), 1 to 200 carbon atoms and 1 or
more heteroatoms within the parent chain ("heteroC.sub.1-C.sub.200
alkynyl"), or 1 to 100 carbon atoms and 1 or more heteroatoms
within the parent chain ("heteroC.sub.1-C.sub.100 alkynyl"). In
certain embodiments, a heteroalkynyl group refers to a group having
from 2 to 10 carbon atoms, at least one triple bond, and 1 or more
heteroatoms within the parent chain ("heteroC.sub.2-10 alkynyl").
In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms,
at least one triple bond, and 1 or more heteroatoms within the
parent chain ("heteroC.sub.2-9 alkynyl"). In some embodiments, a
heteroalkynyl group has 2 to 8 carbon atoms, at least one triple
bond, and 1 or more heteroatoms within the parent chain
("heteroC.sub.2-8 alkynyl"). In some embodiments, a heteroalkynyl
group has 2 to 7 carbon atoms, at least one triple bond, and 1 or
more heteroatoms within the parent chain ("heteroC.sub.2-7
alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6
carbon atoms, at least one triple bond, and 1 or more heteroatoms
within the parent chain ("heteroC.sub.2-6 alkynyl"). In some
embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at
least one triple bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-5 alkynyl"). In some embodiments, a
heteroalkynyl group has 2 to 4 carbon atoms, at least one triple
bond, and 1 or 2 heteroatoms within the parent chain
("heteroC.sub.2-4 alkynyl"). In some embodiments, a heteroalkynyl
group has 2 to 3 carbon atoms, at least one triple bond, and 1
heteroatom within the parent chain ("heteroC.sub.2-3 alkynyl"). In
some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at
least one triple bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-6 alkynyl"). Unless otherwise specified, each
instance of a heteroalkynyl group is independently unsubstituted
(an "unsubstituted heteroalkynyl") or substituted (a "substituted
heteroalkynyl") with one or more substituents. In certain
embodiments, the heteroalkynyl group is an unsubstituted
heteroC.sub.2-10 alkynyl. In certain embodiments, the heteroalkynyl
group is a substituted heteroC.sub.2-10 alkynyl.
[0068] The term "carbocyclyl" or "carbocyclic" or "cycloalkyl"
refers to a radical of a non-aromatic cyclic hydrocarbon group
having from 3 to 10 ring carbon atoms ("C.sub.3-10 carbocyclyl")
and zero heteroatoms in the non-aromatic ring system. In some
embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms
("C.sub.3-8 carbocyclyl"), 3 to 7 ring carbon atoms ("C.sub.3-7
carbocyclyl"), 3 to 6 ring carbon atoms ("C.sub.3-6 carbocyclyl"),
4 to 6 ring carbon atoms ("C.sub.4-6 carbocyclyl"), 5 to 6 ring
carbon atoms ("C.sub.5-6 carbocyclyl"), or 5 to 10 ring carbon
atoms ("C.sub.5-10 carbocyclyl"). Exemplary C.sub.3-6 carbocyclyl
groups include, without limitation, cyclopropyl (C.sub.3),
cyclopropenyl (C.sub.3), cyclobutyl (C.sub.4), cyclobutenyl
(C.sub.4), cyclopentyl (C.sub.5), cyclopentenyl (C.sub.5),
cyclohexyl (C.sub.6), cyclohexenyl (C.sub.6), cyclohexadienyl
(C.sub.6), and the like. Exemplary C.sub.3-8 carbocyclyl groups
include, without limitation, the aforementioned C.sub.3-6
carbocyclyl groups as well as cycloheptyl (C.sub.7), cycloheptenyl
(C.sub.7), cycloheptadienyl (C.sub.7), cycloheptatrienyl (C.sub.7),
cyclooctyl (C.sub.8), cyclooctenyl (C.sub.8),
bicyclo[2.2.1]heptanyl (C.sub.7), bicyclo[2.2.2]octanyl (C.sub.8),
and the like. Exemplary C.sub.3-10 carbocyclyl groups include,
without limitation, the aforementioned C.sub.3-8 carbocyclyl groups
as well as cyclononyl (C.sub.9), cyclononenyl (C.sub.9), cyclodecyl
(C.sub.10), cyclodecenyl (C.sub.10), octahydro-1H-indenyl
(C.sub.9), decahydronaphthalenyl (C.sub.10), spiro[4.5]decanyl
(C.sub.10), and the like. As the foregoing examples illustrate, in
certain embodiments, the carbocyclyl group is either monocyclic
("monocyclic carbocyclyl") or polycyclic (e.g., containing a fused,
bridged or spiro ring system such as a bicyclic system ("bicyclic
carbocyclyl") or tricyclic system ("tricyclic carbocyclyl")) and
can be saturated or can contain one or more carbon-carbon double or
triple bonds. "Carbocyclyl" also includes ring systems wherein the
carbocyclyl ring, as defined above, is fused with one or more aryl
or heteroaryl groups wherein the point of attachment is on the
carbocyclyl ring, and in such instances, the number of carbons
continue to designate the number of carbons in the carbocyclic ring
system. Unless otherwise specified, each instance of a carbocyclyl
group is independently unsubstituted (an "unsubstituted
carbocyclyl") or substituted (a "substituted carbocyclyl") with one
or more substituents.
[0069] The term "heterocyclyl" or "heterocyclic" refers to a
radical of a 3- to 14-membered non-aromatic ring system having ring
carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom
is independently selected from nitrogen, oxygen, phosphorus, and
sulfur ("3-14 membered heterocyclyl"). In heterocyclyl groups that
contain one or more nitrogen atoms, the point of attachment can be
a carbon or nitrogen atom, as valency permits. A heterocyclyl group
can either be monocyclic ("monocyclic heterocyclyl") or polycyclic
(e.g., a fused, bridged or spiro ring system such as a bicyclic
system ("bicyclic heterocyclyl") or tricyclic system ("tricyclic
heterocyclyl")), and can be saturated or can contain one or more
carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring
systems can include one or more heteroatoms in one or both rings.
"Heterocyclyl" also includes ring systems wherein the heterocyclyl
ring, as defined above, is fused with one or more carbocyclyl
groups wherein the point of attachment is either on the carbocyclyl
or heterocyclyl ring, or ring systems wherein the heterocyclyl
ring, as defined above, is fused with one or more aryl or
heteroaryl groups, wherein the point of attachment is on the
heterocyclyl ring, and in such instances, the number of ring
members continue to designate the number of ring members in the
heterocyclyl ring system. Unless otherwise specified, each instance
of heterocyclyl is independently unsubstituted (an "unsubstituted
heterocyclyl") or substituted (a "substituted heterocyclyl") with
one or more substituents.
[0070] In some embodiments, a heterocyclyl group is a 5-10 membered
non-aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms, wherein each heteroatom is independently selected from
nitrogen, oxygen, phosphorus, and sulfur ("5-10 membered
heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-8
membered non-aromatic ring system having ring carbon atoms and 1-4
ring heteroatoms, wherein each heteroatom is independently selected
from nitrogen, oxygen, phosphorus, and sulfur ("5-8 membered
heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6
membered non-aromatic ring system having ring carbon atoms and 1-4
ring heteroatoms, wherein each heteroatom is independently selected
from nitrogen, oxygen, phosphorus, and sulfur ("5-6 membered
heterocyclyl"). In some embodiments, the 5-6 membered heterocyclyl
has 1-3 ring heteroatoms selected from nitrogen, oxygen,
phosphorus, and sulfur. In some embodiments, the 5-6 membered
heterocyclyl has 1-2 ring heteroatoms selected from nitrogen,
oxygen, phosphorus, and sulfur. In some embodiments, the 5-6
membered heterocyclyl has 1 ring heteroatom selected from nitrogen,
oxygen, phosphorus, and sulfur.
[0071] Exemplary 3-membered heterocyclyl groups containing 1
heteroatom include, without limitation, azirdinyl, oxiranyl, and
thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1
heteroatom include, without limitation, azetidinyl, oxetanyl and
thietanyl. Exemplary 5-membered heterocyclyl groups containing 1
heteroatom include, without limitation, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl,
pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary
5-membered heterocyclyl groups containing 2 heteroatoms include,
without limitation, dioxolanyl, oxathiolanyl and dithiolanyl.
Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms
include, without limitation, triazolinyl, oxadiazolinyl, and
thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing
1 heteroatom include, without limitation, piperidinyl,
tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary
6-membered heterocyclyl groups containing 2 heteroatoms include,
without limitation, piperazinyl, morpholinyl, dithianyl, and
dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3
heteroatoms include, without limitation, triazinanyl. Exemplary
7-membered heterocyclyl groups containing 1 heteroatom include,
without limitation, azepanyl, oxepanyl, and thiepanyl. Exemplary
8-membered heterocyclyl groups containing 1 heteroatom include,
without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary
bicyclic heterocyclyl groups include, without limitation,
indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,
tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl,
decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl,
octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl,
naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl,
1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl,
5,6-dihydro-4H-furo[3,2-b]pyrrolyl,
6,7-dihydro-5H-furo[3,2-b]pyranyl,
5,7-dihydro-4H-thieno[2,3-c]pyranyl,
2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl,
2,3-dihydrofuro[2,3-b]pyridinyl,
4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl,
4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl,
4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl,
1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like.
[0072] The term "aryl" refers to a radical of a monocyclic or
polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system
(e.g., having 6, 10, or 14 .pi. electrons shared in a cyclic array)
having 6-14 ring carbon atoms and zero heteroatoms provided in the
aromatic ring system ("C.sub.6-14 aryl"). In some embodiments, an
aryl group has 6 ring carbon atoms ("C.sub.6 aryl"; e.g., phenyl).
In some embodiments, an aryl group has 10 ring carbon atoms
("C.sub.10 aryl"; e.g., naphthyl such as 1-naphthyl and
2-naphthyl). In some embodiments, an aryl group has 14 ring carbon
atoms ("C.sub.14 aryl"; e.g., anthracyl). "Aryl" also includes ring
systems wherein the aryl ring, as defined above, is fused with one
or more carbocyclyl or heterocyclyl groups wherein the radical or
point of attachment is on the aryl ring, and in such instances, the
number of carbon atoms continue to designate the number of carbon
atoms in the aryl ring system. Unless otherwise specified, each
instance of an aryl group is independently unsubstituted (an
"unsubstituted aryl") or substituted (a "substituted aryl") with
one or more substituents.
[0073] The term "heteroaryl" refers to a radical of a 5-14 membered
monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic
ring system (e.g., having 6, 10, or 14 .pi. electrons shared in a
cyclic array) having ring carbon atoms and 1-4 ring heteroatoms
provided in the aromatic ring system, wherein each heteroatom is
independently selected from nitrogen, oxygen, and sulfur ("5-14
membered heteroaryl"). In heteroaryl groups that contain one or
more nitrogen atoms, the point of attachment can be a carbon or
nitrogen atom, as valency permits. Heteroaryl polycyclic ring
systems can include one or more heteroatoms in one or both rings.
"Heteroaryl" includes ring systems wherein the heteroaryl ring, as
defined above, is fused with one or more carbocyclyl or
heterocyclyl groups wherein the point of attachment is on the
heteroaryl ring, and in such instances, the number of ring members
continue to designate the number of ring members in the heteroaryl
ring system. "Heteroaryl" also includes ring systems wherein the
heteroaryl ring, as defined above, is fused with one or more aryl
groups wherein the point of attachment is either on the aryl or
heteroaryl ring, and in such instances, the number of ring members
designates the number of ring members in the fused polycyclic
(aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein
one ring does not contain a heteroatom (e.g., indolyl, quinolinyl,
carbazolyl, and the like) the point of attachment can be on either
ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl)
or the ring that does not contain a heteroatom (e.g., 5-indolyl). A
heteroaryl group be monovalent or may have more than one point of
attachment to another moiety (e.g., it may be divalent, trivalent,
etc), although the valency may be specified directly in the name of
the group. For example, "triazoldiyl" refers to a divalent
triazolyl moiety.
[0074] In some embodiments, a heteroaryl group is a 5-10 membered
aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms provided in the aromatic ring system, wherein each
heteroatom is independently selected from nitrogen, oxygen, and
sulfur ("5-10 membered heteroaryl"). In some embodiments, a
heteroaryl group is a 5-8 membered aromatic ring system having ring
carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring
system, wherein each heteroatom is independently selected from
nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some
embodiments, a heteroaryl group is a 5-6 membered aromatic ring
system having ring carbon atoms and 1-4 ring heteroatoms provided
in the aromatic ring system, wherein each heteroatom is
independently selected from nitrogen, oxygen, and sulfur ("5-6
membered heteroaryl"). In some embodiments, the 5-6 membered
heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen,
and sulfur. In some embodiments, the 5-6 membered heteroaryl has
1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In
some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom
selected from nitrogen, oxygen, and sulfur. Unless otherwise
specified, each instance of a heteroaryl group is independently
unsubstituted (an "unsubstituted heteroaryl") or substituted (a
"substituted heteroaryl") with one or more substituents.
[0075] Exemplary 5-membered heteroaryl groups containing 1
heteroatom include, without limitation, pyrrolyl, furanyl, and
thiophenyl. Exemplary 5-membered heteroaryl groups containing 2
heteroatoms include, without limitation, imidazolyl, pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary
5-membered heteroaryl groups containing 3 heteroatoms include,
without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
Exemplary 5-membered heteroaryl groups containing 4 heteroatoms
include, without limitation, tetrazolyl. Exemplary 6-membered
heteroaryl groups containing 1 heteroatom include, without
limitation, pyridinyl. Exemplary 6-membered heteroaryl groups
containing 2 heteroatoms include, without limitation, pyridazinyl,
pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups
containing 3 or 4 heteroatoms include, without limitation,
triazinyl and tetrazinyl, respectively. Exemplary 7-membered
heteroaryl groups containing 1 heteroatom include, without
limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary
5,6-bicyclic heteroaryl groups include, without limitation,
indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl,
isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl,
benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl,
benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
Exemplary 6,6-bicyclic heteroaryl groups include, without
limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl,
cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary
tricyclic heteroaryl groups include, without limitation,
phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl,
phenothiazinyl, phenoxazinyl and phenazinyl.
[0076] As understood from the above, alkyl, alkenyl, alkynyl,
carbocyclyl, aryl, and heteroaryl groups are, in certain
embodiments, optionally substituted. Optionally substituted refers
to a group which may be substituted or unsubstituted (e.g.,
"substituted" or "unsubstituted" alkyl). In general, the term
"substituted" means that at least one hydrogen present on a group
is replaced with a permissible substituent, e.g., a substituent
which upon substitution results in a stable compound, e.g., a
compound which does not spontaneously undergo transformation such
as by rearrangement, cyclization, elimination, or other reaction.
Unless otherwise indicated, a "substituted" group has a substituent
at one or more substitutable positions of the group, and when more
than one position in any given structure is substituted, the
substituent is either the same or different at each position. The
term "substituted" is contemplated to include substitution with all
permissible substituents of organic compounds, any of the
substituents described herein that results in the formation of a
stable compound. The present disclosure contemplates any and all
such combinations in order to arrive at a stable compound. For
purposes of this disclosure, heteroatoms such as nitrogen may have
hydrogen substituents and/or any suitable substituent as described
herein which satisfy the valencies of the heteroatoms and results
in the formation of a stable moiety.
[0077] Affixing the suffix "ene" to a group indicates the group is
a polyvalent (e.g., bivalent, trivalent, tetravalent, or
pentavalent) moiety. In certain embodiments, affixing the suffix
"ene" to a group indicates the group is a bivalent moiety.
[0078] Exemplary carbon atom substituents include, but are not
limited to, halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H,
--SO.sub.3H, --OH, --OR.sup.aa, --ON(R.sup.bb).sub.2,
--N(R.sup.bb).sub.2, --N(R.sup.bb).sub.3.sup.+X.sup.-,
--N(OR.sup.cc)R.sup.bb, --SH, --SR.sup.aa, --SSR.sup.cc,
--C(.dbd.O)R.sup.aa, --CO.sub.2H, --CHO, --C(OR.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --OC(.dbd.O)R.sup.aa, --OCO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --OC(.dbd.O)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.O)R.sup.aa, --NR.sup.bbCO.sub.2R.sup.aa,
--NR.sup.bbC(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --OC(.dbd.NR.sup.bb)R.sup.aa,
--OC(.dbd.NR.sup.bb)OR.sup.aa,
--C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--OC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--C(.dbd.O)NR.sup.bbSO.sub.2R.sup.aa, --NR.sup.bbSO.sub.2R.sup.aa,
--SO.sub.2N(R.sup.bb).sub.2, --SO.sub.2R.sup.aa,
--SO.sub.2OR.sup.aa, --OSO.sub.2R.sup.aa, --S(.dbd.O)R.sup.aa,
--OS(.dbd.O)R.sup.aa, --Si(R.sup.aa).sub.3,
--OSi(R.sup.aa).sub.3--C(.dbd.S)N(R.sup.bb).sub.2,
--C(.dbd.O)SR.sup.aa, --C(.dbd.S)SR.sup.aa, --SC(.dbd.S)SR.sup.aa,
--SC(.dbd.O)SR.sup.aa, --OC(.dbd.O)SR.sup.aa,
--SC(.dbd.O)OR.sup.aa, --SC(.dbd.O)R.sup.aa,
--P(.dbd.O)(R.sup.aa).sub.2, --P(.dbd.O)(OR.sup.cc).sub.2,
--OP(.dbd.O)(R.sup.aa).sub.2, --OP(.dbd.O)(OR.sup.cc).sub.2,
--P(.dbd.O)(N(R.sup.bb).sub.2).sub.2,
--OP(.dbd.O)(N(R.sup.bb).sub.2).sub.2,
--NR.sup.bbP(.dbd.O)(R.sup.aa).sub.2,
--NR.sup.bbP(.dbd.O)(OR.sup.cc).sub.2,
--NR.sup.bbP(.dbd.O)(N(R.sup.bb).sub.2).sub.2, --P(R.sup.cc).sub.2,
--P(OR.sup.cc).sub.2, --P(R.sup.cc).sub.3.sup.+X.sup.-,
--P(OR.sup.cc).sub.3.sup.+X.sup.-, --P(R.sup.cc).sub.4,
--P(OR.sup.cc).sub.4, --OP(R.sup.cc).sub.2,
--OP(R.sup.cc).sub.3.sup.+X.sup.-, --OP(OR.sup.cc).sub.2,
--OP(OR.sup.cc).sub.3.sup.+X.sup.-, --OP(R.sup.cc).sub.4,
--OP(OR.sup.cc).sub.4, --B(R.sup.aa).sub.2, --B(OR.sup.cc).sub.2,
--BR.sup.aa(OR.sup.cc), C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl,
C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, heteroC.sub.1-10 alkyl,
heteroC.sub.2-10 alkenyl, heteroC.sub.2-10 alkynyl, C.sub.3-10
carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14
membered heteroaryl, wherein each alkyl, alkenyl, alkynyl,
heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted
with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; wherein X.sup.- is a
counterion;
[0079] or two geminal hydrogens on a carbon atom are replaced with
the group .dbd.O, .dbd.S, .dbd.NN(R.sup.bb).sub.2,
.dbd.NNR.sup.bbC(.dbd.O)R.sup.aa,
.dbd.NNR.sup.bbC(.dbd.O)OR.sup.aa,
.dbd.NNR.sup.bbS(.dbd.O).sub.2R.sup.aa, .dbd.NR.sup.bb, or
.dbd.NOR.sup.cc;
[0080] each instance of R.sup.aa is, independently, selected from
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, heteroC.sub.1-10 alkyl,
heteroC.sub.2-10alkenyl, heteroC.sub.2-10alkynyl, C.sub.3-10
carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14
membered heteroaryl, or two R.sup.aa groups are joined to form a
3-14 membered heterocyclyl or 5-14 membered heteroaryl ring,
wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0081] each instance of R.sup.bb is, independently, selected from
hydrogen, --OH, --OR.sup.aa, --N(R.sup.cc).sub.2, --CN,
--C(.dbd.O)R.sup.aa, --C(.dbd.O)N(R.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --SO.sub.2R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc,
--P(.dbd.O)(R.sup.aa).sub.2, --P(.dbd.O)(OR.sup.cc).sub.2,
--P(.dbd.O)(N(R.sup.cc).sub.2).sub.2, C.sub.1-10 alkyl, C.sub.1-10
perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl,
heteroC.sub.1-10alkyl, heteroC.sub.2-10alkenyl,
heteroC.sub.2-10alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two
R.sup.bb groups are joined to form a 3-14 membered heterocyclyl or
5-14 membered heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted
with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; wherein X.sup.- is a
counterion;
[0082] each instance of R.sup.cc is, independently, selected from
hydrogen, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10
alkenyl, C.sub.2-10 alkynyl, heteroC.sub.1-10 alkyl,
heteroC.sub.2-10 alkenyl, heteroC.sub.2-10 alkynyl, C.sub.3-10
carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14
membered heteroaryl, or two R.sup.cc groups are joined to form a
3-14 membered heterocyclyl or 5-14 membered heteroaryl ring,
wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0083] each instance of R.sup.dd is, independently, selected from
halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H,
--OH, --OR.sup.ee, --ON(R.sup.ff).sub.2, --N(R.sup.ff).sub.2,
--N(R.sup.ff).sub.3.sup.+X.sup.-, --N(OR.sup.ee)R.sup.ff, --SH,
--SR.sup.ee, --SSR.sup.ee, --C(.dbd.O)R.sup.ee, --CO.sub.2H,
--CO.sub.2R.sup.ee, --OC(.dbd.O)R.sup.ee, --OCO.sub.2R.sup.ee,
--C(.dbd.O)N(R.sup.ff).sub.2, --OC(.dbd.O)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.O)R.sup.ee, --NR.sup.ffCO.sub.2R.sup.ee,
--NR.sup.ffC(.dbd.O)N(R.sup.ff).sub.2,
--C(.dbd.NR.sup.ff)OR.sup.ee, --OC(.dbd.NR.sup.ff)R.sup.ee,
--OC(.dbd.NR.sup.ff)OR.sup.ee,
--C(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--OC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffSO.sub.2R.sup.ee, --SO.sub.2N(R.sup.ff).sub.2,
--SO.sub.2R.sup.ee, --SO.sub.2OR.sup.ee, --OSO.sub.2R.sup.ee,
--S(.dbd.O)R.sup.ee, --Si(R.sup.ee).sub.3, --OSi(R.sup.ee).sub.3,
--C(.dbd.S)N(R.sup.ff).sub.2, --C(.dbd.O)SR.sup.ee,
--C(.dbd.S)SR.sup.ee, --SC(.dbd.S)SR.sup.ee,
--P(.dbd.O)(OR.sup.ee).sub.2, --P(.dbd.O)(R.sup.ee).sub.2,
--OP(.dbd.O)(R.sup.ee).sub.2, --OP(.dbd.O)(OR.sup.ee).sub.2,
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, heteroC.sub.1-6alkyl, heteroC.sub.2-6alkenyl,
heteroC.sub.2-6alkynyl, C.sub.3-10 carbocyclyl, 3-10 membered
heterocyclyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups,
or two geminal R.sup.dd substituents can be joined to form .dbd.O
or .dbd.S; wherein X.sup.- is a counterion;
[0084] each instance of R.sup.ee is, independently, selected from
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, heteroC.sub.1-6 alkyl, heteroC.sub.2-6alkenyl,
heteroC.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl,
3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg
groups;
[0085] each instance of R.sup.ff is, independently, selected from
hydrogen, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, heteroC.sub.1-6alkyl,
heteroC.sub.2-6alkenyl, heteroC.sub.2-6alkynyl, C.sub.3-10
carbocyclyl, 3-10 membered heterocyclyl, C.sub.6-10 aryl and 5-10
membered heteroaryl, or two R.sup.ff groups are joined to form a
3-10 membered heterocyclyl or 5-10 membered heteroaryl ring,
wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups;
and
[0086] each instance of R.sup.gg is, independently, halogen, --CN,
--NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H, --OH, --OC.sub.1-6
alkyl, --ON(C.sub.1-6 alkyl).sub.2, --N(C.sub.1-6 alkyl).sub.2,
--N(C.sub.1-6 alkyl).sub.3.sup.+X.sup.-, --NH(C.sub.1-6
alkyl).sub.2.sup.+X.sup.-, --NH.sub.2(C.sub.1-6
alkyl).sup.+X.sup.-, --NH.sub.3.sup.+X.sup.-, --N(OC.sub.1-6
alkyl)(C.sub.1-6 alkyl), --N(OH)(C.sub.1-6 alkyl), --NH(OH), --SH,
--SC.sub.1-6 alkyl, --SS(C.sub.1-6 alkyl), --C(.dbd.O)(C.sub.1-6
alkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6 alkyl),
--OC(.dbd.O)(C.sub.1-6 alkyl), --OCO.sub.2(C.sub.1-6 alkyl),
--C(.dbd.O)NH.sub.2, --C(.dbd.O)N(C.sub.1-6 alkyl).sub.2,
--OC(.dbd.O)NH(C.sub.1-6 alkyl), --NHC(.dbd.O)(C.sub.1-6 alkyl),
--N(C.sub.1-6 alkyl)C(.dbd.O)(C.sub.1-6 alkyl),
--NHCO.sub.2(C.sub.1-6 alkyl), --NHC(.dbd.O)N(C.sub.1-6
alkyl).sub.2, --NHC(.dbd.O)NH(C.sub.1-6 alkyl),
--NHC(.dbd.O)NH.sub.2, --C(.dbd.NH)O(C.sub.1-6 alkyl),
--OC(.dbd.NH)(C.sub.1-6 alkyl), --OC(.dbd.NH)OC.sub.1-6 alkyl,
--C(.dbd.NH)N(C.sub.1-6 alkyl).sub.2, --C(.dbd.NH)NH(C.sub.1-6
alkyl), --C(.dbd.NH)NH.sub.2, --OC(.dbd.NH)N(C.sub.1-6
alkyl).sub.2, --OC(NH)NH(C.sub.1-6 alkyl), --OC(NH)NH.sub.2,
--NHC(NH)N(C.sub.1-6 alkyl).sub.2, --NHC(.dbd.NH)NH.sub.2,
--NHSO.sub.2(C.sub.1-6 alkyl), --SO.sub.2N(C.sub.1-6 alkyl).sub.2,
--SO.sub.2NH(C.sub.1-6 alkyl), --SO.sub.2NH.sub.2,
--SO.sub.2C.sub.1-6 alkyl, --SO.sub.2OC.sub.1-6 alkyl,
--OSO.sub.2C.sub.1-6 alkyl, --SOC.sub.1-6 alkyl, --Si(C.sub.1-6
alkyl).sub.3, --OSi(C.sub.1-6 alkyl).sub.3 --C(.dbd.S)N(C.sub.1-6
alkyl).sub.2, C(.dbd.S)NH(C.sub.1-6 alkyl), C(.dbd.S)NH.sub.2,
--C(.dbd.O)S(C.sub.1-6 alkyl), --C(.dbd.S)SC.sub.1-6 alkyl,
--SC(.dbd.S)SC.sub.1-6 alkyl, --P(.dbd.O)(OC.sub.1-6 alkyl).sub.2,
--P(.dbd.O)(C.sub.1-6 alkyl).sub.2, --OP(.dbd.O)(C.sub.1-6
alkyl).sub.2, --OP(.dbd.O)(OC.sub.1-6 alkyl).sub.2, C.sub.1-6
alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, heteroC.sub.1-6alkyl, heteroC.sub.2-6alkenyl,
heteroC.sub.2-6alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl,
3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two
geminal R.sup.gg substituents can be joined to form .dbd.O or
.dbd.S; wherein X.sup.- is a counterion.
[0087] In certain embodiments, the carbon atom substituents are
independently halogen, substituted or unsubstituted C.sub.1-6
alkyl, --OR.sup.aa, --SR.sup.aa, --N(R.sup.bb).sub.2, --CN, --SCN,
--NO.sub.2, --C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --OC(.dbd.O)R.sup.aa,
--OCO.sub.2R.sup.aa, --OC(.dbd.O)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.O)R.sup.aa, --NR.sup.bbCO.sub.2R.sup.aa, or
--NR.sup.bbC(.dbd.O)N(R.sup.bb).sub.2. In certain embodiments, the
carbon atom substituents are independently halogen, substituted or
unsubstituted C.sub.1-6 alkyl, --OR.sup.aa, --SR.sup.aa,
--N(R.sup.bb).sub.2, --CN, --SCN, or --NO.sub.2.
[0088] Nitrogen atoms can be substituted or unsubstituted as
valency permits, and include primary, secondary, tertiary, and
quaternary nitrogen atoms. Exemplary nitrogen atom substituents
include, but are not limited to, hydrogen, --OH, --OR.sup.aa,
--N(R.sup.cc).sub.2, --CN, --C(.dbd.O)R.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --CO.sub.2R.sup.aa,
--SO.sub.2R.sup.aa, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc,
--P(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O)(N(R.sup.cc).sub.2).sub.2, C.sub.1-10 alkyl, C.sub.1-10
perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl,
heteroC.sub.1-10alkyl, heteroC.sub.2-10 alkenyl, heteroC.sub.2-10
alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl,
C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two R.sup.cc
groups attached to an N atom are joined to form a 3-14 membered
heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl,
alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently
substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups, and wherein
R.sup.aa, R.sup.bb, R.sup.cc and R.sup.dd are as defined above.
[0089] In certain embodiments, the substituent present on the
nitrogen atom is an nitrogen protecting group (also referred to
herein as an "amino protecting group"). Nitrogen protecting groups
include, but are not limited to, --OH, --OR.sup.aa,
--N(R.sup.cc).sub.2, --C(.dbd.O)R.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --CO.sub.2R.sup.aa,
--SO.sub.2R.sup.aa, --C(.dbd.NR.sup.cc)R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc, C.sub.1-10 alkyl (e.g.,
aralkyl, heteroaralkyl), C.sub.2-10 alkenyl, C.sub.2-10 alkynyl,
heteroC.sub.1-10 alkyl, heteroC.sub.2-10 alkenyl, heteroC.sub.2-10
alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl,
C.sub.6-14 aryl, and 5-14 membered heteroaryl groups, wherein each
alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups,
and wherein R.sup.aa, R.sup.bb, R.sup.cc and R.sup.dd are as
defined herein. Nitrogen protecting groups are well known in the
art and include those described in detail in Protecting Groups in
Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd
edition, John Wiley & Sons, 1999, incorporated herein by
reference.
[0090] For example, nitrogen protecting groups such as amide groups
(e.g., --C(.dbd.O)R.sup.aa) include, but are not limited to,
formamide, acetamide, chloroacetamide, trichloroacetamide,
trifluoroacetamide, phenylacetamide, 3-phenylpropanamide,
picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl
derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide,
o-nitrophenoxyacetamide, acetoacetamide,
(N'-dithiobenzyloxyacylamino)acetamide,
3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide,
2-methyl-2-(o-nitrophenoxy)propanamide,
2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide,
3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine
derivative, o-nitrobenzamide and o-(benzoyloxymethyl)benzamide.
[0091] Nitrogen protecting groups such as carbamate groups (e.g.,
--C(.dbd.O)OR.sup.aa) include, but are not limited to, methyl
carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc),
9-(2-sulfo)fluorenylmethyl carbamate,
9-(2,7-dibromo)fluoroenylmethyl carbamate,
2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl
carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc),
2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl
carbamate (Teoc), 2-phenylethyl carbamate (hZ),
1-(1-adamantyl)-1-methylethyl carbamate (Adpoc),
1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl
carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate
(TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc),
1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'-
and 4'-pyridyl)ethyl carbamate (Pyoc),
2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate
(BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc),
allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc),
cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc),
8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio
carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz),
p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl
carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl
carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl
carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl
carbamate, 2-(p-toluenesulfonyl)ethyl carbamate,
[2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl
carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc),
2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl
carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate,
m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl
carbamate, 5-benzisoxazolylmethyl carbamate,
2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc),
m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate,
o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate,
phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl
thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate,
cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl
carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl
carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate,
1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate,
1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate,
2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobornyl
carbamate, isobutyl carbamate, isonicotinyl carbamate,
p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl
carbamate, 1-methylcyclohexyl carbamate,
1-methyl-1-cyclopropylmethyl carbamate,
1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate,
1-methyl-1-(p-phenylazophenyl)ethyl carbamate,
1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl
carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate,
2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl
carbamate, and 2,4,6-trimethylbenzyl carbamate.
[0092] Nitrogen protecting groups such as sulfonamide groups (e.g.,
--S(.dbd.O).sub.2R.sup.aa) include, but are not limited to,
p-toluenesulfonamide (Ts), benzenesulfonamide,
2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr),
2,4,6-trimethoxybenzenesulfonamide (Mtb),
2,6-dimethyl-4-methoxybenzenesulfonamide (Pme),
2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte),
4-methoxybenzenesulfonamide (Mbs),
2,4,6-trimethylbenzenesulfonamide (Mts),
2,6-dimethoxy-4-methylbenzenesulfonamide (iMds),
2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc),
methanesulfonamide (Ms), .beta.-trimethylsilylethanesulfonamide
(SES), 9-anthracenesulfonamide,
4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS),
benzylsulfonamide, trifluoromethylsulfonamide, and
phenacylsulfonamide.
[0093] Other nitrogen protecting groups include, but are not
limited to, phenothiazinyl-(10)-acyl derivative,
N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl
derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine
derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide,
N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide,
N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane
adduct (STABASE), 5-substituted
1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted
1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted
3,5-dinitro-4-pyridone, N-methylamine, N-allylamine,
N-[2-(trimethylsilyl)ethoxy]methylamine (SEM),
N-3-acetoxypropylamine,
N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary
ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine,
N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr),
N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr),
N-9-phenylfluorenylamine (PhF),
N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino
(Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethylthiomethyleneamine,
N-benzylideneamine, N-p-methoxybenzylideneamine,
N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine,
N--(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine,
N-p-nitrobenzylideneamine, N-salicylideneamine,
N-5-chlorosalicylideneamine,
N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine,
N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine,
N-borane derivative, N-diphenylborinic acid derivative,
N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper
chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine
N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide
(Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates,
dibenzyl phosphoramidate, diphenyl phosphoramidate,
benzenesulfenamide, o-nitrobenzenesulfenamide (Nps),
2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide,
2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide,
and 3-nitropyridinesulfenamide (Npys).
[0094] In certain embodiments, the substituent present on an oxygen
atom is an oxygen protecting group (also referred to herein as an
"hydroxyl protecting group"). Oxygen protecting groups include, but
are not limited to, --R.sup.aa, --N(R.sup.bb).sub.2,
--C(.dbd.O)SR.sup.aa, --C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3.sup.+X.sup.-,
--P(OR.sup.cc).sub.2, --P(OR.sup.cc).sub.3.sup.+X.sup.-,
--P(.dbd.O)(R.sup.aa).sub.2, --P(.dbd.O)(OR.sup.cc).sub.2, and
--P(.dbd.O)(N(R.sup.bb).sub.2).sub.2, wherein X.sup.-, R.sup.aa,
R.sup.bb, and R.sup.cc are as defined herein. Oxygen protecting
groups are well known in the art and include those described in
detail in Protecting Groups in Organic Synthesis, T. W. Greene and
P. G. M. Wuts, 3.sup.rd edition, John Wiley & Sons, 1999,
incorporated herein by reference.
[0095] Exemplary oxygen protecting groups include, but are not
limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM),
t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM),
benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM),
(4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM),
t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl,
2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl,
bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR),
tetrahydropyranyl (THP), 3-bromotetrahydropyranyl,
tetrahydrothiopyranyl, 1-methoxycyclohexyl,
4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl,
4-methoxytetrahydrothiopyranyl S,S-dioxide,
1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP),
1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl,
2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl,
1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,
1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,
2,2,2-trichloroethyl, 2-trimethylsilylethyl,
2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl,
p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl,
3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl,
2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl,
4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl,
p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl,
.alpha.-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl,
di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl,
4-(4'-bromophenacyloxyphenyl)diphenylmethyl,
4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl,
4,4',4''-tris(levulinoyloxyphenyl)methyl,
4,4',4''-tris(benzoyloxyphenyl)methyl,
3-(imidazol-1-yl)bis(4',4''-dimethoxyphenyl)methyl,
1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl,
9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,
1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido,
trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl
(TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl
(DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS),
t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl,
triphenylsilyl, diphenylmethylsilyl (DPMS),
t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate,
acetate, chloroacetate, dichloroacetate, trichloroacetate,
trifluoroacetate, methoxyacetate, triphenylmethoxyacetate,
phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate,
4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate
(levulinoyldithioacetal), pivaloate, adamantoate, crotonate,
4-methoxycrotonate, benzoate, p-phenylbenzoate,
2,4,6-trimethylbenzoate (mesitoate), methyl carbonate,
9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate,
2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl
carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec),
2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate,
vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC or Boc),
p-nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl
carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate,
p-nitrobenzyl carbonate, S-benzyl thiocarbonate,
4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate,
2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate,
o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate,
2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate,
2-(methylthiomethoxymethyl)benzoate,
2,6-dichloro-4-methylphenoxyacetate,
2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,
2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,
isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate,
o-(methoxyacyl)benzoate, .alpha.-naphthoate, nitrate, alkyl
N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate,
borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate,
sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate
(Ts).
[0096] In certain embodiments, the substituent present on a sulfur
atom is a sulfur protecting group (also referred to as a "thiol
protecting group"). Sulfur protecting groups include, but are not
limited to, --R.sup.aa, --N(R.sup.bb).sub.2, --C(.dbd.O)SR.sup.aa,
--C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3.sup.+X.sup.-,
--P(OR.sup.cc).sub.2, --P(OR.sup.cc).sub.3.sup.+X.sup.-,
--P(.dbd.O)(R.sup.aa).sub.2, --P(.dbd.O)(OR.sup.cc).sub.2, and
--P(.dbd.O)(N(R.sup.bb).sub.2).sub.2, wherein R.sup.aa, R.sup.bb,
and R.sup.cc are as defined herein. Sulfur protecting groups are
well known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0097] The term "halo" or "halogen" refers to fluorine (fluoro,
--F), chlorine (chloro, --Cl), bromine (bromo, --Br), or iodine
(iodo, --I).
[0098] The term "hydroxyl" or "hydroxy" refers to the group
--OH.
[0099] The term "thiol" or "thio" refers to the group --SH.
[0100] The term "amine" or "amino" refers to the group --NH-- or
--NH.sub.2.
[0101] The term "acyl" refers to a group having the general formula
--C(.dbd.O)R.sup.X1, --C(.dbd.O)OR.sup.X1,
--C(.dbd.O)--O--C(.dbd.O)R.sup.X1, --C(.dbd.O)SR.sup.X1,
--C(.dbd.O)N(R.sup.X1).sub.2, --C(.dbd.S)R.sup.X1,
--C(.dbd.S)N(R.sup.X1).sub.2, and --C(.dbd.S)S(R.sup.X1),
--C(.dbd.NR.sup.X1)R.sup.X1, --C(.dbd.NR.sup.X1)OR.sup.X1,
--C(.dbd.NR.sup.X1)SR.sup.X1, and
--C(.dbd.NR.sup.X1)N(R.sup.X1).sub.2, wherein R.sup.X1 is hydrogen;
halogen; substituted or unsubstituted hydroxyl; substituted or
unsubstituted thiol; substituted or unsubstituted amino;
substituted or unsubstituted acyl, cyclic or acyclic, substituted
or unsubstituted, branched or unbranched aliphatic; cyclic or
acyclic, substituted or unsubstituted, branched or unbranched
heteroaliphatic; cyclic or acyclic, substituted or unsubstituted,
branched or unbranched alkyl; cyclic or acyclic, substituted or
unsubstituted, branched or unbranched alkenyl; substituted or
unsubstituted alkynyl; substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, aliphaticoxy,
heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy,
heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy,
heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or
di-aliphaticamino, mono- or di-heteroaliphaticamino, mono- or
di-alkylamino, mono- or di-heteroalkylamino, mono- or di-arylamino,
or mono- or di-heteroarylamino; or two R.sup.X1 groups taken
together form a 5- to 6-membered heterocyclic ring. Exemplary acyl
groups include aldehydes (--CHO), carboxylic acids (--CO.sub.2H),
ketones, acyl halides, esters, amides, imines, carbonates,
carbamates, and ureas. Acyl substituents include, but are not
limited to, any of the substituents described herein, that result
in the formation of a stable moiety (e.g., aliphatic, alkyl,
alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl,
acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro,
hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino,
alkylamino, heteroalkylamino, arylamino, heteroarylamino,
alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy,
heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy,
heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy,
heteroarylthioxy, acyloxy, and the like, each of which may or may
not be further substituted).
[0102] The term "polymer" refers to a molecule including two or
more (e.g., 3 or more, 4 or more, 5 or more, 10 or more) repeating
units which are covalently bound together. In certain embodiments,
a polymer comprises 3 or more, 5 or more, 10 or more, 20 or more,
50 or more, 100 or more, 500 or more, 1000 or more, 2000 or more,
3000 or more, 4000 or more, 5000 or more, 6000 or more, 7000 or
more, 8000 or more, 9000 or more, or 10000 or more repeating units.
In certain embodiments, a polymer comprises more than 5000
repeating units. The repeating units of a polymer are referred to
as "monomers." A "homopolymer" is a polymer that consists of a
single repeating monomer. A "copolymer" is a polymer that comprises
two or more different monomer subunits. Copolymers include, but are
not limited to, random, block, alternating, segmented, linear,
branched, grafted, and tapered copolymers. A "graft polymer" is a
segmented copolymer with a linear backbone of one composite and
randomly distributed branches of another composite. The major
difference between graft polymers and bottlebrush polymers (or
brush-arm polymers) is the grafting density. The targeted graft
density for bottlebrush polymers is that in at least one segment of
the copolymer is one graft from each backbone monomer unit. A "star
polymer" is a polymer that consists of several polymers chains
connected at a core atom, core molecule, or core polymer. Polymers
may be natural (such as biopolymers like naturally occurring
polypeptides), or synthetic (e.g., non-naturally occurring). A
polymer may have an overall molecular weight of 500 g/mol or
greater, 1 Da or greater, 5 Da or greater, 10 Da or greater, 50 Da
or greater, 100 Da or greater, 500 Da or greater, 1000 Da or
greater, 2000 Da or greater, 5000 Da or greater, 10000 Da or
greater, 20000 Da or greater, or 50000 Da or greater.
[0103] The terms "living polymer" and "living polymerization" refer
a polymerization where the ability of a growing polymer chain to
terminate has been removed. Chain termination and chain transfer
reactions are absent, and the rate of the chain initiation is also
much larger than the rate of chain propagation.
[0104] The term "average molecular weight" may encompass the number
average molecular weight (M.sub.n), weight average molecular weight
(M.sub.w), higher average molecular weight (M.sub.z or M.sub.z+1),
GPC/SEC (gel permeation chromatography/size-exclusion
chromatography)-determined average molecular weight (M.sub.p), and
viscosity average molecular weight (M.sub.v).
[0105] The terms "number average molecular weight," "number average
molar mass," and "M.sub.n" are measurements of the molecular mass
of a polymer. The number average molecular mass is the ordinary
arithmetic mean or average of the molecular masses of the
individual polymers. It is determined by measuring the molecular
mass of n polymer molecules, summing the masses, and dividing by n.
For example, a polymer having 100 repeating units of a monomer with
a molecular weight of 100 g/mol would have a number average
molecular weight (M.sub.n) of 10,000 g/mol [M.sub.n=(100)*(100
g/mol)/(1)=10,000 g/mol)]. The number average molecular mass of a
polymer can be determined by gel permeation chromatography,
viscometry via the Mark-Houwink equation, colligative methods such
as vapor pressure osmometry, end-group determination, or .sup.1H
NMR (nuclear magnetic resonance).
[0106] The term "monomer" refers to a molecule that may be
covalently joined to other monomers to form a polymer. The process
by which the monomers are combined to form a polymer is called
polymerization. A macromolecule with a reactive moiety that enables
it to act as a monomer is called a macromonomer. Molecules made of
a small number of monomer units (up to a few dozen) are called
oligomers.
[0107] The term "average hydrodynamic diameter" (D.sub.H) as used
herein refers to the average size of a polymer or particle. The
average hydrodynamic diameter may or may not encompass the
solvation layers of polymer or particle, and may be determined
through a number of methods including dynamic light scattering,
electron microscopy (e.g., scanning electron microscopy,
transmission electron microscopy), atomic force microscopy, and
X-ray diffraction.
[0108] The term "average polydispersity" (PDI) as used herein
refers to a measure of the distribution of molecular size in a
mixture, e.g., as determined by a chromatographic method, such as
gel permeation chromatography or size exclusion chromatography, or
through dynamic light scattering.
[0109] As used herein, the term "polyethylene glycol" or "PEG"
refers to an ethylene glycol polymer that contains about 20 to
about 2,000,000 linked monomers, typically about 50-1,000 linked
monomers, usually about 100-300. Polyethylene glycols include
ethylene glycol polymer containing various numbers of linked
monomers, e.g., PEG20, PEG30, PEG40, PEG60, PEG80, PEG100, PEG115,
PEG200, PEG300, PEG400, PEG500, PEG600, PEG1000, PEG1500, PEG2000,
PEG3350, PEG4000, PEG4600, PEG5000, PEG6000, PEG8000, PEG11000,
PEG12000, PEG2000000, and any mixtures thereof.
[0110] The term "salt" refers to ionic compounds that result from
the neutralization reaction of an acid and a base. A salt is
composed of one or more cations (positively charged ions) and one
or more anions (negative ions) so that the salt is electrically
neutral (without a net charge). Salts of the compounds of this
disclosure include those derived from inorganic and organic acids
and bases. Examples of acid addition salts are salts of an amino
group formed with inorganic acids such as hydrochloric acid,
hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric
acid, or with organic acids such as acetic acid, oxalic acid,
maleic acid, tartaric acid, citric acid, succinic acid, or malonic
acid or by using other methods known in the art such as ion
exchange. Other salts include adipate, alginate, ascorbate,
aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate,
camphorate, camphorsulfonate, citrate, cyclopentanepropionate,
digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,
glucoheptonate, glycerophosphate, gluconate, hemisulfate,
heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate,
lactobionate, lactate, laurate, lauryl sulfate, malate, maleate,
malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate,
nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
persulfate, 3-phenylpropionate, phosphate, picrate, pivalate,
propionate, stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4 alkyl).sub.4 salts.
Representative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like. Further salts
include ammonium, quaternary ammonium, and amine cations formed
using counterions such as halide, hydroxide, carboxylate, sulfate,
phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0111] The term "pharmaceutically acceptable salt" refers to those
salts which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response, and
the like, and are commensurate with a reasonable benefit/risk
ratio. Pharmaceutically acceptable salts are well known in the art.
For example, Berge et al. describe pharmaceutically acceptable
salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19,
incorporated herein by reference. Pharmaceutically acceptable salts
of the compounds of this disclosure include those derived from
suitable inorganic and organic acids and bases. Examples of
pharmaceutically acceptable, nontoxic acid addition salts are salts
of an amino group formed with inorganic acids, such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid, and
perchloric acid or with organic acids, such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid, or
malonic acid or by using other methods known in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium, and N.sup.+(C.sub.1-4 alkyl).sub.4.sup.-
salts. Representative alkali or alkaline earth metal salts include
sodium, lithium, potassium, calcium, magnesium, and the like.
Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate,
and aryl sulfonate.
[0112] The term "leaving group" is given its ordinary meaning in
the art of synthetic organic chemistry and refers to an atom or a
group capable of being displaced by a nucleophile. Examples of
suitable leaving groups include halogen (such as F, Cl, Br, or I
(iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy,
alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g.,
acetoxy), arylcarbonyloxy, aryloxy, methoxy,
N,O-dimethylhydroxylamino, pixyl, and haloformates. In some cases,
the leaving group is a sulfonic acid ester, such as
toluenesulfonate (tosylate, --OTs), methanesulfonate (mesylate,
--OMs), p-bromobenzenesulfonyloxy (brosylate, --OBs),
--OS(.dbd.O).sub.2(CF.sub.2).sub.3CF.sub.3 (nonaflate, --ONf), or
trifluoromethanesulfonate (triflate, --OTf). In some cases, the
leaving group is a brosylate, such as p-bromobenzenesulfonyloxy. In
some cases, the leaving group is a nosylate, such as
2-nitrobenzenesulfonyloxy. In some embodiments, the leaving group
is a sulfonate-containing group. In some embodiments, the leaving
group is a tosylate group. The leaving group may also be a
phosphineoxide (e.g., formed during a Mitsunobu reaction) or an
internal leaving group such as an epoxide or cyclic sulfate. Other
examples of leaving groups are water, ammonia, alcohols, ether
moieties, thioether moieties, zinc halides, magnesium moieties,
diazonium salts, and copper moieties.
[0113] The term "solvent" refers to a substance that dissolves one
or more solutes, resulting in a solution. A solvent may serve as a
medium for any reaction or transformation described herein. The
solvent may dissolve one or more reactants or reagents in a
reaction mixture. The solvent may facilitate the mixing of one or
more reagents or reactants in a reaction mixture. The solvent may
also serve to increase or decrease the rate of a reaction relative
to the reaction in a different solvent. Solvents can be polar or
non-polar, protic or aprotic. Common solvents useful in the methods
described herein include, but are not limited to, acetone,
acetonitrile, benzene, benzonitrile, 1-butanol, 2-butanone, butyl
acetate, tert-butyl methyl ether, carbon disulfide carbon
tetrachloride, chlorobenzene, 1-chlorobutane, chloroform,
cyclohexane, cyclopentane, 1,2-dichlorobenzene, 1,2-dichloroethane,
dichloromethane (DCM), N,N-dimethylacetamide N,N-dimethylformamide
(DMF), 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (DMPU),
1,4-dioxane, 1,3-dioxane, diethylether, 2-ethoxyethyl ether, ethyl
acetate, ethyl alcohol, ethylene glycol, dimethyl ether, heptane,
n-hexane, hexanes, hexamethylphosphoramide (HMPA),
2-methoxyethanol, 2-methoxyethyl acetate, methyl alcohol,
2-methylbutane, 4-methyl-2-pentanone, 2-methyl-1-propanol,
2-methyl-2-propanol, 1-methyl-2-pyrrolidinone, dimethylsulfoxide
(DMSO), nitromethane, 1-octanol, pentane, 3-pentanone, 1-propanol,
2-propanol, pyridine, tetrachloroethylene, tetrahyrdofuran (THF),
2-methyltetrahydrofuran, toluene, trichlorobenzene,
1,1,2-trichlorotrifluoroethane, 2,2,4-trimethylpentane,
trimethylamine, triethylamine, N,N-diisopropylethylamine,
diisopropylamine, water, o-xylene, and p-xylene.
[0114] As used herein, the term "agent" means a molecule, group of
molecules, complex or substance administered to an organism for
diagnostic, therapeutic, preventative medical, or veterinary
purposes. In certain embodiments, the agent is a pharmaceutical
agent (e.g., a therapeutic agent, a diagnostic agent, or a
prophylactic agent). In certain embodiments, the compositions
disclosed herein comprise an agent(s), e.g., a first therapeutic
agent (e.g., at least one (including, e.g., at least two, at least
three). In some embodiments, the compositions (e.g., macromonomers,
conjugates, or particles) can further comprise a second therapeutic
agent, a targeting moiety, a diagnostic moiety as described
herein.
[0115] As used herein, the term "therapeutic agent" includes an
agent that is capable of providing a local or systemic biological,
physiological, or therapeutic effect in the biological system to
which it is applied. For example, a therapeutic agent can act to
control tumor growth, control infection or inflammation, act as an
analgesic, promote anti-cell attachment, and enhance bone growth,
among other functions. Other suitable therapeutic agents can
include anti-viral agents, hormones, antibodies, or therapeutic
proteins. Other therapeutic agents include prodrugs, which are
agents that are not biologically active when administered but, upon
administration to a subject are converted into biologically active
agents through metabolism or some other mechanism.
[0116] An agent (e.g., a therapeutic agent) can include a wide
variety of different compounds, including chemical compounds and
mixtures of chemical compounds (e.g., small organic or inorganic
molecules) such as drug compounds (e.g., compounds approved for
human or veterinary use by the U.S. Food and Drug Administration as
provided in the Code of Federal Regulations (CFR)); targeting
agents; isotopically labeled chemical compounds; carbohydrates;
saccharines; monosaccharides; oligosaccharides; polysaccharides;
biological macromolecules (e.g., peptides, proteins, and peptide
analogs and derivatives); peptidomimetics; antibodies and antigen
binding fragments thereof; nucleic acids (e.g., DNA or RNA);
nucleotides; nucleosides; oligonucleotides; antisense
oligonucleotides; polynucleotides; nucleic acid analogs and
derivatives; nucleoproteins; mucoproteins; lipoproteins; synthetic
polypeptides or proteins; small molecules linked to proteins;
glycoproteins; steroids; lipids; hormones; vitamins; vaccines;
immunological agents; an extract made from biological materials
such as bacteria, plants, fungi, or animal cells; animal tissues;
naturally occurring or synthetic compositions; and any combinations
thereof.
[0117] In some embodiments, the agent is in the form of a prodrug.
The term "prodrug" refer to a compound that becomes active, e.g.,
by solvolysis, reduction, oxidation, or under physiological
conditions, to provide a pharmaceutically active compound, e.g., in
vivo. A prodrug can include a derivative of a pharmaceutically
active compound, such as, for example, to form an ester by reaction
of the acid, or acid anhydride, or mixed anhydrides moieties of the
prodrug moiety with the hydroxyl moiety of the pharmaceutical
active compound, or to form an amide prepared by the acid, or acid
anhydride, or mixed anhydrides moieties of the prodrug moiety with
a substituted or unsubstituted amine of the pharmaceutically active
compound. Simple aliphatic or aromatic esters, amides, and
anhydrides derived from acidic groups may comprise prodrugs. In
some embodiments, the conjugate or particle described herein
incorporates one therapeutic agent or prodrug thereof. In some
embodiments, the conjugate or particle described herein
incorporates more than one therapeutic agents or prodrugs.
[0118] In some embodiments, the agent (e.g., a therapeutic agent)
is a small molecule. As used herein, the term "small molecule" can
refer to compounds that are "natural product-like." However, the
term "small molecule" is not limited to "natural product-like"
compounds. Rather, a small molecule is typically characterized in
that it contains several carbon-carbon bonds, and has a molecular
weight of less than 5000 Daltons (5 kDa), preferably less than 3
kDa, still more preferably less than 2 kDa, and most preferably
less than 1 kDa. In some cases it is preferred that a small
molecule have a molecular weight equal to or less than 700
Daltons.
[0119] Exemplary agents (e.g., a therapeutic agents) in the
compositions include, but are not limited to, those found in
Harrison's Principles of Internal Medicine, 13th Edition, Eds. T.
R. Harrison et al. McGraw-Hill N.Y., NY; Physicians' Desk
Reference, 50th Edition, 1997, Oradell N.J., Medical Economics Co.;
Pharmacological Basis of Therapeutics, 8th Edition, Goodman and
Gilman, 1990; United States Pharmacopeia, The National Formulary,
USP XII NF XVII, 1990; current edition of Goodman and Gilman's The
Pharmacological Basis of Therapeutics; and current edition of The
Merck Index, the complete contents of all of which are incorporated
herein by reference.
[0120] Agents, e.g., therapeutic agents, include the herein
disclosed categories and specific examples. It is not intended that
the category be limited by the specific examples. Those of ordinary
skill in the art will recognize also numerous other compounds that
fall within the categories and that are useful according to the
present disclosure.
[0121] Examples of therapeutic agents include, but are not limited
to, antimicrobial agents, analgesics, antiinflammatory agents,
counterirritants, coagulation modifying agents, diuretics,
sympathomimetics, anorexics, antacids and other gastrointestinal
agents; antiparasitics, antidepressants, anti-hypertensives,
anticholinergics, stimulants, antihormones, central and respiratory
stimulants, drug antagonists, lipid-regulating agents, uricosurics,
cardiac glycosides, electrolytes, ergot and derivatives thereof,
expectorants, hypnotics and sedatives, antidiabetic agents,
dopaminergic agents, antiemetics, muscle relaxants,
para-sympathomimetics, anticonvulsants, antihistamines,
beta-blockers, purgatives, antiarrhythmics, contrast materials,
radiopharmaceuticals, antiallergic agents, tranquilizers,
vasodilators, antiviral agents, and antineoplastic or cytostatic
agents or other agents with anti-cancer properties, or a
combination thereof. Other suitable therapeutic agents include
contraceptives and vitamins as well as micro- and macronutrients.
Still other examples include antiinfectives such as antibiotics and
antiviral agents; analgesics and analgesic combinations; anorexics;
antiheimintics; antiarthritics; antiasthmatic agents;
anticonvulsants; antidepressants; antidiuretic agents;
antidiarrleals; antihistamines; antiinflammatory agents;
antimigraine preparations; antinauseants; antineoplastics;
antiparkinsonism drugs; antipruritics; antipsychotics;
antipyretics, antispasmodics; anticholinergics; sympathomimetics;
xanthine derivatives; cardiovascular preparations including calcium
channel blockers and beta-blockers such as pindolol and
antiarrhythmics; anti-hypertensives; diuretics; vasodilators
including general coronary, peripheral and cerebral; central
nervous system stimulants; cough and cold preparations, including
decongestants; hormones such as estradiol and other steroids,
including corticosteroids; hypnotics; immunosuppressives; muscle
relaxants; parasympatholytics; psychostimulants; sedatives; and
tranquilizers; and naturally derived or genetically engineered
proteins, polysaccharides, glycoproteins, or lipoproteins.
[0122] In certain instances, the diagnostic agent is an imaging
agent or contrast agent. The terms "imaging agent" and "contrast
agent" refer to a substance used to enhance the contrast of
structures or fluids within the body in medical imaging. It is
commonly used to enhance the visibility of blood vessels and the
gastrointestinal tract in medical imaging.
[0123] The terms "composition" and "formulation" are used
interchangeably.
[0124] A "subject" to which administration is contemplated refers
to a human (i.e., male or female of any age group, e.g., pediatric
subject (e.g., infant, child, or adolescent) or adult subject
(e.g., young adult, middle-aged adult, or senior adult)) or
non-human animal. In certain embodiments, the non-human animal is a
mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey),
commercially relevant mammal (e.g., cattle, pig, horse, sheep,
goat, cat, or dog), or bird (e.g., commercially relevant bird, such
as chicken, duck, goose, or turkey)). In certain embodiments, the
non-human animal is a fish, reptile, or amphibian. The non-human
animal may be a male or female at any stage of development. The
non-human animal may be a transgenic animal or genetically
engineered animal.
[0125] The term "administer," "administering," or "administration"
refers to implanting, absorbing, ingesting, injecting, inhaling, or
otherwise introducing a compound described herein, or a composition
thereof, in or on a subject.
[0126] The terms "treatment," "treat," and "treating" refer to
reversing, alleviating, delaying the onset of, or inhibiting the
progress of a disease described herein. In some embodiments,
treatment may be administered after one or more signs or symptoms
of the disease have developed or have been observed. In other
embodiments, treatment may be administered in the absence of signs
or symptoms of the disease. For example, treatment may be
administered to a susceptible subject prior to the onset of
symptoms (e.g., in light of a history of symptoms and/or in light
of exposure to a pathogen). Treatment may also be continued after
symptoms have resolved, for example, to delay and/or prevent
recurrence.
[0127] The term "prevent," "preventing," or "prevention" refers to
a prophylactic treatment of a subject who is not and was not with a
disease but is at risk of developing the disease or who was with a
disease, is not with the disease, but is at risk of regression of
the disease. In certain embodiments, the subject is at a higher
risk of developing the disease or at a higher risk of regression of
the disease than an average healthy member of a population of
subjects.
[0128] The terms "condition," "disease," and "disorder" are used
interchangeably.
[0129] The term "genetic disease" refers to a disease caused by one
or more abnormalities in the genome of a subject, such as a disease
that is present from birth of the subject. Genetic diseases may be
heritable and may be passed down from the parents' genes. A genetic
disease may also be caused by mutations or changes of the DNAs
and/or RNAs of the subject. In such cases, the genetic disease will
be heritable if it occurs in the germline. Exemplary genetic
diseases include, but are not limited to, Aarskog-Scott syndrome,
Aase syndrome, achondroplasia, acrodysostosis, addiction,
adreno-leukodystrophy, albinism, ablepharon-macrostomia syndrome,
alagille syndrome, alkaptonuria, alpha-1 antitrypsin deficiency,
Alport's syndrome, Alzheimer's disease, asthma, autoimmune
polyglandular syndrome, androgen insensitivity syndrome, Angelman
syndrome, ataxia, ataxia telangiectasia, atherosclerosis, attention
deficit hyperactivity disorder (ADHD), autism, baldness, Batten
disease, Beckwith-Wiedemann syndrome, Best disease, bipolar
disorder, brachydactyl), breast cancer, Burkitt lymphoma, chronic
myeloid leukemia, Charcot-Marie-Tooth disease, Crohn's disease,
cleft lip, Cockayne syndrome, Coffin Lowry syndrome, colon cancer,
congenital adrenal hyperplasia, Cornelia de Lange syndrome,
Costello syndrome, Cowden syndrome, craniofrontonasal dysplasia,
Crigler-Najjar syndrome, Creutzfeldt-Jakob disease, cystic
fibrosis, deafness, depression, diabetes, diastrophic dysplasia,
DiGeorge syndrome, Down's syndrome, dyslexia, Duchenne muscular
dystrophy, Dubowitz syndrome, ectodermal dysplasia Ellis-van
Creveld syndrome, Ehlers-Danlos, epidermolysis bullosa, epilepsy,
essential tremor, familial hypercholesterolemia, familial
Mediterranean fever, fragile X syndrome, Friedreich's ataxia,
Gaucher disease, glaucoma, glucose galactose malabsorption,
glutaricaciduria, gyrate atrophy, Goldberg Shprintzen syndrome
(velocardiofacial syndrome), Gorlin syndrome, Hailey-Hailey
disease, hemihypertrophy, hemochromatosis, hemophilia, hereditary
motor and sensory neuropathy (HMSN), hereditary non polyposis
colorectal cancer (HNPCC), Huntington's disease, immunodeficiency
with hyper-IgM, juvenile onset diabetes, Klinefelter's syndrome,
Kabuki syndrome, Leigh's disease, long QT syndrome, lung cancer,
malignant melanoma, manic depression, Marfan syndrome, Menkes
syndrome, miscarriage, mucopolysaccharide disease, multiple
endocrine neoplasia, multiple sclerosis, muscular dystrophy,
myotrophic lateral sclerosis, myotonic dystrophy,
neurofibromatosis, Niemann-Pick disease, Noonan syndrome, obesity,
ovarian cancer, pancreatic cancer, Parkinson's disease, paroxysmal
nocturnal hemoglobinuria, Pendred syndrome, peroneal muscular
atrophy, phenylketonuria (PKU), polycystic kidney disease,
Prader-Willi syndrome, primary biliary cirrhosis, prostate cancer,
REAR syndrome, Refsum disease, retinitis pigmentosa,
retinoblastoma, Rett syndrome, Sanfilippo syndrome, schizophrenia,
severe combined immunodeficiency, sickle cell anemia, spina bifida,
spinal muscular atrophy, spinocerebellar atrophy, sudden adult
death syndrome, Tangier disease, Tay-Sachs disease,
thrombocytopenia absent radius syndrome, Townes-Brocks syndrome,
tuberous sclerosis, Turner syndrome, Usher syndrome, von
Hippel-Lindau syndrome, Waardenburg syndrome, Weaver syndrome,
Werner syndrome, Williams syndrome, Wilson's disease, xeroderma
piginentosum, and Zellweger syndrome.
[0130] A "proliferative disorder" refers to a condition that occurs
due to abnormal growth or extension by the multiplication of cells
(Walker, Cambridge Dictionary of Biology; Cambridge University
Press: Cambridge, UK, 1990). A proliferative disease may be
associated with: 1) the pathological proliferation of normally
quiescent cells; 2) the pathological migration of cells from their
normal location (e.g., metastasis of neoplastic cells); 3) the
pathological expression of proteolytic enzymes such as the matrix
metalloproteinases (e.g., collagenases, gelatinases, and
elastases); or 4) the pathological angiogenesis as in proliferative
retinopathy and tumor metastasis. Exemplary proliferative disorders
include cancers (i.e., "malignant neoplasms"), benign neoplasms,
angiogenesis, inflammatory diseases, and autoimmune diseases.
[0131] The term "angiogenesis" refers to the physiological process
through which new blood vessels form from pre-existing vessels.
Angiogenesis is distinct from vasculogenesis, which is the de novo
formation of endothelial cells from mesoderm cell precursors. The
first vessels in a developing embryo form through vasculogenesis,
after which angiogenesis is responsible for most blood vessel
growth during normal or abnormal development. Angiogenesis is a
vital process in growth and development, as well as in wound
healing and in the formation of granulation tissue. However,
angiogenesis is also a fundamental step in the transition of tumors
from a benign state to a malignant one, leading to the use of
angiogenesis inhibitors in the treatment of cancer. Angiogenesis
may be chemically stimulated by angiogenic proteins, such as growth
factors (e.g., VEGF). "Pathological angiogenesis" refers to
abnormal (e.g., excessive or insufficient) angiogenesis that
amounts to and/or is associated with a disease.
[0132] The terms "neoplasm" and "tumor" are used herein
interchangeably and refer to an abnormal mass of tissue wherein the
growth of the mass surpasses and is not coordinated with the growth
of a normal tissue. A neoplasm or tumor may be "benign" or
"malignant," depending on the following characteristics: degree of
cellular differentiation (including morphology and functionality),
rate of growth, local invasion, and metastasis. A "benign neoplasm"
is generally well differentiated, has characteristically slower
growth than a malignant neoplasm, and remains localized to the site
of origin. In addition, a benign neoplasm does not have the
capacity to infiltrate, invade, or metastasize to distant sites.
Exemplary benign neoplasms include, but are not limited to, lipoma,
chondroma, adenomas, acrochordon, senile angiomas, seborrheic
keratoses, lentigos, and sebaceous hyperplasias. In some cases,
certain "benign" tumors may later give rise to malignant neoplasms,
which may result from additional genetic changes in a subpopulation
of the tumor's neoplastic cells, and these tumors are referred to
as "pre-malignant neoplasms." An exemplary pre-malignant neoplasm
is a teratoma. In contrast, a "malignant neoplasm" is generally
poorly differentiated (anaplasia) and has characteristically rapid
growth accompanied by progressive infiltration, invasion, and
destruction of the surrounding tissue. Furthermore, a malignant
neoplasm generally has the capacity to metastasize to distant
sites. The term "metastasis," "metastatic," or "metastasize" refers
to the spread or migration of cancerous cells from a primary or
original tumor to another organ or tissue and is typically
identifiable by the presence of a "secondary tumor" or "secondary
cell mass" of the tissue type of the primary or original tumor and
not of that of the organ or tissue in which the secondary
(metastatic) tumor is located. For example, a prostate cancer that
has migrated to bone is said to be metastasized prostate cancer and
includes cancerous prostate cancer cells growing in bone
tissue.
[0133] The term "cancer" refers to a class of diseases
characterized by the development of abnormal cells that proliferate
uncontrollably and have the ability to infiltrate and destroy
normal body tissues. See, e.g., Stedman's Medical Dictionary, 25th
ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990.
Exemplary cancers include, but are not limited to, acoustic
neuroma; adenocarcinoma; adrenal gland cancer; anal cancer;
angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma,
hemangiosarcoma); appendix cancer; benign monoclonal gammopathy;
biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast
cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of
the breast, mammary cancer, medullary carcinoma of the breast);
brain cancer (e.g., meningioma, glioblastomas, glioma (e.g.,
astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer;
carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma);
choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer
(e.g., colon cancer, rectal cancer, colorectal adenocarcinoma);
connective tissue cancer; epithelial carcinoma; ependymoma;
endotheliosarcoma (e.g., Kaposi's sarcoma, multiple idiopathic
hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer,
uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the
esophagus, Barrett's adenocarcinoma); Ewing's sarcoma; ocular
cancer (e.g., intraocular melanoma, retinoblastoma); familiar
hypereosinophilia; gall bladder cancer; gastric cancer (e.g.,
stomach adenocarcinoma); gastrointestinal stromal tumor (GIST);
germ cell cancer; head and neck cancer (e.g., head and neck
squamous cell carcinoma, oral cancer (e.g., oral squamous cell
carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal
cancer, nasopharyngeal cancer, oropharyngeal cancer));
hematopoietic cancers (e.g., leukemia such as acute lymphocytic
leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic
leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic
leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic
lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL));
lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL)
and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse
large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma),
follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone
B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT)
lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal
zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt
lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenstrom's
macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large
cell lymphoma, precursor B-lymphoblastic lymphoma and primary
central nervous system (CNS) lymphoma; and T-cell NHL such as
precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell
lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g.,
mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell
lymphoma, extranodal natural killer T-cell lymphoma, enteropathy
type T-cell lymphoma, subcutaneous panniculitis-like T-cell
lymphoma, and anaplastic large cell lymphoma); a mixture of one or
more leukemia/lymphoma as described above; and multiple myeloma
(MM)), heavy chain disease (e.g., alpha chain disease, gamma chain
disease, mu chain disease); hemangioblastoma; hypopharynx cancer;
inflammatory myofibroblastic tumors; immunocytic amyloidosis;
kidney cancer (e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell
carcinoma); liver cancer (e.g., hepatocellular cancer (HCC),
malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma,
small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC),
adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis
(e.g., systemic mastocytosis); muscle cancer; myelodysplastic
syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD)
(e.g., polycythemia vera (PV), essential thrombocytosis (ET),
agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF),
chronic idiopathic myelofibrosis, chronic myelocytic leukemia
(CML), chronic neutrophilic leukemia (CNL), hypereosinophilic
syndrome (HES)); neuroblastoma; neurofibroma (e.g.,
neurofibromatosis (NF) type 1 or type 2, schwannomatosis);
neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine
tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g., bone
cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian
embryonal carcinoma, ovarian adenocarcinoma); papillary
adenocarcinoma; pancreatic cancer (e.g., pancreatic
andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN),
Islet cell tumors); penile cancer (e.g., Paget's disease of the
penis and scrotum); pinealoma; primitive neuroectodermal tumor
(PNT); plasma cell neoplasia; paraneoplastic syndromes;
intraepithelial neoplasms; prostate cancer (e.g., prostate
adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland
cancer; skin cancer (e.g., squamous cell carcinoma (SCC),
keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small
bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g.,
malignant fibrous histiocytoma (MFH), liposarcoma, malignant
peripheral nerve sheath tumor (MPNST), chondrosarcoma,
fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small
intestine cancer; sweat gland carcinoma; synovioma; testicular
cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid
cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid
carcinoma (PTC), medullary thyroid cancer); urethral cancer;
vaginal cancer; and vulvar cancer (e.g., Paget's disease of the
vulva).
[0134] The term "inflammatory disease" refers to a disease caused
by, resulting from, or resulting in inflammation. The term
"inflammatory disease" may also refer to a dysregulated
inflammatory reaction that causes an exaggerated response by
macrophages, granulocytes, and/or T-lymphocytes leading to abnormal
tissue damage and/or cell death. An inflammatory disease can be
either an acute or chronic inflammatory condition and can result
from infections or non-infectious causes. Inflammatory diseases
include, without limitation, atherosclerosis, arteriosclerosis,
autoimmune disorders, multiple sclerosis, systemic lupus
erythematosus, polymyalgia rheumatica (PMR), gouty arthritis,
degenerative arthritis, tendonitis, bursitis, psoriasis, cystic
fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory
arthritis, Sjogren's syndrome, giant cell arteritis, progressive
systemic sclerosis (scleroderma), ankylosing spondylitis,
polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes
(e.g., Type I), myasthenia gravis, Hashimoto's thyroiditis, Graves'
disease, Goodpasture's disease, mixed connective tissue disease,
sclerosing cholangitis, inflammatory bowel disease, Crohn's
disease, ulcerative colitis, pernicious anemia, inflammatory
dermatoses, usual interstitial pneumonitis (UIP), asbestosis,
silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis,
sarcoidosis, desquamative interstitial pneumonia, lymphoid
interstitial pneumonia, giant cell interstitial pneumonia, cellular
interstitial pneumonia, extrinsic allergic alveolitis, Wegener's
granulomatosis and related forms of angiitis (temporal arteritis
and polyarteritis nodosa), inflammatory dermatoses, hepatitis,
delayed-type hypersensitivity reactions (e.g., poison ivy
dermatitis), pneumonia, respiratory tract inflammation, Adult
Respiratory Distress Syndrome (ARDS), encephalitis, immediate
hypersensitivity reactions, asthma, hayfever, allergies, acute
anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis,
cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic
injury), reperfusion injury, allograft rejection, host-versus-graft
rejection, appendicitis, arteritis, blepharitis, bronchiolitis,
bronchitis, cervicitis, cholangitis, chorioamnionitis,
conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis,
endometritis, enteritis, enterocolitis, epicondylitis,
epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis,
gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis,
nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis,
pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis,
phlebitis, pneumonitis, proctitis, prostatitis, rhinitis,
salpingitis, sinusitis, stomatitis, synovitis, testitis,
tonsillitis, urethritis, urocystitis, uveitis, vaginitis,
vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis,
osteomyelitis, optic neuritis, temporal arteritis, transverse
myelitis, necrotizing fasciitis, and necrotizing enterocolitis. An
ocular inflammatory disease includes, but is not limited to,
post-surgical inflammation.
[0135] An "autoimmune disease" refers to a disease arising from an
inappropriate immune response of the body of a subject against
substances and tissues normally present in the body. In other
words, the immune system mistakes some part of the body as a
pathogen and attacks its own cells. This may be restricted to
certain organs (e.g., in autoimmune thyroiditis) or involve a
particular tissue in different places (e.g., Goodpasture's disease
which may affect the basement membrane in both the lung and
kidney). The treatment of autoimmune diseases is typically with
immunosuppression, e.g., medications which decrease the immune
response. Exemplary autoimmune diseases include, but are not
limited to, glomerulonephritis, Goodpasture's syndrome, necrotizing
vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus
erythematosis, rheumatoid arthritis, psoriatic arthritis, systemic
lupus erythematosis, psoriasis, ulcerative colitis, systemic
sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody
syndrome, scleroderma, pemphigus vulgaris, ANCA-associated
vasculitis (e.g., Wegener's granulomatosis, microscopic
polyangiitis), uveitis, Sjogren's syndrome, Crohn's disease,
Reiter's syndrome, ankylosing spondylitis, Lyme disease,
Guillain-Barre syndrome, Hashimoto's thyroiditis, and
cardiomyopathy.
[0136] The term "liver disease" or "hepatic disease" refers to
damage to or a disease of the liver. Non-limiting examples of liver
disease include intrahepatic cholestasis (e.g., alagille syndrome,
biliary liver cirrhosis), fatty liver (e.g., alcoholic fatty liver,
Reye's syndrome), hepatic vein thrombosis, hepatolenticular
degeneration (i.e., Wilson's disease), hepatomegaly, liver abscess
(e.g., amebic liver abscess), liver cirrhosis (e.g., alcoholic,
biliary, and experimental liver cirrhosis), alcoholic liver
diseases (e.g., fatty liver, hepatitis, cirrhosis), parasitic liver
disease (e.g., hepatic echinococcosis, fascioliasis, amebic liver
abscess), jaundice (e.g., hemolytic, hepatocellular, cholestatic
jaundice), cholestasis, portal hypertension, liver enlargement,
ascites, hepatitis (e.g., alcoholic hepatitis, animal hepatitis,
chronic hepatitis (e.g., autoimmune, hepatitis B, hepatitis C,
hepatitis D, drug induced chronic hepatitis), toxic hepatitis,
viral human hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C,
hepatitis D, hepatitis E), granulomatous hepatitis, secondary
biliary cirrhosis, hepatic encephalopathy, varices, primary biliary
cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma,
hemangiomas, bile stones, liver failure (e.g., hepatic
encephalopathy, acute liver failure), angiomyolipoma, calcified
liver metastases, cystic liver metastases, fibrolamellar
hepatocarcinoma, hepatic adenoma, hepatoma, hepatic cysts (e.g.,
Simple cysts, Polycystic liver disease, hepatobiliary cystadenoma,
choledochal cyst), mesenchymal tumors (mesenchymal hamartoma,
infantile hemangioendothelioma, hemangioma, peliosis hepatis,
lipomas, inflammatory pseudotumor), epithelial tumors (e.g., bile
duct hamartoma, bile duct adenoma), focal nodular hyperplasia,
nodular regenerative hyperplasia, hepatoblastoma, hepatocellular
carcinoma, cholangiocarcinoma, cystadenocarcinoma, tumors of blood
vessels, angiosarcoma, Karposi's sarcoma, hemangioendothelioma,
embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma,
carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary
lymphoma, peliosis hepatis, erythrohepatic porphyria, hepatic
porphyria (e.g., acute intermittent porphyria, porphyria cutanea
tarda), and Zellweger syndrome.
[0137] The term "spleen disease" refers to a disease of the spleen.
Example of spleen diseases include, but are not limited to,
splenomegaly, spleen cancer, asplenia, spleen trauma, idiopathic
purpura, Felty's syndrome, Hodgkin's disease, and immune-mediated
destruction of the spleen.
[0138] The term "lung disease" or "pulmonary disease" refers to a
disease of the lung. Examples of lung diseases include, but are not
limited to, bronchiectasis, bronchitis, bronchopulmonary dysplasia,
interstitial lung disease, occupational lung disease, emphysema,
cystic fibrosis, acute respiratory distress syndrome (ARDS), severe
acute respiratory syndrome (SARS), asthma (e.g., intermittent
asthma, mild persistent asthma, moderate persistent asthma, severe
persistent asthma), chronic bronchitis, chronic obstructive
pulmonary disease (COPD), emphysema, interstitial lung disease,
sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia
(e.g., lobar pneumonia, multilobar pneumonia, bronchial pneumonia,
interstitial pneumonia), pulmonary fibrosis, pulmonary
tuberculosis, rheumatoid lung disease, pulmonary embolism, and lung
cancer (e.g., non-small-cell lung carcinoma (e.g., adenocarcinoma,
squamous-cell lung carcinoma, large-cell lung carcinoma),
small-cell lung carcinoma).
[0139] A "hematological disease" includes a disease which affects a
hematopoietic cell or tissue. Hematological diseases include
diseases associated with aberrant hematological content and/or
function. Examples of hematological diseases include diseases
resulting from bone marrow irradiation or chemotherapy treatments
for cancer, diseases such as pernicious anemia, hemorrhagic anemia,
hemolytic anemia, aplastic anemia, sickle cell anemia,
sideroblastic anemia, anemia associated with chronic infections
such as malaria, trypanosomiasis, HTV, hepatitis virus or other
viruses, myelophthisic anemias caused by marrow deficiencies, renal
failure resulting from anemia, anemia, polycythemia, infectious
mononucleosis (EVI), acute non-lymphocytic leukemia (ANLL), acute
myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute
myelomonocytic leukemia (AMMoL), polycythemia vera, lymphoma, acute
lymphocytic leukemia (ALL), chronic lymphocytic leukemia, Wilm's
tumor, Ewing's sarcoma, retinoblastoma, hemophilia, disorders
associated with an increased risk of thrombosis, herpes,
thalassemia, antibody-mediated disorders such as transfusion
reactions and erythroblastosis, mechanical trauma to red blood
cells such as micro-angiopathic hemolytic anemias, thrombotic
thrombocytopenic purpura and disseminated intravascular
coagulation, infections by parasites such as Plasmodium, chemical
injuries from, e.g., lead poisoning, and hypersplenism.
[0140] The term "neurological disease" refers to any disease of the
nervous system, including diseases that involve the central nervous
system (brain, brainstem and cerebellum), the peripheral nervous
system (including cranial nerves), and the autonomic nervous system
(parts of which are located in both central and peripheral nervous
system). Neurodegenerative diseases refer to a type of neurological
disease marked by the loss of nerve cells, including, but not
limited to, Alzheimer's disease, Parkinson's disease, amyotrophic
lateral sclerosis, tauopathies (including frontotemporal dementia),
and Huntington's disease. Examples of neurological diseases
include, but are not limited to, headache, stupor and coma,
dementia, seizure, sleep disorders, trauma, infections, neoplasms,
neuro-ophthalmology, movement disorders, demyelinating diseases,
spinal cord disorders, and disorders of peripheral nerves, muscle
and neuromuscular junctions. Addiction and mental illness, include,
but are not limited to, bipolar disorder and schizophrenia, are
also included in the definition of neurological diseases. Further
examples of neurological diseases include acquired epileptiform
aphasia; acute disseminated encephalomyelitis;
adrenoleukodystrophy; agenesis of the corpus callosum; agnosia;
Aicardi syndrome; Alexander disease; Alpers' disease; alternating
hemiplegia; Alzheimer's disease; amyotrophic lateral sclerosis;
anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia;
apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari
malformation; arteriovenous malformation; Asperger syndrome; ataxia
telangiectasia; attention deficit hyperactivity disorder; autism;
autonomic dysfunction; back pain; Batten disease; Behcet's disease;
Bell's palsy; benign essential blepharospasm; benign focal;
amyotrophy; benign intracranial hypertension; Binswanger's disease;
blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury;
brain abscess; bbrain injury; brain tumors (including glioblastoma
multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease;
carpal tunnel syndrome (CTS); causalgia; central pain syndrome;
central pontine myelinolysis; cephalic disorder; cerebral aneurysm;
cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism;
cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced
neuropathy and neuropathic pain; Chiari malformation; chorea;
chronic inflammatory demyelinating polyneuropathy (CIDP); chronic
pain; chronic regional pain syndrome; Coffin Lowry syndrome; coma,
including persistent vegetative state; congenital facial diplegia;
corticobasal degeneration; cranial arteritis; craniosynostosis;
Creutzfeldt-Jakob disease; cumulative trauma disorders; Cushing's
syndrome; cytomegalic inclusion body disease (CIBD);
cytomegalovirus infection; dancing eyes-dancing feet syndrome;
Dandy-Walker syndrome; Dawson disease; De Morsier's syndrome;
Dejerine-Klumpke palsy; dementia; dermatomyositis; diabetic
neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia;
dystonias; early infantile epileptic encephalopathy; empty sella
syndrome; encephalitis; encephaloceles; encephalotrigeminal
angiomatosis; epilepsy; Erb's palsy; essential tremor; Fabry's
disease; Fahr's syndrome; fainting; familial spastic paralysis;
febrile seizures; Fisher syndrome; Friedreich's ataxia;
frontotemporal dementia and other "tauopathies"; Gaucher's disease;
Gerstmann's syndrome; giant cell arteritis; giant cell inclusion
disease; globoid cell leukodystrophy; Guillain-Barre syndrome;
HTLV-1 associated myelopathy; Hallervorden-Spatz disease; head
injury; headache; hemifacial spasm; hereditary spastic paraplegia;
heredopathia atactica polyneuritiformis; herpes zoster oticus;
herpes zoster; Hirayama syndrome; HIV-associated dementia and
neuropathy (see also neurological manifestations of AIDS);
holoprosencephaly; Huntington's disease and other polyglutamine
repeat diseases; hydranencephaly; hydrocephalus; hypercortisolism;
hypoxia; immune-mediated encephalomyelitis; inclusion body
myositis; incontinentia pigmenti; infantile; phytanic acid storage
disease; Infantile Refsum disease; infantile spasms; inflammatory
myopathy; intracranial cyst; intracranial hypertension; Joubert
syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbourne
syndrome; Klippel Feil syndrome; Krabbe disease; Kugelberg-Welander
disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome;
Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome;
learning disabilities; Leigh's disease; Lennox-Gastaut syndrome;
Lesch-Nyhan syndrome; leukodystrophy; Lewy body dementia;
lissencephaly; locked-in syndrome; Lou Gehrig's disease (aka motor
neuron disease or amyotrophic lateral sclerosis); lumbar disc
disease; lyme disease-neurological sequelae; Machado-Joseph
disease; macrencephaly; megalencephaly; Melkersson-Rosenthal
syndrome; Menieres disease; meningitis; Menkes disease;
metachromatic leukodystrophy; microcephaly; migraine; Miller Fisher
syndrome; mini-strokes; mitochondrial myopathies; Mobius syndrome;
monomelic amyotrophy; motor neurone disease; moyamoya disease;
mucopolysaccharidoses; multi-infarct dementia; multifocal motor
neuropathy; multiple sclerosis and other demyelinating disorders;
multiple system atrophy with postural hypotension; muscular
dystrophy; myasthenia gravis; myelinoclastic diffuse sclerosis;
myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia
congenital; narcolepsy; neurofibromatosis; neuroleptic malignant
syndrome; neurological manifestations of AIDS; neurological
sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis;
neuronal migration disorders; Niemann-Pick disease;
O'Sullivan-McLeod syndrome; occipital neuralgia; occult spinal
dysraphism sequence; Ohtahara syndrome; olivopontocerebellar
atrophy; opsoclonus myoclonus; optic neuritis; orthostatic
hypotension; overuse syndrome; paresthesia; Parkinson's disease;
paramyotonia congenita; paraneoplastic diseases; paroxysmal
attacks; Parry Romberg syndrome; Pelizaeus-Merzbacher disease;
periodic paralyses; peripheral neuropathy; painful neuropathy and
neuropathic pain; persistent vegetative state; pervasive
developmental disorders; photic sneeze reflex; phytanic acid
storage disease; Pick's disease; pinched nerve; pituitary tumors;
polymyositis; porencephaly; Post-Polio syndrome; postherpetic
neuralgia (PHN); postinfectious encephalomyelitis; postural
hypotension; Prader-Willi syndrome; primary lateral sclerosis;
prion diseases; progressive; hemifacial atrophy; progressive
multifocal leukoencephalopathy; progressive sclerosing
poliodystrophy; progressive supranuclear palsy; pseudotumor
cerebri; Ramsay-Hunt syndrome (Type I and Type II); Rasmussen's
Encephalitis; reflex sympathetic dystrophy syndrome; Refsum
disease; repetitive motion disorders; repetitive stress injuries;
restless legs syndrome; retrovirus-associated myelopathy; Rett
syndrome; Reye's syndrome; Saint Vitus Dance; Sandhoff disease;
Schilder's disease; schizencephaly; septo-optic dysplasia; shaken
baby syndrome; shingles; Shy-Drager syndrome; Sjogren's syndrome;
sleep apnea; Soto's syndrome; spasticity; spina bifida; spinal cord
injury; spinal cord tumors; spinal muscular atrophy; stiff-person
syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing
panencephalitis; subarachnoid hemorrhage; subcortical
arteriosclerotic encephalopathy; sydenham chorea; syncope;
syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal
arteritis; tethered spinal cord syndrome; Thomsen disease; thoracic
outlet syndrome; tic douloureux; Todd's paralysis; Tourette
syndrome; transient ischemic attack; transmissible spongiform
encephalopathies; transverse myelitis; traumatic brain injury;
tremor; trigeminal neuralgia; tropical spastic paraparesis;
tuberous sclerosis; vascular dementia (multi-infarct dementia);
vasculitis including temporal arteritis; Von Hippel-Lindau Disease
(VHL); Wallenberg's syndrome; Werdnig-Hoffman disease; West
syndrome; whiplash; Williams syndrome; Wilson's disease; and
Zellweger syndrome.
[0141] The term "painful condition" includes, but is not limited
to, neuropathic pain (e.g., peripheral neuropathic pain), central
pain, deafferentiation pain, chronic pain (e.g., chronic
nociceptive pain, and other forms of chronic pain such as
post-operative pain, e.g., pain arising after hip, knee, or other
replacement surgery), pre-operative pain, stimulus of nociceptive
receptors (nociceptive pain), acute pain (e.g., phantom and
transient acute pain), noninflammatory pain, inflammatory pain,
pain associated with cancer, wound pain, burn pain, postoperative
pain, pain associated with medical procedures, pain resulting from
pruritus, painful bladder syndrome, pain associated with
premenstrual dysphoric disorder and/or premenstrual syndrome, pain
associated with chronic fatigue syndrome, pain associated with
pre-term labor, pain associated with withdrawal symptoms from drug
addiction, joint pain, arthritic pain (e.g., pain associated with
crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty
arthritis, reactive arthritis, rheumatoid arthritis or Reiter's
arthritis), lumbosacral pain, musculo-skeletal pain, headache,
migraine, muscle ache, lower back pain, neck pain, toothache,
dental/maxillofacial pain, visceral pain and the like. One or more
of the painful conditions contemplated herein can comprise mixtures
of various types of pain provided above and herein (e.g.
nociceptive pain, inflammatory pain, neuropathic pain, etc.). In
some embodiments, a particular pain can dominate. In other
embodiments, the painful condition comprises two or more types of
pains without one dominating. A skilled clinician can determine the
dosage to achieve a therapeutically effective amount for a
particular subject based on the painful condition.
[0142] The term "psychiatric disorder" refers to a disease of the
mind and includes diseases and disorders listed in the Diagnostic
and Statistical Manual of Mental Disorders--Fourth Edition
(DSM-IV), published by the American Psychiatric Association,
Washington D. C. (1994). Psychiatric disorders include, but are not
limited to, anxiety disorders (e.g., acute stress disorder
agoraphobia, generalized anxiety disorder, obsessive-compulsive
disorder, panic disorder, posttraumatic stress disorder, separation
anxiety disorder, social phobia, and specific phobia), childhood
disorders, (e.g., attention-deficit/hyperactivity disorder, conduct
disorder, and oppositional defiant disorder), eating disorders
(e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g.,
depression, bipolar disorder, cyclothymic disorder, dysthymic
disorder, and major depressive disorder), personality disorders
(e.g., antisocial personality disorder, avoidant personality
disorder, borderline personality disorder, dependent personality
disorder, histrionic personality disorder, narcissistic personality
disorder, obsessive-compulsive personality disorder, paranoid
personality disorder, schizoid personality disorder, and
schizotypal personality disorder), psychotic disorders (e.g., brief
psychotic disorder, delusional disorder, schizoaffective disorder,
schizophreniform disorder, schizophrenia, and shared psychotic
disorder), substance-related disorders (e.g., alcohol dependence,
amphetamine dependence, Cannabis dependence, cocaine dependence,
hallucinogen dependence, inhalant dependence, nicotine dependence,
opioid dependence, phencyclidine dependence, and sedative
dependence), adjustment disorder, autism, delirium, dementia,
multi-infarct dementia, learning and memory disorders (e.g.,
amnesia and age-related memory loss), and Tourette's disorder.
[0143] The term "metabolic disorder" refers to any disorder that
involves an alteration in the normal metabolism of carbohydrates,
lipids, proteins, nucleic acids, or a combination thereof. A
metabolic disorder is associated with either a deficiency or excess
in a metabolic pathway resulting in an imbalance in metabolism of
nucleic acids, proteins, lipids, and/or carbohydrates. Factors
affecting metabolism include, and are not limited to, the endocrine
(hormonal) control system (e.g., the insulin pathway, the
enteroendocrine hormones including GLP-1, PYY or the like), the
neural control system (e.g., GLP-1 in the brain), or the like.
Examples of metabolic disorders include, but are not limited to,
diabetes (e.g., Type I diabetes, Type II diabetes, gestational
diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and
obesity.
[0144] An "effective amount" of a polymer or composition described
herein refers to an amount sufficient to elicit the desired
biological response. An effective amount of a polymer or
composition described herein may vary depending on such factors as
the desired biological endpoint, the pharmacokinetics of the
composition, the condition being treated, the mode of
administration, and the age and health of the subject. In certain
embodiments, an effective amount is a therapeutically effective
amount. In certain embodiments, an effective amount is a
prophylactically effective amount. In certain embodiments, an
effective amount is the amount of a composition or pharmaceutical
composition described herein in a single dose. In certain
embodiments, an effective amount is the combined amounts of a
composition or pharmaceutical composition described herein in
multiple doses.
[0145] A "therapeutically effective amount" of a polymer or
composition described herein is an amount sufficient to provide a
therapeutic benefit in the treatment of a condition or to delay or
minimize one or more symptoms associated with the condition. A
therapeutically effective amount of a polymer or composition means
an amount of therapeutic agent, alone or in combination with other
therapies, which provides a therapeutic benefit in the treatment of
the condition. The term "therapeutically effective amount" can
encompass an amount that improves overall therapy, reduces or
avoids symptoms, signs, or causes of the condition, and/or enhances
the therapeutic efficacy of another therapeutic agent.
[0146] A "prophylactically effective amount" of a polymer or
composition described herein is an amount sufficient to prevent a
condition, or one or more symptoms associated with the condition or
prevent its recurrence. A prophylactically effective amount of a
polymer or composition means an amount of a therapeutic agent,
alone or in combination with other agents, which provides a
prophylactic benefit in the prevention of the condition. The term
"prophylactically effective amount" can encompass an amount that
improves overall prophylaxis or enhances the prophylactic efficacy
of another prophylactic agent.
[0147] The terms "nucleic acid" or "nucleic acid sequence",
"nucleic acid molecule", "nucleic acid fragment" or
"polynucleotide" are used interchangeably. A polynucleotide
molecule is a biopolymer composed of nucleotide monomers covalently
bonded in a chain. DNA (deoxyribonucleic acid) and RNA (ribonucleic
acid) are examples of polynucleotides with distinct biological
function. DNA consists of two chains of polynucleotides, with each
chain in the form of a helical spiral. RNA is more often found in
nature as a single-strand folded onto itself. Exemplary types of
RNA include double-stranded RNA (dsRNA), small interfering RNA
(siRNA), short hairpin (shRNA), microRNA (miRNA), messenger RNA
(mRNA), antisense RNA, transfer RNA (tRNA), small nuclear RNA
(snRNA), and ribosomal RNA (rRNA).
[0148] The term "mRNA" or "mRNA molecule" refers to messenger RNA,
or the RNA that serves as a template for protein synthesis in a
cell. The sequence of a strand of mRNA is based on the sequence of
a complementary strand of DNA comprising a sequence coding for the
protein to be synthesized.
[0149] The term "siRNA" or "siRNA molecule" refers to small
inhibitory RNA duplexes that induce the RNA interference (RNAi)
pathway, where the siRNA interferes with the expression of specific
genes with a complementary nucleotide sequence. siRNA molecules can
vary in length (e.g., between 18-30 or 20-25 basepairs) and contain
varying degrees of complementarity to their target mRNA in the
antisense strand. Some siRNA have unpaired overhanging bases on the
5' or 3' end of the sense strand and/or the antisense strand. The
term siRNA includes duplexes of two separate strands, as well as
single strands that can form hairpin structures comprising a duplex
region.
[0150] The term "RNA interference" or "RNAi" refers to a biological
process in which RNA molecules inhibit gene expression or
translation, by neutralizing targets mRNA molecules. Since the
discovery of RNAi and its regulatory potentials, it has become
evident that RNAi has immense potential in suppression of desired
genes. RNAi is now known as precise, efficient, stable, and better
than antisense technology for gene suppression. Two types of small
ribonucleic acids molecules are central to RNA interference: miRNA
and siRNA. These small RNAs can bind to mRNA molecules and either
increase or decrease their activity (e.g., preventing an mRNA from
being translated into a protein). The RNAi pathway is found in many
eukaryotes, including animals, and is initiated by the enzyme
Dicer, which cleaves long dsRNA molecules into short
double-stranded fragments of .about.20 nucleotide siRNAs. Each
siRNA is unwound into two single-stranded RNAs (ssRNAs), the
passenger strand and the guide strand. The passenger strand is
degraded and the guide strand is incorporated into the RNA-induced
silencing complex (RISC). The most well-studied outcome is
post-transcriptional gene silencing, which occurs when the guide
strand pairs with a complementary sequence in a mRNA molecule and
induces cleavage by Argonaute 2 (Ago2), the catalytic component of
the RISC complex. In some organisms, this process spreads
systematically, despite the initially limited molar concentrations
of siRNA.
[0151] The term "biodegradable" or "biodegradation" refers to the
disintegration of materials by biological means. Organic material
can be degraded aerobically or anaerobically. Decomposition of
biodegradable substances may include both biological and abiotic
steps, such as hydrolysis.
[0152] The term "biocompatible" or "biocompatibility" refers to the
ability of a material to perform with an appropriate host response
in a specific situation. In particular, the terms refer to the
ability of a biomaterial to perform its desired function with
respect to a medical therapy without eliciting any undesirable
local or systematic effects in the recipient or beneficiary of that
therapy, but generating the most appropriate beneficial cellular or
tissue response in that specific situation, and optimizing the
clinically relevant performance of that therapy.
[0153] The disclosure is not intended to be limited in any manner
by the above exemplary listing of substituents. Additional terms
may be defined in other sections of this disclosure.
Detailed Description of Certain Embodiments
[0154] Before the disclosed systems, compositions, methods,
reagents, and kits are described in more detail, it should be
understood that the aspects described herein are not limited to
specific embodiments, methods, apparati, or configurations, and as
such can, of course, vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
aspects only and, unless specifically defined herein, is not
intended to be limiting.
[0155] Described herein are novel PBAEs derived from polylactone
(PCL) diacrylates. In some embodiments, the PBAEs include
dipolymers derived from one diacrylate monomers and one amine,
terpolymers derived from one diacrylate monomer and two different
amines. The PCL-derived PBAEs promote stable formulations with
agents such as oligonucleotides, leading to transfection efficacy
several times higher than transfection agents such as PEI, for
example, and further leading to target organ specificity. The
PCL-derived PBAEs are biodegradable and biocompatible, offering
higher efficacy and lower toxicity for a variety of
applications.
Polymers
[0156] In one aspect, provided herein is a polymer of Formula
(I):
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein:
[0157] is a single bond or a double bond;
[0158] A is hydrogen or --XR.sub.3;
[0159] each B independently is a diradical of the formula:
##STR00008##
[0160] each D independently is:
##STR00009##
[0161] E is hydrogen or --XR.sub.4;
[0162] each R, R', and R'' independently is optionally substituted,
cyclic or acyclic aliphatic; optionally substituted, cyclic or
acyclic heteroaliphatic; or a combination thereof;
[0163] each R.sub.a independently is hydrogen or optionally
substituted aliphatic;
[0164] R.sub.1 and R.sub.2 independently are selected from
hydrogen; optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic;
optionally substituted aryl; optionally substituted heteroaryl; and
a nitrogen protecting group; or R.sub.1 and R.sub.2 are combined to
form a ring;
[0165] R.sub.3 and R.sub.4 independently are selected from
hydrogen; optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic;
optionally substituted aryl; optionally substituted heteroaryl; and
a protecting group;
[0166] X is O, S, NH or NR.sub.X, wherein R.sub.X is optionally
substituted, cyclic or acyclic aliphatic; optionally substituted,
cyclic or acyclic heteroaliphatic; optionally substituted aryl; or
optionally substituted heteroaryl;
[0167] X' is O or NR.sub.y, wherein R.sub.y is hydrogen or
optionally substituted aliphatic;
[0168] each m independently is an integer between 1 and 100,
inclusive; and
[0169] n is an integer between 1 and 10,000, inclusive.
[0170] In certain embodiments, the polymer of Formula (I) is of
Formula (II):
##STR00010##
or a pharmaceutically acceptable salt thereof.
[0171] In certain embodiments, the polymer of Formula (I) is of
Formula (III):
##STR00011##
or a pharmaceutically acceptable salt thereof.
[0172] In certain embodiments, the polymer of Formula (I) is of
Formula (IV):
##STR00012##
or a pharmaceutically acceptable salt thereof.
[0173] In certain embodiments, the polymer of Formula (I) is of
Formula (V):
##STR00013##
or a pharmaceutically acceptable salt thereof.
Variable A
[0174] In certain embodiments, A is hydrogen or --XR.sub.3, wherein
X and R.sub.3 are defined herein. In certain particular
embodiments, A is --NHR.sub.3. In certain particular embodiments, A
is --NR.sub.xR.sub.3. In certain particular embodiments, A is
hydrogen. In certain particular embodiments, A is --NH.sub.2. In
certain embodiments, A is
##STR00014##
wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In certain particular
embodiments, A is
##STR00015##
Variable B
[0175] In certain embodiments, each B independently is a diradical
of the formula:
##STR00016##
wherein R, R', and m are as defined herein. In certain embodiments,
m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In certain particular
embodiments, m is 3. In certain particular embodiments, m is 5. In
certain particular embodiments, m is 7.
[0176] In certain embodiments, B is of the formula:
##STR00017##
wherein p and q independently are 2, 3, 4, 5 or 6. In certain
embodiments, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In certain
particular embodiments, m is 3. In certain particular embodiments,
m is 5. In certain particular embodiments, m is 7. In certain
embodiments, B is of the formula:
##STR00018##
In certain embodiments, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In
certain particular embodiments, m is 3. In certain particular
embodiments, m is 5. In certain particular embodiments, m is 7.
Variable D
[0177] In certain embodiments, each D independently is:
##STR00019##
wherein R.sub.1 and R.sub.2 are defined herein.
[0178] When D is
##STR00020##
the groups R.sub.1 and/or R.sub.2 may be covalently bonded to R''
to form one or two cyclic structures. In certain embodiments,
R.sub.1 and R.sub.2 are combined to form a ring.
[0179] In certain embodiments, each D is
##STR00021##
and independently is selected from Table 1.
TABLE-US-00001 TABLE 1 ##STR00022## ##STR00023## ##STR00024##
##STR00025## ##STR00026## ##STR00027## ##STR00028## ##STR00029##
##STR00030## ##STR00031## ##STR00032## ##STR00033## ##STR00034##
##STR00035## ##STR00036## ##STR00037## ##STR00038## ##STR00039##
##STR00040## ##STR00041## ##STR00042## ##STR00043## ##STR00044##
##STR00045## ##STR00046## ##STR00047## ##STR00048## ##STR00049##
##STR00050## ##STR00051## ##STR00052## ##STR00053## ##STR00054##
##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059##
##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064##
##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074##
##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079##
##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084##
##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089##
##STR00090## ##STR00091## ##STR00092## ##STR00093## ##STR00094##
##STR00095## ##STR00096## ##STR00097## ##STR00098## ##STR00099##
##STR00100## ##STR00101## ##STR00102## ##STR00103## ##STR00104##
##STR00105## ##STR00106## ##STR00107## ##STR00108## ##STR00109##
##STR00110## ##STR00111## ##STR00112## ##STR00113## ##STR00114##
##STR00115## ##STR00116## ##STR00117## ##STR00118## ##STR00119##
##STR00120## ##STR00121## ##STR00122## ##STR00123##
##STR00124##
[0180] In certain particular embodiments, at least one D diradical
is of the formula:
##STR00125##
[0181] In certain embodiments, each D is
##STR00126##
and independently is selected from Table 2.
TABLE-US-00002 TABLE 2 ##STR00127## ##STR00128## ##STR00129##
##STR00130## ##STR00131## ##STR00132## ##STR00133## ##STR00134##
##STR00135## ##STR00136## ##STR00137## ##STR00138## ##STR00139##
##STR00140## ##STR00141## ##STR00142## ##STR00143## ##STR00144##
##STR00145## ##STR00146## ##STR00147## ##STR00148## ##STR00149##
##STR00150##
[0182] In certain particular embodiments, at least one D diradical
is
##STR00151##
[0183] In certain embodiments, each D diradical independently
is
##STR00152##
and is selected from the moieties in Table 1 and Table 2.
[0184] In certain embodiments, the polymer comprises only one type
of D diradical. In certain embodiments, the polymer comprises at
least two types of D diradical. In certain embodiments, the polymer
comprises only two types of D diradical. In certain embodiments,
the polymer comprises at least three types of D diradical. In
certain embodiments, the polymer comprises only three types of D
diradical. In certain embodiments, the polymer comprises at least
four types of D diradical. In certain embodiments, the polymer
comprises only four types of D diradical.
Variable E
[0185] In certain embodiments, E is hydrogen or --XR.sub.4, wherein
X and R.sub.4 are defined herein. In certain particular
embodiments, E is --XR.sub.4. In certain particular embodiments, E
is hydrogen. In certain particular embodiments, E is --NH.sub.2. In
certain embodiments, E is
##STR00153##
wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In certain particular
embodiments, E is
##STR00154##
Variable R
[0186] R is divalent (i.e., a diradical). In certain embodiments,
each R independently is optionally substituted, cyclic or acyclic
aliphatic, optionally substituted, cyclic or acyclic
heteroaliphatic, or a combination thereof. In certain embodiments,
each R independently is substituted acyclic aliphatic. In certain
embodiments, each R independently is unsubstituted acyclic
aliphatic. In certain embodiments, each R independently is
substituted cyclic aliphatic. In certain embodiments, each R
independently is unsubstituted cyclic aliphatic. In certain
embodiments, each R independently is substituted acyclic
heteroaliphatic. In certain embodiments, each R independently is
unsubstituted acyclic heteroaliphatic. In certain embodiments, each
R independently is substituted cyclic heteroaliphatic. In certain
embodiments, each R independently is unsubstituted cyclic
heteroaliphatic.
[0187] In certain embodiments, R is of the formula:
##STR00155##
wherein R.sub.5 is selected from the group consisting of alkyl,
heteroalkyl, alkenyl, alkynyl, haloalkyl, alkoxy, thioalkoxy,
amino, alkylamino, dialkylamino, trialkylamino, acylamino, cyano,
hydroxy, halo, mercapto, nitro, carboxyaldehyde, carboxy,
alkoxycarbonyl, and carboxamide, wherein said alkyl, heteroalkyl,
alkenyl, and alkynyl are optionally substituted, cyclic or acyclic,
and branched or linear. In certain embodiments, R.sub.5 is
optionally substituted C.sub.2-C.sub.20 alkyl or optionally
substituted C.sub.2-C.sub.20 heteroalkyl, and r is 1-19.
Variable R'
[0188] R' is divalent (i.e., a diradical). In certain embodiments,
each R' independently is optionally substituted, cyclic or acyclic
aliphatic, optionally substituted, cyclic or acyclic
heteroaliphatic, or a combination thereof. In certain embodiments,
each R' independently is substituted acyclic aliphatic. In certain
embodiments, each R' independently is unsubstituted acyclic
aliphatic. In certain embodiments, each R' independently is
substituted cyclic aliphatic. In certain embodiments, each R'
independently is unsubstituted cyclic aliphatic. In certain
embodiments, each R' independently is substituted acyclic
heteroaliphatic. In certain embodiments, each R' independently is
unsubstituted acyclic heteroaliphatic. In certain embodiments, each
R' independently is substituted cyclic heteroaliphatic. In certain
embodiments, each R' independently is unsubstituted cyclic
heteroaliphatic.
[0189] In certain embodiments, R' is of the formula:
##STR00156##
wherein R.sub.6 is selected from the group consisting of alkyl,
heteroalkyl, alkenyl, alkynyl, haloalkyl, alkoxy, thioalkoxy,
amino, alkylamino, dialkylamino, trialkylamino, acylamino, cyano,
hydroxy, halo, mercapto, nitro, carboxyaldehyde, carboxy,
alkoxycarbonyl, and carboxamide, wherein said alkyl, heteroalkyl,
alkenyl, and alkynyl are optionally substituted, cyclic or acyclic,
and branched or linear. In certain embodiments, R.sub.6 is
optionally substituted C.sub.2-C.sub.20 alkyl or optionally
substituted C.sub.2-C.sub.20 heteroalkyl, and r is 1-19.
Variable R''
[0190] R'' is divalent (i.e., a diradical). In certain embodiments,
each R'' independently is optionally substituted, cyclic or acyclic
aliphatic, optionally substituted, cyclic or acyclic
heteroaliphatic, or a combination thereof. In certain embodiments,
each R'' independently is substituted acyclic aliphatic. In certain
embodiments, each R'' independently is unsubstituted acyclic
aliphatic. In certain embodiments, each R'' independently is
substituted cyclic aliphatic. In certain embodiments, each R''
independently is unsubstituted cyclic aliphatic. In certain
embodiments, each R'' independently is substituted acyclic
heteroaliphatic. In certain embodiments, each R'' independently is
unsubstituted acyclic heteroaliphatic. In certain embodiments, each
R'' independently is substituted cyclic heteroaliphatic. In certain
embodiments, each R'' independently is unsubstituted cyclic
heteroaliphatic.
[0191] In certain embodiments, each R'' independently is
##STR00157##
wherein n is an integer between 1 and 20, inclusive. In certain
embodiments, each R'' independently is
##STR00158##
wherein n is an integer between 1 and 20, inclusive. In certain
embodiments, each R'' independently is
##STR00159##
wherein n is an integer between 1 and 20, inclusive; and each m
independently is an integer between 1 and 6, inclusive.
Variable R.sub.a
[0192] In certain embodiments, each R.sub.a independently is
hydrogen or optionally substituted aliphatic. In certain
embodiments, each R.sub.a is hydrogen. In certain embodiments, each
R.sub.a independently is substituted aliphatic. In certain
embodiments, each R.sub.a is independently unsubstituted aliphatic.
In certain embodiments, each R.sub.a is independently substituted
or unsubstituted C.sub.1-6 alkyl. In certain embodiments, each
R.sub.a is hydrogen or unsubstituted methyl. In certain
embodiments, each R.sub.a is unsubstituted methyl.
Variable R.sub.1
[0193] In certain embodiments, each R.sub.1 independently is
hydrogen, optionally substituted, cyclic or acyclic aliphatic,
optionally substituted, cyclic or acyclic heteroaliphatic,
optionally substituted aryl, or optionally substituted heteroaryl,
or R.sub.1 and R.sub.2 are combined to form a ring. In certain
embodiments, each R.sub.1 independently is hydrogen. In certain
embodiments, each R.sub.1 independently is substituted acyclic
aliphatic. In certain embodiments, each R.sub.1 independently is
unsubstituted acyclic aliphatic. In certain embodiments, each
R.sub.1 independently is substituted cyclic aliphatic. In certain
embodiments, each R.sub.1 independently is unsubstituted cyclic
aliphatic. In certain embodiments, each R.sub.1 independently is
substituted acyclic heteroaliphatic. In certain embodiments, each
R.sub.1 independently is unsubstituted acyclic heteroaliphatic. In
certain embodiments, each R.sub.1 independently is substituted
cyclic heteroaliphatic. In certain embodiments, each R.sub.1
independently is unsubstituted cyclic heteroaliphatic. In certain
embodiments, each R.sub.1 independently is substituted aryl. In
certain embodiments, each R.sub.1 independently is unsubstituted
aryl. In certain embodiments, each R.sub.1 independently is
substituted heteroaryl. In certain embodiments, each R.sub.1
independently is unsubstituted heteroaryl.
[0194] In certain embodiments, at least one R.sub.1 is optionally
substituted C.sub.1-6 alkyl. In certain embodiments, each R.sub.1
is optionally substituted C.sub.1-6 alkyl. In certain embodiments,
at least one R.sub.1 is
##STR00160##
In certain embodiments, each R.sub.1 is
##STR00161##
In certain embodiments, at least one R.sub.1 is
##STR00162##
In certain embodiments, each R.sub.1 is
##STR00163##
In certain embodiments, at least one R.sub.1 is
##STR00164##
In certain embodiments, each R.sub.1 is
##STR00165##
In certain embodiments, at least one R.sub.1 is
##STR00166##
In certain embodiments, each R.sub.1 is
##STR00167##
Variable R.sub.2
[0195] In certain embodiments, each R.sub.2 independently is
hydrogen, optionally substituted, cyclic or acyclic aliphatic,
optionally substituted, cyclic or acyclic heteroaliphatic,
optionally substituted aryl, or optionally substituted heteroaryl,
or R.sub.1 and R.sub.2 are combined to form a ring. In certain
embodiments, each R.sub.2 independently is hydrogen. In certain
embodiments, each R.sub.2 independently is substituted acyclic
aliphatic. In certain embodiments, each R.sub.2 independently is
unsubstituted acyclic aliphatic. In certain embodiments, each
R.sub.2 independently is substituted cyclic aliphatic. In certain
embodiments, each R.sub.2 independently is unsubstituted cyclic
aliphatic. In certain embodiments, each R.sub.2 independently is
substituted acyclic heteroaliphatic. In certain embodiments, each
R.sub.2 independently is unsubstituted acyclic heteroaliphatic. In
certain embodiments, each R.sub.2 independently is substituted
cyclic heteroaliphatic. In certain embodiments, each R.sub.2
independently is unsubstituted cyclic heteroaliphatic. In certain
embodiments, each R.sub.2 independently is substituted aryl. In
certain embodiments, each R.sub.2 independently is unsubstituted
aryl. In certain embodiments, each R.sub.2 independently is
substituted heteroaryl. In certain embodiments, each R.sub.2
independently is unsubstituted heteroaryl. In certain embodiments,
at least one R.sub.2 is C.sub.1-6 alkyl. In certain embodiments,
each R.sub.2 is C.sub.1-6 alkyl. In certain embodiments, R.sub.1
and R.sub.2 are combined to form a 4-, 5-, 6-, or 7-membered
optionally substituted, saturated or partially-unsaturated
ring.
Variables R.sub.3 and R.sub.4
[0196] In certain embodiments, R.sub.3 and R.sub.4 independently,
for each occurrence, are hydrogen, optionally substituted, cyclic
or acyclic aliphatic, optionally substituted, cyclic or acyclic
heteroaliphatic, optionally substituted aryl, or optionally
substituted heteroaryl. In certain embodiments, R.sub.3 and R.sub.4
independently, for each occurrence, are hydrogen. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are substituted acyclic aliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are unsubstituted acyclic aliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are substituted cyclic aliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are unsubstituted cyclic aliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are substituted acyclic heteroaliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are unsubstituted acyclic heteroaliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are substituted cyclic heteroaliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are unsubstituted cyclic heteroaliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are substituted aryl. In certain embodiments, R.sub.3
and R.sub.4 independently, for each occurrence, are unsubstituted
aryl. In certain embodiments, R.sub.3 and R.sub.4 independently,
for each occurrence, are substituted heteroaryl. In certain
embodiments, R.sub.3 and R.sub.4 independently, for each
occurrence, are unsubstituted heteroaryl.
[0197] In certain embodiments, R.sup.3 and R.sup.4 are the same. In
certain embodiments, R.sup.3 and R.sup.4 are different. In certain
embodiments, R.sup.3 and R.sup.4 are different from R.sub.1. In
certain embodiments, R.sub.3 and R.sub.4 independently are
optionally substituted, cyclic or acyclic aliphatic, or optionally
substituted, cyclic or acyclic heteroaliphatic. In certain
embodiments, R.sub.3 and R.sub.4 independently are:
##STR00168##
wherein: o, p, q, and r are each independently an integer between 0
and 20, inclusive; each instance of V is independently --O--,
--S--, --NH--, --NR.sub.V--, or C(R.sub.V).sub.2, wherein each
instance of R.sub.V is independently hydrogen, halogen, hydroxyl,
C.sub.1-6aliphatic, C.sub.1-6heteroaliphatic, C.sub.1-6alkoxy,
amino, C.sub.1-6alkylamino, di(C.sub.1-6alkyl)amino, aryl,
heteroaryl, thiol, alkylthioxy, or acyl. In certain embodiments,
R.sub.3 and R.sub.4 independently are
##STR00169##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00170##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00171##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00172##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00173##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00174##
wherein m is an integer between 1 and 20, inclusive. In certain
embodiments, R.sub.3 and R.sub.4 independently are
##STR00175##
wherein m is an integer between 1 and 20, inclusive.
[0198] In certain embodiments, R.sup.3 and R.sup.4 independently
are selected from the group consisting of:
##STR00176## ##STR00177## ##STR00178## ##STR00179##
In certain embodiments, R.sub.3 and R.sub.4 are both
##STR00180##
wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0199] In certain embodiments, R.sub.3 and R.sub.4 are both
##STR00181##
Variable X
[0200] In certain embodiments, each X independently is O, S, NH, or
NR.sub.X, wherein R.sub.X is optionally substituted, aliphatic;
optionally substituted carbocyclyl; optionally substituted
heteroaliphatic; optionally substituted heterocyclyl; optionally
substituted aryl; or optionally substituted heteroaryl. The
compositions and polymers provided herein, each X may be the
different, or both X may be the same. In certain embodiments, each
X is S. In certain embodiments, each X is NH. In certain
embodiments, each X is NR.sub.x. In certain embodiments, each
R.sub.x independently is substituted acyclic aliphatic. In certain
embodiments, each R.sub.x independently is unsubstituted acyclic
aliphatic. In certain embodiments, each R.sub.x independently is
substituted cyclic aliphatic. In certain embodiments, each R.sub.x
independently is unsubstituted cyclic aliphatic. In certain
embodiments, each R.sub.x independently is substituted acyclic
heteroaliphatic. In certain embodiments, each R.sub.x independently
is unsubstituted acyclic heteroaliphatic. In certain embodiments,
each R.sub.x independently is substituted cyclic heteroaliphatic.
In certain embodiments, each R.sub.x independently is unsubstituted
cyclic heteroaliphatic. In certain embodiments, each R.sub.x
independently is C.sub.1-6 alkyl.
Variable X'
[0201] In certain embodiments, each X' independently is O or
NR.sub.y, wherein R.sub.y is hydrogen; optionally substituted,
aliphatic; optionally substituted carbocyclyl; optionally
substituted heteroaliphatic; optionally substituted heterocyclyl;
optionally substituted aryl; or optionally substituted heteroaryl.
In certain embodiments, each X' is the same. In certain
embodiments, X' is O. In certain embodiments, X' is NR.sub.y. In
certain embodiments, X' is NH. In certain embodiments, each R.sub.y
independently is substituted acyclic aliphatic. In certain
embodiments, each R.sub.y independently is unsubstituted acyclic
aliphatic. In certain embodiments, each R.sub.y independently is
substituted cyclic aliphatic. In certain embodiments, each R.sub.y
independently is unsubstituted cyclic aliphatic. In certain
embodiments, each R.sub.y independently is substituted acyclic
heteroaliphatic. In certain embodiments, each R.sub.y independently
is unsubstituted acyclic heteroaliphatic. In certain embodiments,
each R.sub.y independently is substituted cyclic heteroaliphatic.
In certain embodiments, each R.sub.y independently is unsubstituted
cyclic heteroaliphatic.
[0202] In certain embodiments, each R.sub.y independently is
C.sub.1-6 alkyl.
Variable m
[0203] In certain embodiments, each m independently is an integer
between 1 and 100, inclusive. In certain embodiments, each m
independently is an integer between 1 and 50, inclusive. In certain
embodiments, each m independently is an integer between 1 and 20,
inclusive. In certain embodiments, each m independently is an
integer between 1 and 10, inclusive. In certain embodiments, each m
independently is an integer between 2 and 10, inclusive. In certain
embodiments, each m independently is an integer between 3 and 10,
inclusive. In certain embodiments, each m independently is an
integer between 4 and 10, inclusive. In certain embodiments, each m
independently is an integer between 5 and 10, inclusive. In certain
embodiments, each m independently is an integer between 6 and 10,
inclusive. In certain embodiments, each m independently is an
integer between 7 and 10, inclusive. In certain embodiments, each m
independently is an integer between 8 and 10, inclusive. In certain
embodiments, m is 3, 5, or 7.
[0204] In certain embodiments, at least 50%, at least 60%, at least
70%, at least 80%, at least 90%, at least 95%, or at least 99% of
the polymers have the same value of m.
Variable n
[0205] In certain embodiments, n is an integer between 1 and
10,000, inclusive. In certain embodiments, n is an integer between
1,000 and 10,000, inclusive. In certain embodiments, n is an
integer between 5,000 and 10,000, inclusive. In certain
embodiments, n is an integer between 1 and 1,000, inclusive. In
certain embodiments, n is an integer between 10 and 500, inclusive.
In certain embodiments, n is an integer between 1 and 100,
inclusive. In certain embodiments, n is an integer between 1 and
10, inclusive.
Polymer (1)
[0206] In certain embodiments, the polymer is of the formula:
##STR00182##
wherein:
[0207] each R.sub.1 is independently
##STR00183##
[0208] at least one R.sub.1 is
##STR00184##
and
[0209] at least one R.sub.1 is
##STR00185##
[0210] In certain particular embodiments, the ratio of
##STR00186##
to
##STR00187##
is about 4:2, for example, about 3.9 to about 1.7.
[0211] In certain embodiments, each X is as defined herein. In
certain particular embodiments, each X is --NH--.
[0212] In certain embodiments, R.sub.3 and R.sub.4 are as defined
herein. In certain particular embodiments, R.sub.3 and R.sub.4 are
both
##STR00188##
[0213] In certain embodiments, m is as defined herein. In certain
particular embodiments, m is about 3-4. In certain particular
embodiments, m is about 5-6. In certain embodiments, m is about
7-8.
[0214] In certain embodiments, n is as defined herein. In certain
particular embodiments, n is between 1 and 10, inclusive. In a
particular embodiment, n is about 5.
[0215] In a particular embodiments, Polymer (1) is of Formula B1:
m=3, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00189##
[0216] In a particular embodiments, Polymer (1) is of Formula C1:
m=5, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00190##
[0217] In a particular embodiments, Polymer (1) is of Formula D1:
m=7, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00191##
[0218] In certain embodiments, Polymer (1) is selected from B1, C1,
and D1.
Polymer (2)
[0219] In certain embodiments, the polymer is of the formula:
##STR00192##
wherein:
[0220] each R.sub.1 is independently
##STR00193##
at least
[0221] one R.sub.1 is
##STR00194##
and
[0222] at least one R.sub.1 is
##STR00195##
[0223] In certain embodiments, the ratio of
##STR00196##
to
##STR00197##
is about 4:2, for example, about 3.9 to about 1.7.
[0224] In certain embodiments, each X is as defined herein. In
certain particular embodiments, each X is --NH--.
[0225] In certain embodiments, R.sub.3 and R.sub.4 are as defined
herein. In certain particular embodiments, R.sub.3 and R.sub.4 are
both
##STR00198##
[0226] In certain embodiments, m is as defined herein. In certain
particular embodiments, m is about 3-4. In certain particular
embodiments, m is about 5-6. In certain embodiments, m is about
7-8.
[0227] In certain embodiments, n is as defined herein. In certain
particular embodiments, n is between 1 and 10, inclusive. In a
particular embodiment, n is about 5.
[0228] In a particular embodiments, Polymer (2) is of Formula B2:
m=3, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00199##
[0229] In a particular embodiments, Polymer (2) is of Formula C2:
m=5, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00200##
[0230] In a particular embodiments, Polymer (2) is of Formula D2:
m=7, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00201##
[0231] In certain embodiments, Polymer (2) is selected from B2, C2,
and D2.
Polymer (3)
[0232] In certain embodiments, the polymer is of the formula:
##STR00202##
wherein:
[0233] each D is independently
##STR00203##
at least one D is
##STR00204##
and
[0234] at least one D is
##STR00205##
[0235] In certain embodiments, the ratio of
##STR00206##
is about 3.9 to about 1.7.
[0236] In certain embodiments, each X is as defined herein. In
certain particular embodiments, each X is --NH--.
[0237] In certain embodiments, R.sub.3 and R.sub.4 are as defined
herein. In certain particular embodiments, R.sub.3 and R.sub.4 are
both
##STR00207##
[0238] In certain embodiments, m is as defined herein. In certain
particular embodiments, m is about 3-4. In certain particular
embodiments, m is about 5-6. In certain embodiments, m is about
7-8.
[0239] In certain embodiments, n is as defined herein. In certain
particular embodiments, n is between 1 and 10, inclusive. In a
particular embodiment, n is about 5.
[0240] In a particular embodiments, Polymer (3) is of Formula B3:
m=3, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00208##
[0241] In a particular embodiments, Polymer (3) is of Formula C3:
m=5, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00209##
[0242] In a particular embodiments, Polymer (3) is of Formula D3:
m=7, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00210##
[0243] In certain embodiments, Polymer (3) is selected from B3,
C.sub.3, and D3.
Polymer (4)
[0244] In certain embodiments, the polymer is of the formula:
##STR00211##
wherein:
[0245] each R.sub.1 is independently
##STR00212##
[0246] at least one R.sub.1 is
##STR00213##
and
[0247] at least one R.sub.1 is
##STR00214##
[0248] In certain embodiments, the ratio of
##STR00215##
is about 3.9 to about 1.7.
[0249] In certain embodiments, each X is as defined herein. In
certain particular embodiments, each X is --NH--.
[0250] In certain embodiments, R.sub.3 and R.sub.4 are as defined
herein. In certain particular embodiments, R.sub.3 and R.sub.4 are
both
##STR00216##
[0251] In certain embodiments, m is as defined herein. In certain
particular embodiments, m is about 3-4. In certain particular
embodiments, m is about 5-6. In certain embodiments, m is about
7-8.
[0252] In certain embodiments, n is as defined herein. In certain
particular embodiments, n is between 1 and 10, inclusive. In a
particular embodiment, n is about 5.
[0253] In a particular embodiments, Polymer (4) is of Formula B4:
m=3, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00217##
[0254] In a particular embodiments, Polymer (4) is of Formula C4:
m=5, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00218##
[0255] In a particular embodiments, Polymer (4) is of Formula D4:
m=7, n is about 5, each X is --NH--, and R.sub.3 and R.sub.4 are
both
##STR00219##
[0256] In certain embodiments, Polymer (4) is selected from B4, C4,
and D4.
Polymer Properties
[0257] Exemplary polymers may be described in terms of properties
including, weight average molecular weight (M.sub.w), number
average molecular weight (M.sub.n), average hydrodynamic diameter
(D.sub.H), and polydispersity ( ).
[0258] In certain embodiments, the M.sub.n is determined with
viscometry via the (Mark-Houwink equation), colligative methods
(such as vapor pressure osmometry), end-group determination, or
proton NMR. In certain embodiments, the M.sub.w is determined with
gel permeation chromatography, static light scattering, small angle
neutron scattering, X-ray scattering, and sedimentation
velocity.
[0259] In some embodiments, M.sub.w is about 1000 to about 5000 Da,
e.g., as determined by gel permeation chromatography. In some
embodiments, M.sub.W is about 1000 to about 3000 Da. In some
embodiments, M.sub.W is about 1000 to about 2000 Da. In some
embodiments, M.sub.W is about 2000 to about 3000 Da. See, e.g.,
FIG. 9.
[0260] In some embodiments, M.sub.w of the polymer is between about
1 kDa and about 100 kDa, e.g., between about 1 kDa and about 50
kDa, about 15 kDa and about 85 kDa, about 20 kDa and about 60 kDa,
or about 30 kDa and about 50 kDa. In one embodiment, the average
molecular weight of the polymer is between about 20 kDa and about
60 kDa. In one embodiment, the average molecular weight of the
polymer is between about 30 kDa and about 50 kDa.
[0261] In some embodiments, the polydispersity ( ) of the polymer
is between 1 and 3, inclusive. In some embodiments, the
polydispersity ( ) of the polymer is between 2 and 3, inclusive. In
some embodiments, the average polydispersity of the polymer is less
than bout 2.6 (e.g., less than about 2.5, about 2.4, about 2.3,
about 2.2, about 2.1, or less). See, e.g., FIG. 9.
Compounds
[0262] Also provided are polylactone derived diacrylate compounds
that can be used to make PBAEs of the present disclosure. In one
aspect, provided herein is a compound of Formula (VI):
##STR00220##
wherein:
[0263] R is optionally substituted, cyclic or acyclic aliphatic;
optionally substituted, cyclic or acyclic heteroaliphatic; or a
combination thereof;
[0264] each R' independently is optionally substituted, cyclic or
acyclic aliphatic; optionally substituted, cyclic or acyclic
heteroaliphatic; or a combination thereof;
[0265] each R.sub.a independently is hydrogen or optionally
substituted aliphatic;
[0266] X' is O or NR.sub.y, wherein R.sub.y is hydrogen or
optionally substituted aliphatic; and
[0267] m is an integer between 1 and 100, inclusive.
[0268] In certain embodiments, R is a substituted aliphatic. In
certain embodiments, R is unsubstituted aliphatic. In certain
embodiments, R is substituted heteroaliphatic. In certain
embodiments, R is unsubstituted heteroaliphatic.
[0269] In certain embodiments, R' is substituted aliphatic. In
certain embodiments, R' is unsubstituted aliphatic. In certain
embodiments, R' is substituted heteroaliphatic. In certain
embodiments, R' is unsubstituted heteroaliphatic.
[0270] In certain embodiments, R' is of the formula:
##STR00221##
wherein R.sub.5 is selected from the group consisting of alkyl,
heteroalkyl, alkenyl, alkynyl, haloalkyl, alkoxy, thioalkoxy,
amino, alkylamino, dialkylamino, trialkylamino, acylamino, cyano,
hydroxy, halo, mercapto, nitro, carboxyaldehyde, carboxy,
alkoxycarbonyl, and carboxamide, wherein said alkyl, heteroalkyl,
alkenyl, and alkynyl are optionally substituted, cyclic or acyclic,
and branched or linear. In certain embodiments, R.sub.5 is
optionally substituted C.sub.2-C.sub.20 alkyl or optionally
substituted C.sub.2-C.sub.20 heteroalkyl. In certain embodiments, r
is 1-19.
[0271] In certain embodiments, X' is O. In certain embodiments, X'
is NR.sub.y. In certain embodiments, X' is NH.
[0272] In certain embodiments, m is selected from the group of
integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and
30. In certain embodiments, m is an integer between 31 and 40,
inclusive. In certain embodiments, m is an integer between 41 and
50, inclusive. In certain embodiments, m is an integer between 51
and 60, inclusive. In certain embodiments, m is an integer between
61 and 70, inclusive. In certain embodiments, m is an integer
between 71 and 80, inclusive. In certain embodiments, m is an
integer between 81 and 90, inclusive. In certain embodiments, m is
an integer between 91 and 100, inclusive. In certain embodiments, m
is 3, 5 or 7.
[0273] In certain embodiments, the compound is of the formula:
##STR00222##
[0274] In certain embodiments, the compound is of the formula:
##STR00223##
[0275] In certain embodiments, the compound is of the formula:
##STR00224##
Methods of Preparing Polymers and Compounds
[0276] The present disclosure provides methods of preparing PBAE
polymers of Formula (II), Formula (III), Formula (IV), and Formula
(V), and compounds of Formula (VI).
[0277] In one aspect, provided herein is a method of preparing a
polymer of Formula (II) as described herein:
##STR00225##
or a pharmaceutically acceptable salt thereof, comprising reacting
a polymer of Formula (IV) as described herein:
##STR00226##
or a pharmaceutically acceptable salt thereof, with one or more
nucleophiles selected from R.sub.3XH and R.sub.4XH, to obtain the
polymer of Formula (II).
[0278] In another aspect, provided herein is a method of preparing
a polymer of Formula (III) as described herein:
##STR00227##
or a pharmaceutically acceptable salt thereof, comprising reacting
a polymer of Formula (V) as described herein:
##STR00228##
or a pharmaceutically acceptable salt thereof, with one or more
nucleophiles selected from R.sub.3XH and R.sub.4XH; to obtain the
polymer of Formula (III).
[0279] In another aspect, provided herein is a method of preparing
a polymer of Formula (IV) as described herein:
##STR00229##
or a pharmaceutically acceptable salt thereof, comprising reacting
a compound of Formula (VI) as described herein:
##STR00230##
with one or more amines of the formula R.sub.1NH.sub.2, to obtain
the polymer of Formula (IV).
[0280] In yet another aspect, provided herein is a method of
preparing a polymer of Formula (V) as described herein:
##STR00231##
or a pharmaceutically acceptable salt thereof, comprising reacting
a compound of Formula (VI) as described herein:
##STR00232##
with one or more diamines of the formula
##STR00233##
to obtain the polymer of Formula (IV).
[0281] In another aspect, provided herein is a method of preparing
a compound of Formula (VI) as described herein:
##STR00234##
comprising:
[0282] reacting a compound of Formula (VIa):
##STR00235##
[0283] with a lactone to obtain a compound of Formula (VIb):
##STR00236##
and
[0284] acylating the compound of Formula (VIb) to obtain the
compound of Formula (VI).
[0285] Any lactone may be used in the methods provided above. In
certain embodiments, the lactone is of the formula:
##STR00237##
wherein R' is defined herein.
[0286] In certain embodiments, the lactone is selected from the
group consisting of:
##STR00238## ##STR00239## ##STR00240##
[0287] In certain embodiments, step of reacting comprises reacting
a compound of Formula (VIa) with a lactone in the presence of a
catalyst to obtain a compound of Formula (VIb). In certain
embodiments, the catalyst is a Lewis acid. In certain embodiments,
the Lewis acid is tin(II) 2-ethylhexanoate.
[0288] In certain embodiments, step of acylating comprises
acylating the compound of Formula (VIb) with an electrophile of the
formula:
##STR00241##
wherein LG is a leaving group, to obtain the compound of Formula
(VI).
[0289] In certain embodiments, the acylating reagent is an acryloyl
halide. In certain embodiments, the acylating agent is acryloyl
chloride.
[0290] In certain embodiments, step of acylating further comprises
acylating the compound of Formula (VIb) in the presence of a base.
In certain embodiments, the base is a trialkylamine (e.g.,
trimethylamine, diisopropylethylamine, and the like).
[0291] The reactions described herein, which constitute the methods
of preparing the compounds and polymers of the present disclosure,
may further include the use of one or more solvents. Common
solvents useful in the methods described herein include, but are
not limited to, acetone, acetonitrile, benzene, benzonitrile,
1-butanol, 2-butanone, butyl acetate, tert-butyl methyl ether,
carbon disulfide carbon tetrachloride, chlorobenzene,
1-chlorobutane, chloroform, cyclohexane, cyclopentane,
1,2-dichlorobenzene, 1,2-dichloroethane, dichloromethane (DCM),
N,N-dimethylacetamide N,N-dimethylformamide (DMF),
1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (DMPU), 1,4-dioxane,
1,3-dioxane, diethylether, 2-ethoxyethyl ether, ethyl acetate,
ethyl alcohol, ethylene glycol, dimethyl ether, heptane, n-hexane,
hexanes, hexamethylphosphoramide (HMPA), 2-methoxyethanol,
2-methoxyethyl acetate, methyl alcohol, 2-methylbutane,
4-methyl-2-pentanone, 2-methyl-1-propanol, 2-methyl-2-propanol,
1-methyl-2-pyrrolidinone, dimethylsulfoxide (DMSO), nitromethane,
1-octanol, pentane, 3-pentanone, 1-propanol, 2-propanol, pyridine,
tetrachloroethylene, tetrahyrdofuran (THF),
2-methyltetrahydrofuran, toluene, trichlorobenzene,
1,1,2-trichlorotrifluoroethane, 2,2,4-trimethylpentane,
trimethylamine, triethylamine, N,N-diisopropylethylamine,
diisopropylamine, water, o-xylene, and p-xylene. In certain
embodiments, each reaction independently is comprised of 1 to 10
solvents, inclusive. In certain embodiments, the reaction is
comprised of one solvent. In certain embodiments, at least one
solvent is dichloromethane (DCM). In certain embodiments, at least
one solvent is dimethylsulfoxide (DMSO).
[0292] The reactions described herein, which constitute the methods
of preparing the compounds and polymers of the present disclosure,
are performed at temperatures ranging between -10.degree. C. and
150.degree. C. In certain embodiments, the reaction is performed at
temperatures below or at 50.degree. C. In certain embodiments, the
reaction is performed at temperatures above 50.degree. C. In
certain embodiments, the reaction is performed at approximately
0.degree. C. In certain embodiments, the reaction is performed at
room temperature. In certain embodiments, the reaction is performed
at approximately 60.degree. C. In certain embodiments, the reaction
is performed at approximately 90.degree. C. In certain embodiments,
the reaction is performed at approximately 130.degree. C.
[0293] The reactions described herein, which constitute the methods
of preparing the compounds and polymers of the present disclosure,
are performed for about 1 hour to about 120 hours. In certain
embodiments, the reaction is performed for about 3 hours to about
72 hours. In certain embodiments, the reaction is performed for
about 3 hours. In certain embodiments, the reaction is performed
for about 24 hours. In certain embodiments, the reaction is
performed for about 48 hours. In certain embodiments, the reaction
is performed for about 72 hours.
[0294] In certain embodiments, the preparation of a compound of
Formula (VI):
##STR00242##
comprises reacting a compound of Formula (VIa):
##STR00243##
a lactone, a Lewis acid, and an acylating agent. Specific reaction
conditions can be determined by those of ordinary skill in the art
using no more than routine experimentation.
[0295] In certain embodiments, the compound of Formula (VIa):
##STR00244##
hydroxyethyl acrylate (HEA).
[0296] The lactone is used in an amount of about 1 to 15
equivalents of a compound of Formula (VIa). In certain embodiments,
the lactone is used in an amount of about 1 to 10 equivalents of a
compound of Formula (VIa). In certain embodiments, the lactone is
used in an amount of about 1 to 7 equivalents of a compound of
Formula (VIa). In certain embodiments, the lactone is used in an
amount of about 1 to 5 equivalents of a compound of Formula (VIa).
In certain embodiments, the lactone is used in an amount of about 1
to 3 equivalents of a compound of Formula (VIa). In certain
embodiments, the lactone is used in an amount of about 7
equivalents of a compound of Formula (VIa). In certain embodiments,
the lactone is used in an amount of about 5 equivalents of a
compound of Formula (VIa). In certain embodiments, the lactone is
used in an amount of about 3 equivalents of a compound of Formula
(VIa).
[0297] The compound of Formula (VIa) is used in an amount of about
1 to 500 equivalents of the Lewis acid. In certain embodiments, the
compound of Formula (VIa) is used in an amount of about 1 to 200
equivalents of the Lewis acid. In certain embodiments, the compound
of Formula (VIa) is used in an amount of about 200 equivalents of
the Lewis acid.
[0298] In certain embodiments, the preparation of a polymer of
Formula (IV) comprises reacting a compound of Formula (VI), or a
pharmaceutically acceptable salt thereof, with one or more amines
of the formula: R.sub.1NH.sub.2. In certain embodiments, the
preparation of a polymer of Formula (V) comprises reacting a
compound of Formula (VI), or a pharmaceutically acceptable salt
thereof, with one or more diamines of the formula:
##STR00245##
[0299] In certain embodiments, the preparation of a polymer of
Formula (II), or a pharmaceutically acceptable salt thereof,
comprises the reaction of a polymer of Formula (IV), or a
pharmaceutically acceptable salt thereof, with one or more amines
selected from R.sub.3NH.sub.2 and R.sub.4NH.sub.2. In certain
embodiments, the preparation of a polymer of Formula (III), or a
pharmaceutically acceptable salt thereof, comprises the reaction of
a polymer of Formula (V), or a pharmaceutically acceptable salt
thereof, with one or more amines selected from R.sub.3NH.sub.2 and
R.sub.4NH.sub.2, as described herein.
[0300] In certain embodiments, the amine or diamine is selected
from the group consisting of dodecyl amine,
3-amino-1,2-propanediol, 5-amino-pentanol,
N,N-dimethylethylenediamine, 2-morpholinoethylamine, and
2,2'-((oxybis(ethane-2,1-diyl))bis(oxy))diethanamine.
Compositions and Kits
[0301] The present disclosure provides compositions (e.g.,
pharmaceutical compositions) comprising a polymer described herein,
and an excipient (e.g., pharmaceutically acceptable excipient). In
certain embodiments, the composition is a pharmaceutical
composition. In certain embodiments, the composition is a cosmetic
composition. In certain embodiments, the composition is a
nutraceutical composition. In certain embodiments, the composition
is a composition with a non-medical application. In certain
embodiments, the excipient is a pharmaceutically acceptable
excipient.
[0302] Compositions described herein can be prepared by any method
known in the art. In general, such preparatory methods include
bringing the polymer described herein into association with one or
more excipients, and may include one or more agents and then, if
necessary and/or desirable, shaping, and/or packaging the product
into a desired single- or multi-dose unit. In certain embodiments,
the agent and the polymer of the composition are not covalently
attached.
[0303] In certain embodiments, the composition is in the form of a
particle. In certain embodiments, the particle is a nanoparticle or
a microparticle. In certain embodiments, the particle is a micelle,
liposome, or lipoplex. In certain embodiments, the particle
encapsulates an agent, as described herein. In certain embodiments,
the particle facilitates delivery of the agent to a cell. See,
e.g., FIGS. 5 and 10. In certain embodiments, the particle
facilitates delivery of the agent to a subject, e.g., a human.
[0304] Nanoparticles and nanoparticle formulations are described
herein. In certain embodiments, the nanoparticle comprises one or
more additional lipids. In certain particular embodiments, the
nanoparticle comprises a PEG-lipid. As described herein, PCL-based
PBAE nanoparticles can be prepared using a pre-mixing protocol or a
direct-mixing protocol. See, e.g., FIGS. 10 and 11.
[0305] Compositions can be prepared, packaged, and/or sold in bulk,
as a single unit dose, and/or as a plurality of single unit doses.
A "unit dose" is a discrete amount of the composition comprising a
predetermined amount of the agent. The amount of the agent is
generally equal to the dosage of the agent which would be
administered to a subject and/or a convenient fraction of such a
dosage, such as one-half or one-third of such a dosage.
[0306] Relative amounts of the polymer, excipient, agent, and/or
any additional ingredients in a composition described herein will
vary, depending upon the identity, size, and/or condition of the
subject treated and further depending upon the route by which the
composition is to be administered. The composition may comprise
between 0.1% and 100% (w/w) agent.
[0307] Excipients and accessory ingredients used in the manufacture
of provided compositions include inert diluents, dispersing and/or
granulating agents, surface active agents and/or emulsifiers,
disintegrating agents, binding agents, preservatives, buffering
agents, lubricating agents, and/or oils. Excipients and accessory
ingredients, such as cocoa butter, PEGylated lipids, phospholipids,
suppository waxes, coloring agents, coating agents, sweetening,
flavoring, and perfuming agents, may also be present in the
composition.
[0308] Exemplary diluents include calcium carbonate, sodium
carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate,
calcium hydrogen phosphate, sodium phosphate lactose, sucrose,
cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol,
inositol, sodium chloride, dry starch, cornstarch, powdered sugar,
and mixtures thereof.
[0309] Exemplary granulating and/or dispersing agents include
potato starch, corn starch, tapioca starch, sodium starch
glycolate, clays, alginic acid, guar gum, citrus pulp, agar,
bentonite, cellulose, and wood products, natural sponge,
cation-exchange resins, calcium carbonate, silicates, sodium
carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone),
sodium carboxymethyl starch (sodium starch glycolate),
carboxymethyl cellulose, cross-linked sodium carboxymethyl
cellulose (croscarmellose), methylcellulose, pregelatinized starch
(starch 1500), microcrystalline starch, water insoluble starch,
calcium carboxymethyl cellulose, magnesium aluminum silicate
(Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and
mixtures thereof.
[0310] Exemplary surface active agents and/or emulsifiers include
natural emulsifiers (e.g., acacia, agar, alginic acid, sodium
alginate, tragacanth, chondrux, xanthan, pectin, gelatin, egg yolk,
casein, wool fat, cholesterol, wax, and lecithin), colloidal clays
(e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum
silicate)), long chain amino acid derivatives, high molecular
weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl
alcohol, triacetin monostearate, ethylene glycol distearate,
glyceryl monostearate, and propylene glycol monostearate, polyvinyl
alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid,
acrylic acid polymer, and carboxyvinyl polymer), carrageenan,
cellulosic derivatives (e.g., carboxymethylcellulose sodium,
powdered cellulose, hydroxymethyl cellulose, hydroxypropyl
cellulose, hydroxypropyl methylcellulose, methylcellulose),
sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan
monolaurate (Tween.RTM. 20), polyoxyethylene sorbitan monostearate
(Tween.RTM. 60), polyoxyethylene sorbitan monooleate (Tween.RTM.
80), sorbitan monopalmitate (Span.RTM. 40), sorbitan monostearate
(Span.RTM. 60), sorbitan tristearate (Span.RTM. 65), glyceryl
monooleate, sorbitan monooleate (Span.RTM. 80), polyoxyethylene
esters (e.g., polyoxyethylene monostearate (Myrj.RTM. 45),
polyoxyethylene hydrogenated castor oil, polyethoxylated castor
oil, polyoxymethylene stearate, and Solutol.RTM.), sucrose fatty
acid esters, polyethylene glycol fatty acid esters (e.g.,
Cremophor.RTM.), polyoxyethylene ethers, (e.g., polyoxyethylene
lauryl ether (Brij.RTM. 30)), poly(vinyl-pyrrolidone), diethylene
glycol monolaurate, triethanolamine oleate, sodium oleate,
potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium
lauryl sulfate, Pluronic.RTM. F-68, poloxamer P-188, cetrimonium
bromide, cetylpyridinium chloride, benzalkonium chloride, docusate
sodium, and/or mixtures thereof.
[0311] Exemplary binding agents include starch (e.g., cornstarch
and starch paste), gelatin, sugars (e.g., sucrose, glucose,
dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.),
natural and synthetic gums (e.g., acacia, sodium alginate, extract
of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks,
carboxymethylcellulose, methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, microcrystalline cellulose, cellulose acetate,
poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum.RTM.),
and larch arabogalactan), alginates, polyethylene oxide,
polyethylene glycol, inorganic calcium salts, silicic acid,
polymethacrylates, waxes, water, alcohol, and/or mixtures
thereof.
[0312] Exemplary preservatives include antioxidants, chelating
agents, antimicrobial preservatives, antifungal preservatives,
antiprotozoan preservatives, alcohol preservatives, acidic
preservatives, and other preservatives. In certain embodiments, the
preservative is an antioxidant. In other embodiments, the
preservative is a chelating agent.
[0313] Exemplary antioxidants include alpha tocopherol, ascorbic
acid, acorbyl palmitate, butylated hydroxyanisole, butylated
hydroxytoluene, monothioglycerol, potassium metabisulfite,
propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite,
sodium metabisulfite, and sodium sulfite.
[0314] Exemplary chelating agents include
ethylenediaminetetraacetic acid (EDTA) and salts and hydrates
thereof (e.g., sodium edetate, disodium edetate, trisodium edetate,
calcium disodium edetate, dipotassium edetate, and the like),
citric acid and salts and hydrates thereof (e.g., citric acid
monohydrate), fumaric acid and salts and hydrates thereof, malic
acid and salts and hydrates thereof, phosphoric acid and salts and
hydrates thereof, and tartaric acid and salts and hydrates thereof.
Exemplary antimicrobial preservatives include benzalkonium
chloride, benzethonium chloride, benzyl alcohol, bronopol,
cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol,
chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin,
hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol,
phenylmercuric nitrate, propylene glycol, and thimerosal.
[0315] Exemplary antifungal preservatives include butyl paraben,
methyl paraben, ethyl paraben, propyl paraben, benzoic acid,
hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium
benzoate, sodium propionate, and sorbic acid.
[0316] Exemplary alcohol preservatives include ethanol,
polyethylene glycol, phenol, phenolic compounds, bisphenol,
chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0317] Exemplary acidic preservatives include vitamin A, vitamin C,
vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic
acid, ascorbic acid, sorbic acid, and phytic acid.
[0318] Other preservatives include tocopherol, tocopherol acetate,
deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA),
butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl
sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium
bisulfite, sodium metabisulfite, potassium sulfite, potassium
metabisulfite, Glydant.RTM. Plus, Phenonip.RTM., methylparaben,
Germall.RTM. 115, Germaben.RTM. II, Neolone.RTM., Kathon.RTM., and
Euxyl.RTM..
[0319] Exemplary buffering agents include citrate buffer solutions,
acetate buffer solutions, phosphate buffer solutions, ammonium
chloride, calcium carbonate, calcium chloride, calcium citrate,
calcium glubionate, calcium gluceptate, calcium gluconate,
D-gluconic acid, calcium glycerophosphate, calcium lactate,
propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium
phosphate, phosphoric acid, tribasic calcium phosphate, calcium
hydroxide phosphate, potassium acetate, potassium chloride,
potassium gluconate, potassium mixtures, dibasic potassium
phosphate, monobasic potassium phosphate, potassium phosphate
mixtures, sodium acetate, sodium bicarbonate, sodium chloride,
sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic
sodium phosphate, sodium phosphate mixtures, tromethamine,
magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free
water, isotonic saline, Ringer's solution, ethyl alcohol, and
mixtures thereof.
[0320] Exemplary lubricating agents include magnesium stearate,
calcium stearate, stearic acid, silica, talc, malt, glyceryl
behanate, hydrogenated vegetable oils, polyethylene glycol, sodium
benzoate, sodium acetate, sodium chloride, leucine, magnesium
lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0321] Exemplary natural oils include almond, apricot kernel,
avocado, babassu, bergamot, black current seed, borage, cade,
camomile, canola, caraway, carnauba, castor, cinnamon, cocoa
butter, coconut, cod liver, coffee, corn, cotton seed, emu,
Eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd,
grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui
nut, lavandin, lavender, lemon, Litsea cubeba, macademia nut,
mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange,
orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed,
pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood,
sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,
soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut,
and wheat germ oils. Exemplary synthetic oils include butyl
stearate, caprylic triglyceride, capric triglyceride,
cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl
myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone
oil, and mixtures thereof.
[0322] In certain embodiments, the compositions, further comprise
an agent, and are useful for delivering said agent (e.g., to a
subject or cell). In certain embodiments, the compositions are
pharmaceutical compositions which are useful for treating a disease
in a subject in need thereof. In certain embodiments, the
pharmaceutical compositions are useful for preventing a disease in
a subject. In certain embodiments, the pharmaceutical compositions
are useful for diagnosing a disease in a subject.
[0323] A composition as described herein may further comprise, or
can be administered in combination with, one or more additional
agents. In certain embodiments, the agent is a small organic
molecule, inorganic molecule, nucleic acid, protein, peptide, or
polynucleotide. In certain embodiments, the agent is a
pharmaceutical agent (e.g., therapeutically and/or prophylactically
active agent). Pharmaceutical agents include therapeutically active
agents. Pharmaceutical agents also include prophylactically active
agents. Pharmaceutical agents include small organic molecules such
as drug compounds (e.g., compounds approved for human or veterinary
use by the U.S. Food and Drug Administration as provided in the
Code of Federal Regulations (CFR)), peptides, proteins,
carbohydrates, monosaccharides, oligosaccharides, polysaccharides,
nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides
or proteins, small molecules linked to proteins, glycoproteins,
steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides,
oligonucleotides, antisense oligonucleotides, polynucleotides,
lipids, hormones, vitamins, vaccines, immunological agents, and
cells or other biological materials.
[0324] In certain embodiments, the agent is a polynucleotide. In
certain embodiments, the polynucleotide is DNA. In certain
embodiments, the polynucleotide is RNA. In certain embodiments, the
polynucleotide carries out RNA interference. The RNA is selected
from the group consisting of double-stranded RNA (dsRNA), small
interfering RNA (siRNA), short hairpin (shRNA), microRNA (miRNA),
messenger RNA (mRNA), antisense RNA, transfer RNA (tRNA), small
nuclear RNA (snRNA), and ribosomal RNA (rRNA). In certain
embodiments, the RNA is dsRNA. In certain embodiments, the RNA is
siRNA. In certain embodiments, the RNA is shRNA. In certain
embodiments, the RNA is miRNA. In certain embodiments, the RNA is
mRNA. In certain embodiments, the RNA is antisense RNA.
[0325] In certain embodiments, the agent described herein is
provided in an effective amount in the composition. In certain
embodiments, the effective amount is a therapeutically effective
amount. In certain embodiments, the effective amount is a
prophylactically effective amount. In certain embodiments, the
effective amount is an amount effective for treating a
proliferative disease in a subject in need thereof. In certain
embodiments, the effective amount is an amount effective for
preventing a proliferative disease in a subject in need thereof. In
certain embodiments, the effective amount is an amount effective
for treating a hematological disease in a subject in need thereof.
In certain embodiments, the effective amount is an amount effective
for preventing a hematological disease in a subject in need
thereof. In certain embodiments, the effective amount is an amount
effective for treating a neurological disease in a subject in need
thereof. In certain embodiments, the effective amount is an amount
effective for preventing a neurological disease in a subject in
need thereof. In certain embodiments, the effective amount is an
amount effective for treating a in a painful condition subject in
need thereof. In certain embodiments, the effective amount is an
amount effective for preventing a painful condition in a subject in
need thereof. In certain embodiments, the effective amount is an
amount effective for treating a psychiatric disorder in a subject
in need thereof. In certain embodiments, the effective amount is an
amount effective for preventing a psychiatric disorder in a subject
in need thereof. In certain embodiments, the effective amount is an
amount effective for treating a metabolic disorder in a subject in
need thereof. In certain embodiments, the effective amount is an
amount effective for preventing a metabolic disorder in a subject
in need thereof. In certain embodiments, the effective amount is an
amount effective for reducing the risk of developing a disease
(e.g., proliferative disease, hematological disease, neurological
disease, infectious disease, inflammatory disease, autoimmune
disease, gastrointestinal disease, liver disease, lung disease,
kidney disease, spleen disease, familial amyloid neuropathies,
painful condition, psychiatric disorder, or metabolic disorder) in
a subject in need thereof.
[0326] In certain embodiments, the cell is in vitro. In certain
embodiments, the cell is in vivo.
[0327] Compositions may be formulated into liquid dosage forms for
oral and parenteral administration include pharmaceutically
acceptable emulsions, microemulsions, solutions, suspensions,
syrups and elixirs. In addition to the agents, the liquid dosage
forms may comprise inert diluents commonly used in the art such as,
for example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils
(e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame
oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols
and fatty acid esters of sorbitan, and mixtures thereof. Besides
inert diluents, the oral compositions can include adjuvants such as
wetting agents, emulsifying and suspending agents, sweetening,
flavoring, and perfuming agents. In certain embodiments for
parenteral administration, the particles described herein are mixed
with solubilizing agents, such as Cremophor.RTM., alcohols, oils,
modified oils, glycols, polysorbates, cyclodextrins, polymers, and
mixtures thereof.
[0328] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions can be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation can be a
sterile injectable solution, suspension, or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that can be employed are water, Ringer's solution, U.S.P.,
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or di-glycerides. In addition, fatty acids, such as
oleic acid, are used in the preparation of injectables.
[0329] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0330] In order to prolong the effect of an agent, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This can be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the agent then depends
upon its rate of dissolution, which, in turn, may depend upon
crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form may be
accomplished by dissolving or suspending the agent in an oil
vehicle.
[0331] Compositions for rectal or vaginal administration are
typically suppositories which can be prepared by mixing the
particles described herein with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol, or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the agent.
[0332] Compositions may be formulated into solid dosage forms for
oral administration include capsules, tablets, pills, powders, and
granules. In such solid dosage forms, the agent is mixed with at
least one inert, pharmaceutically acceptable excipient or carrier
such as sodium citrate or dicalcium phosphate and/or (a) fillers or
extenders such as starches, lactose, sucrose, glucose, mannitol,
and silicic acid, (b) binders such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,
sucrose, and acacia, (c) humectants such as glycerol, (d)
disintegrating agents such as agar, calcium carbonate, potato or
tapioca starch, alginic acid, certain silicates, and sodium
carbonate, (e) solution retarding agents such as paraffin, (f)
absorption accelerators such as quaternary ammonium compounds, (g)
wetting agents such as, for example, cetyl alcohol and glycerol
monostearate, (h) absorbents such as kaolin and bentonite clay, and
(i) lubricants such as talc, calcium stearate, magnesium stearate,
solid polyethylene glycols, sodium lauryl sulfate, and mixtures
thereof. In the case of capsules, tablets, and pills, the dosage
form may include a buffering agent.
[0333] Solid compositions of a similar type can be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the art of pharmacology. They may optionally
comprise opacifying agents and can be of a composition that they
release the agent(s) only, or preferentially, in a certain part of
the intestinal tract, optionally, in a delayed manner. Examples of
encapsulating compositions which can be used include polymeric
substances and waxes. Solid compositions of a similar type can be
employed as fillers in soft and hard-filled gelatin capsules using
such excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0334] The agent can be in a micro-encapsulated form with one or
more excipients as noted above. The solid dosage forms of tablets,
dragees, capsules, pills, and granules can be prepared with
coatings and shells such as enteric coatings, release controlling
coatings, and other coatings well known in the pharmaceutical
formulating art. In such solid dosage forms the agent can be
admixed with at least one inert diluent such as sucrose, lactose,
or starch. Such dosage forms may comprise, as is normal practice,
additional substances other than inert diluents, e.g., tableting
lubricants and other tableting aids such a magnesium stearate and
microcrystalline cellulose. In the case of capsules, tablets and
pills, the dosage forms may comprise buffering agents. They may
optionally comprise opacifying agents and can be of a composition
that they release the agent(s) only, or preferentially, in a
certain part of the intestinal tract, optionally, in a delayed
manner. Examples of encapsulating agents which can be used include
polymeric substances and waxes.
[0335] Dosage forms for topical and/or transdermal administration
of a composition described herein may include ointments, pastes,
creams, lotions, gels, powders, solutions, sprays, inhalants,
and/or patches. Generally, the agent is admixed under sterile
conditions with a pharmaceutically acceptable carrier or excipient
and/or any needed preservatives and/or buffers as can be required.
Additionally, the present disclosure contemplates the use of
transdermal patches, which often have the added advantage of
providing controlled delivery of an agent to the body. Such dosage
forms can be prepared, for example, by dissolving and/or dispensing
the agent in the proper medium. Alternatively or additionally, the
rate can be controlled by either providing a rate controlling
membrane and/or by dispersing the agent in a polymer matrix and/or
gel.
[0336] Suitable devices for use in delivering intradermal
compositions described herein include short needle devices.
Intradermal compositions can be administered by devices which limit
the effective penetration length of a needle into the skin.
Alternatively or additionally, conventional syringes can be used in
the classical mantoux method of intradermal administration. Jet
injection devices which deliver liquid formulations to the dermis
via a liquid jet injector and/or via a needle which pierces the
stratum corneum and produces a jet which reaches the dermis are
suitable. Ballistic powder/particle delivery devices which use
compressed gas to accelerate the polymer in powder form through the
outer layers of the skin to the dermis are suitable.
[0337] Formulations suitable for topical administration include
liquid and/or semi-liquid preparations such as liniments, lotions,
oil-in-water and/or water-in-oil emulsions such as creams,
ointments, and/or pastes, and/or solutions and/or suspensions.
Topically administrable formulations may, for example, comprise
from about 1% to about 10% (w/w) agent, although the concentration
of the agent can be as high as the solubility limit of the agent in
the solvent. Formulations for topical administration may further
comprise one or more of the additional ingredients described
herein.
[0338] A composition described herein can be prepared, packaged,
and/or sold in a formulation suitable for pulmonary administration
via the buccal cavity. Such a formulation may comprise dry
particles which comprise the agent and which have a diameter in the
range from about 0.5 to about 7 nanometers, or from about 1 to
about 6 nanometers. Such compositions are conveniently in the form
of dry powders for administration using a device comprising a dry
powder reservoir to which a stream of propellant can be directed to
disperse the powder and/or using a self-propelling solvent/powder
dispensing container such as a device comprising the agent
dissolved and/or suspended in a low-boiling propellant in a sealed
container. Such powders comprise particles wherein at least 98% of
the particles by weight have a diameter greater than 0.5 nanometers
and at least 95% of the particles by number have a diameter less
than 7 nanometers. Alternatively, at least 95% of the particles by
weight have a diameter greater than 1 nanometer and at least 90% of
the particles by number have a diameter less than 6 nanometers. Dry
powder compositions may include a solid fine powder diluent such as
sugar and are conveniently provided in a unit dose form.
[0339] Low boiling propellants generally include liquid propellants
having a boiling point of below 65.degree. F. at atmospheric
pressure. Generally the propellant may constitute 50 to 99.9% (w/w)
of the composition, and the agent may constitute 0.1 to 20% (w/w)
of the composition. The propellant may further comprise additional
ingredients such as a liquid non-ionic and/or solid anionic
surfactant and/or a solid diluent (which may have a particle size
of the same order as particles comprising the agent).
[0340] Compositions described herein formulated for pulmonary
delivery may provide the agent in the form of droplets of a
solution and/or suspension. Such formulations can be prepared,
packaged, and/or sold as aqueous and/or dilute alcoholic solutions
and/or suspensions, optionally sterile, comprising the agent, and
may conveniently be administered using any nebulization and/or
atomization device. Such formulations may further comprise one or
more additional ingredients including a flavoring agent such as
saccharin sodium, a volatile oil, a buffering agent, a surface
active agent, and/or a preservative such as
methylhydroxybenzoate.
[0341] Formulations described herein as being useful for pulmonary
delivery are useful for intranasal delivery of a pharmaceutical
composition described herein. Another formulation suitable for
intranasal administration is a coarse powder comprising the agent
and having an average particle from about 0.2 to 500 micrometers.
Such a formulation is administered by rapid inhalation through the
nasal passage from a container of the powder held close to the
nares.
[0342] Formulations for nasal administration may, for example,
comprise from about as little as 0.1% (w/w) to as much as 100%
(w/w) of the agent, and may comprise one or more of the additional
ingredients described herein. A pharmaceutical composition
described herein can be prepared, packaged, and/or sold in a
formulation for buccal administration. Such formulations may, for
example, be in the form of tablets and/or lozenges made using
conventional methods, and may contain, for example, 0.1 to 20%
(w/w) agent, the balance comprising an orally dissolvable and/or
degradable composition and, optionally, one or more of the
additional ingredients described herein. Alternately, formulations
for buccal administration may comprise a powder and/or an
aerosolized and/or atomized solution and/or suspension comprising
the agent. Such powdered, aerosolized, and/or aerosolized
formulations, when dispersed, may have an average particle and/or
droplet size in the range from about 0.1 to about 200 nanometers,
and may further comprise one or more of the additional ingredients
described herein.
[0343] A composition described herein can be prepared, packaged,
and/or sold in a formulation for ophthalmic administration. Such
formulations may, for example, be in the form of eye drops
including, for example, a 0.1-1.0% (w/w) solution and/or suspension
of the agent in an aqueous or oily liquid carrier or excipient.
Such drops may further comprise buffering agents, salts, and/or one
or more other of the additional ingredients described herein. Other
ophthalmically-administrable formulations which are useful include
those which comprise the agent in microcrystalline form and/or in a
liposomal preparation. Ear drops and/or eye drops are also
contemplated as being within the scope of this disclosure.
[0344] Although the descriptions of compositions provided herein
are principally directed to compositions which are suitable for
administration to humans, it will be understood by the skilled
artisan that such compositions are generally suitable for
administration to animals of all sorts. Modification of
compositions suitable for administration to humans in order to
render the compositions suitable for administration to various
animals is well understood, and the ordinarily skilled veterinary
pharmacologist can design and/or perform such modification with
ordinary experimentation.
[0345] Compositions provided herein are typically formulated in
dosage unit form for ease of administration and uniformity of
dosage. It will be understood, however, that the total daily usage
of the compositions described herein will be decided by a physician
within the scope of sound medical judgment. The specific
therapeutically effective dose level for any particular subject or
organism will depend upon a variety of factors including the
disease being treated and the severity of the disorder; the
activity of the specific agent employed; the specific composition
employed; the age, body weight, general health, sex, and diet of
the subject; the time of administration, route of administration,
and rate of excretion of the specific agent employed; the duration
of the treatment; drugs used in combination or coincidental with
the specific agent employed; and like factors well known in the
medical arts.
[0346] The compositions provided herein can be administered by any
route, including enteral (e.g., oral), parenteral, intravenous,
intramuscular, intra-arterial, intramedullary, intrathecal,
subcutaneous, intraventricular, transdermal, interdermal, rectal,
intravaginal, intraperitoneal, topical (as by powders, ointments,
creams, and/or drops), mucosal, nasal, bucal, sublingual; by
intratracheal instillation, bronchial instillation, and/or
inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
Specifically contemplated routes are oral administration,
intravenous administration (e.g., systemic intravenous injection),
regional administration via blood and/or lymph supply, and/or
direct administration to an affected site. In general, the most
appropriate route of administration will depend upon a variety of
factors including the nature of the agent (e.g., its stability in
the environment of the gastrointestinal tract), and/or the
condition of the subject (e.g., whether the subject is able to
tolerate oral administration). In certain embodiments, the
composition described herein is suitable for topical administration
to the eye of a subject.
[0347] The exact amount of an agent required to achieve an
effective amount will vary from subject to subject, depending, for
example, on species, age, and general condition of a subject,
severity of the side effects or disorder, identity of the
particular agent, mode of administration, and the like. An
effective amount may be included in a single dose (e.g., single
oral dose) or multiple doses (e.g., multiple oral doses). In
certain embodiments, when multiple doses are administered to a
subject or applied to a tissue or cell, any two doses of the
multiple doses include different or substantially the same amounts
of an agent described herein. In certain embodiments, when multiple
doses are administered to a subject or applied to a tissue or cell,
the frequency of administering the multiple doses to the subject or
applying the multiple doses to the tissue or cell is three doses a
day, two doses a day, one dose a day, one dose every other day, one
dose every third day, one dose every week, one dose every two
weeks, one dose every three weeks, or one dose every four weeks. In
certain embodiments, the frequency of administering the multiple
doses to the subject or applying the multiple doses to the tissue
or cell is one dose per day. In certain embodiments, the frequency
of administering the multiple doses to the subject or applying the
multiple doses to the tissue or cell is two doses per day. In
certain embodiments, the frequency of administering the multiple
doses to the subject or applying the multiple doses to the tissue
or cell is three doses per day. In certain embodiments, when
multiple doses are administered to a subject or applied to a tissue
or cell, the duration between the first dose and last dose of the
multiple doses is one day, two days, four days, one week, two
weeks, three weeks, one month, two months, three months, four
months, six months, nine months, one year, two years, three years,
four years, five years, seven years, ten years, fifteen years,
twenty years, or the lifetime of the subject, tissue, or cell. In
certain embodiments, the duration between the first dose and last
dose of the multiple doses is three months, six months, or one
year. In certain embodiments, the duration between the first dose
and last dose of the multiple doses is the lifetime of the subject,
tissue, or cell. In certain embodiments, a dose (e.g., a single
dose, or any dose of multiple doses) described herein includes
independently between 0.1 .mu.g and 1 .mu.g, between 0.001 mg and
0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg,
between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30
mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between
300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a
polymer described herein. In certain embodiments, a dose described
herein includes independently between 1 mg and 3 mg, inclusive, of
a polymer described herein. In certain embodiments, a dose
described herein includes independently between 3 mg and 10 mg,
inclusive, of a polymer described herein. In certain embodiments, a
dose described herein includes independently between 10 mg and 30
mg, inclusive, of a polymer described herein. In certain
embodiments, a dose described herein includes independently between
30 mg and 100 mg, inclusive, of a polymer described herein.
[0348] Dose ranges as described herein provide guidance for the
administration of provided compositions to an adult. The amount to
be administered to, for example, a child or an adolescent can be
determined by a medical practitioner or person skilled in the art
and can be lower or the same as that administered to an adult. In
certain embodiments, a dose described herein is a dose to an adult
human whose body weight is 70 kg.
[0349] The compositions can be administered in combination with
additional agents that improve their activity (e.g., activity
(e.g., potency and/or efficacy) in treating a disease in a subject
in need thereof, in preventing a disease in a subject in need
thereof, in reducing the risk to develop a disease in a subject in
need thereof, and/or in inhibiting the activity of a protein kinase
in a subject or cell), improve bioavailability, improve safety,
reduce drug resistance, reduce and/or modify metabolism, inhibit
excretion, and/or modify distribution in a subject or cell. It will
also be appreciated that the therapy employed may achieve a desired
effect for the same disorder, and/or it may achieve different
effects. In certain embodiments, a composition described herein
including a polymer described herein and an agent shows a
synergistic effect that is absent in a composition including one of
the polymer and an agent, but not both.
[0350] The composition can be administered concurrently with, prior
to, or subsequent to one or more additional agents, which are
different from the composition and may be useful as, e.g.,
combination therapies. Pharmaceutical agents include
therapeutically active agents. Pharmaceutical agents also include
prophylactically active agents. Pharmaceutical agents include small
organic molecules such as drug compounds (e.g., compounds approved
for human or veterinary use by the U.S. Food and Drug
Administration as provided in the Code of Federal Regulations
(CFR)), peptides, proteins, carbohydrates, monosaccharides,
oligosaccharides, polysaccharides, nucleoproteins, mucoproteins,
lipoproteins, synthetic polypeptides or proteins, small molecules
linked to proteins, glycoproteins, steroids, nucleic acids, DNAs,
RNAs, nucleotides, nucleosides, oligonucleotides, antisense
oligonucleotides, lipids, hormones, vitamins, and cells. In certain
embodiments, the additional pharmaceutical agent is a
pharmaceutical agent useful for treating and/or preventing a
disease (e.g., proliferative disease, hematological disease,
neurological disease, painful condition, psychiatric disorder, or
metabolic disorder). Each additional pharmaceutical agent may be
administered at a dose and/or on a time schedule determined for
that pharmaceutical agent. The additional pharmaceutical agents may
also be administered together with each other and/or with the
polymer or composition described herein in a single dose or
administered separately in different doses. The particular
combination to employ in a regimen will take into account
compatibility of the polymer described herein with the additional
pharmaceutical agent(s) and/or the desired therapeutic and/or
prophylactic effect to be achieved. In general, it is expected that
the additional pharmaceutical agent(s) in combination be utilized
at levels that do not exceed the levels at which they are utilized
individually. In some embodiments, the levels utilized in
combination will be lower than those utilized individually.
[0351] The additional pharmaceutical agents include
anti-proliferative agents, anti-cancer agents, cytotoxic agents,
anti-angiogenesis agents, anti-inflammatory agents,
immunosuppressants, anti-bacterial agents, anti-viral agents,
cardiovascular agents, cholesterol-lowering agents, antidiabetic
agents, anti-allergic agents, contraceptive agents, and
pain-relieving agents. In certain embodiments, the additional
pharmaceutical agent is an anti-proliferative agent. In certain
embodiments, the additional pharmaceutical agent is an anti-cancer
agent. In certain embodiments, the additional pharmaceutical agent
is an anti-viral agent. In certain embodiments, the additional
pharmaceutical agent is a binder or inhibitor of a protein kinase.
In certain embodiments, the additional pharmaceutical agent is
selected from the group consisting of epigenetic or transcriptional
modulators (e.g., DNA methyltransferase inhibitors, histone
deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase
inhibitors), antimitotic drugs (e.g., taxanes and vinca alkaloids),
hormone receptor modulators (e.g., estrogen receptor modulators and
androgen receptor modulators), cell signaling pathway inhibitors
(e.g., tyrosine protein kinase inhibitors), modulators of protein
stability (e.g., proteasome inhibitors), Hsp90 inhibitors,
glucocorticoids, all-trans retinoic acids, and other agents that
promote differentiation. In certain embodiments, the polymers
described herein or pharmaceutical compositions can be administered
in combination with an anti-cancer therapy including surgery,
radiation therapy, transplantation (e.g., stem cell
transplantation, bone marrow transplantation), immunotherapy, and
chemotherapy.
[0352] In some embodiments, the composition is a particle (e.g., a
nanoparticle). In some embodiments, the particle is substantially
soluble in water (e.g., hydrophilic). In some embodiments, the
particle is substantially insoluble in water (e.g., hydrophobic).
In some embodiments, the particle is substantially insoluble in
water and greater than about 10,000 parts water are required to
dissolve 1 part polymer. In one embodiment, the particle is
amphiphilic. In one embodiment, the particle comprises a segment
that is hydrophobic and a segment that is hydrophilic.
[0353] In some embodiments, the percentage of the particles that
comprise an agent is between about 1 and about 100% (e.g., about
1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%,
about 20%, about 30%, about 40%, about 50%, about 60%, about 70%,
about 80%, about 90%, or about 100%). In some embodiments, the
percentage of the particles that comprise an agent is less than
about 50%, e.g., less than about 40%, less than about 35%, less
than about 30%, less than about 25%, less than about 20%, less than
about 15%, or less than about 10%. In some embodiments, the
percentage of the particles that comprise an agent is between about
5% and about 50%, about 5% and about 40%, about 5% and about 30%,
about 5% and about 25%, or about 5% and about 20%. In some
embodiments, the percentage of the particles that comprise an agent
is between about 5% and 90%. In some embodiments, the percentage of
the particles that comprise an agent is between about 5% and about
75%. In the some embodiments, the percentage of particles that
comprise an agent is between about 5% and about 50%. In the some
embodiments, the percentage of the particles that comprise an agent
is between about 10% and about 25%.
[0354] In some embodiments, the total amount of the agent present
in the particle is greater than about 5% (e.g., about 6%, about 7%,
about 8%, about 9%, about 10%, about 12%, about 15%, about 20%,
about 25%, about 30%, or more) of the total size or weight of the
conjugate or particle. In some embodiments, the total amount of the
agent present in the conjugate or particle is greater than about
10% (e.g., about 12%, about 15%, about 20%, about 25%, about 30%,
or more) of the total size or weight of the conjugate or
particle.
[0355] Without being bound by theory, the polymers or particles
disclosed herein may improve the efficiency of an agent by one or
more of increasing the localization and/or release (e.g.,
preferential release) of the agent to a target cell (e.g., a cancer
or a fibrotic cell; a cell associated with a hypoxic environment),
or increasing the half life of the agent, thus resulting in a
significantly higher amount of a released agent at a target site
(e.g., a tumor or liver (e.g., cirrhotic cell). According, the
conjugates and particles disclosed herein can be more effective
therapeutically than the free agent (e.g., due to enhanced drug
uptake in the target tissue) and/or allow for a lower therapeutic
dose of the agent, e.g., without substantially compromising the
resulting drug concentration at a target tissue. In some
embodiments, the conjugates and particles disclosed herein can
reduce the adverse effect associated with systemic administration
of an agent in free form (e.g., not coupled to a polymer, conjugate
or particle described herein).
[0356] Without being bound by theory, due to the localized delivery
of the compositions described herein (e.g., the agent-containing
particles), a lower dose or amount of the agent in the particles
can be administered (e.g., through local sustained delivery)
compared to the agent in free form. In other embodiments, the
agent-containing particles are administered at a dose or amount of
the agent that is less than the dose or amount of said agent in
free form to have a desired effect (e.g., a desired therapeutic
effect).
[0357] In some embodiments, the agent is incorporated into a
particle at a dose that is less than the dose or amount of said
agent in free form to have a desired effect (e.g., a desired
therapeutic effect), e.g., the standard of care dose for the
intended use of the free agent. In one embodiment, the agent are
incorporated into the particles at a dose or amount of the agent
that is less than the standard of care dose of the agent for a
desired therapy (e.g., a dose that is less than about 0.01, about
0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07,
about 0.08, about 0.09, about 0.1, about 0.2, about 0.3, about 0.4,
about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about
0.95 that of the standard of care dose of the agent).
[0358] In some embodiments, the agent is incorporated into a
particle at a dose equivalent to the dose or amount of said agent
in free form to have a desired effect (e.g., a desired therapeutic
effect), e.g., the standard of care dose for the intended use of
the free agent. In these embodiments, the particle produces a
greater therapeutic effect and/or a less adverse effect than the
free agent. In certain embodiments, the particle increases the
amount of the agent delivered to a tissue or cell in need thereof
and reduces the amount of the agent exposed to a non-target tissue
or cell, as compared to the free agent.
[0359] In some embodiments, the agent is incorporated into a
particle at a dose higher than the dose or amount of said agent in
free form to have a desired effect (e.g., a desired therapeutic
effect), e.g., the standard of care dose for the intended use of
the free agent. In some embodiments, the agent is incorporated into
a particle at a dose higher than the dose or amount of said agent
in free form that would produce an adverse effect by systemic
administration (e.g., a reduction in blood pressure). In some
embodiments, since the particle described herein releases the agent
at a target site based on pH microenvironment, other non-target
sites (e.g., blood vessels) with different pH would be less likely
to be exposed to the agent.
[0360] In another aspect, provided are kits including a first
container comprising a polymer or composition described herein and
instructions for use. The kits may further comprise a container
(e.g., a vial, ampule, bottle, syringe, and/or dispenser package,
or other suitable container). In some embodiments, provided kits
may optionally further include a second container comprising an
excipient for dilution or suspension of a composition or polymer
described herein. In some embodiments, the composition described
herein provided in the first container and the second container are
combined to form one unit dosage form.
[0361] In certain embodiments, the kits are useful for delivering
an agent (e.g., to a subject or cell). In certain embodiments, the
kits are useful for treating a disease (e.g., proliferative
disease, hematological disease, neurological disease, painful
condition, psychiatric disorder, or metabolic disorder) in a
subject in need thereof. In certain embodiments, the kits are
useful for preventing a disease (e.g., proliferative disease,
hematological disease, neurological disease, painful condition,
psychiatric disorder, or metabolic disorder) in a subject in need
thereof. In certain embodiments, the kits are useful for reducing
the risk of developing a disease (e.g., proliferative disease,
hematological disease, neurological disease, painful condition,
psychiatric disorder, or metabolic disorder) in a subject in need
thereof. In certain embodiments, the kits are useful for inhibiting
the activity (e.g., aberrant activity, such as increased activity)
of a protein kinase in a subject or cell.
[0362] In certain embodiments, a kit described herein further
includes instructions for using the kit. A kit described herein may
also include information as required by a regulatory agency such as
the U.S. Food and Drug Administration (FDA). In certain
embodiments, the information included in the kits is prescribing
information. In certain embodiments, the kits and instructions
provide for delivering an agent. In certain embodiments, the kits
and instructions provide for treating a disease (e.g.,
proliferative disease, hematological disease, neurological disease,
painful condition, psychiatric disorder, or metabolic disorder) in
a subject in need thereof. In certain embodiments, the kits and
instructions provide for preventing a disease (e.g., proliferative
disease, hematological disease, neurological disease, painful
condition, psychiatric disorder, or metabolic disorder) in a
subject in need thereof. In certain embodiments, the kits and
instructions provide for reducing the risk of developing a disease
(e.g., proliferative disease, hematological disease, neurological
disease, painful condition, psychiatric disorder, or metabolic
disorder) in a subject in need thereof. In certain embodiments, the
kits and instructions provide for inhibiting the activity (e.g.,
aberrant activity, such as increased activity) of a protein kinase
in a subject or cell. A kit described herein may include one or
more additional pharmaceutical agents described herein as a
separate composition.
Methods of Treatment and Uses
[0363] The present disclosure also provides methods of using the
compositions described herein, or a pharmaceutical composition
thereof, for delivering an agent. The present disclosure also
provides methods of using the polymers described herein, or a
pharmaceutical composition thereof, for the treatment, prevention,
or diagnosis of a disease or condition.
[0364] In certain embodiments, the methods described herein include
treating a disease, disorder, or condition from which a subject
suffers, comprising administering to a subject in need thereof an
effective amount of a composition described herein. In certain
embodiments, the methods described herein include implanting in a
subject an effective amount of the composition described herein. In
certain embodiments, the methods described herein comprise treating
a disease or condition in a subject in need thereof by
administering to or implanting in the subject a therapeutically
effective amount of a composition. In certain embodiments, the
methods described herein comprise preventing a disease or condition
in a subject in need thereof by administering to or implanting in
the subject a prophylactically effective amount of a composition.
In certain embodiments, the methods described herein comprise
diagnosing a disease or condition in a subject in need thereof by
administering to or implanting in the subject a diagnostically
effective amount of a composition.
[0365] In certain embodiments, the disease or condition is a
genetic disease, proliferative disease, hematological disease,
neurological disease, painful condition, psychiatric disorder,
metabolic disorder, long-term medical condition, cancer (e.g. lung
cancer, large bowel cancer, pancreas cancer, biliary tract cancer,
or endometrial cancer), neoplasm, angiogenesis, inflammatory
disease, autoinflammatory disease, liver disease, lung disease,
spleen disease, familial amyloid neuropathy, cardiovascular
disease, viral infection, fibrotic condition, or autoimmune
disease.
[0366] In some embodiments, the compositions are useful in treating
lung cancer, head-and-neck cancer, esophagus cancer, stomach
cancer, breast cancer, pancreas cancer, liver cancer, kidney
cancer, prostate caner, glioblastomas, metastatic melanomas,
peritoneal or pleural mesotheliomas.
[0367] In some embodiments, the proliferative disease is a benign
neoplasm. All types of benign neoplasms disclosed herein or known
in the art are contemplated as being within the scope of the
disclosure. In some embodiments, the proliferative disease is
associated with angiogenesis. All types of angiogenesis disclosed
herein or known in the art are contemplated as being within the
scope of the disclosure. In certain embodiments, the proliferative
disease is an inflammatory disease. All types of inflammatory
diseases disclosed herein or known in the art are contemplated as
being within the scope of the disclosure. In certain embodiments,
the inflammatory disease is rheumatoid arthritis. In some
embodiments, the proliferative disease is an autoinflammatory
disease. All types of autoinflammatory diseases disclosed herein or
known in the art are contemplated as being within the scope of the
disclosure. In some embodiments, the proliferative disease is an
autoimmune disease. All types of autoimmune diseases disclosed
herein or known in the art are contemplated as being within the
scope of the disclosure.
[0368] In certain embodiments, the disease is a cardiovascular
disease. In certain embodiments, the disease is atherogenesis or
atherosclerosis. In certain embodiments, the disease is arterial
stent occlusion, heart failure (e.g., congestive heart failure), a
coronary arterial disease, myocarditis, pericarditis, a cardiac
valvular disease, stenosis, restenosis, in-stent-stenosis, angina
pectoris, myocardial infarction, acute coronary syndromes, coronary
artery bypass grafting, a cardio-pulmonary bypass procedure,
endotoxemia, ischemia-reperfusion injury, cerebrovascular ischemia
(stroke), renal reperfusion injury, embolism (e.g., pulmonary,
renal, hepatic, gastrointestinal, or peripheral limb embolism), or
myocardial ischemia.
[0369] In certain embodiments, the disease is a viral infection. In
certain embodiments, the disease is an infection caused by DNA
virus. In certain embodiments, the disease is an infection caused
by a dsDNA virus. In certain embodiments, the disease is an
infection caused by an ssDNA virus. In certain embodiments, the
disease is an infection caused by an RNA virus. In certain
embodiments, the disease is an infection caused by a dsRNA virus.
In certain embodiments, the disease is an infection caused by a
(+)ssRNA virus. In certain embodiments, the disease is an infection
caused by a (-)ssRNA virus. In certain embodiments, the disease is
an infection caused by a reverse transcribing (RT) virus. In
certain embodiments, the disease is an infection caused by an
ssRNA-RT virus. In certain embodiments, the disease is an infection
caused by a dsDNA-RT virus. In certain embodiments, the disease is
an infection caused by human immunodeficiency virus (HIV). In
certain embodiments, the disease is an infection caused by acquired
immunodeficiency syndrome (AIDS). In certain embodiments, the
disease is an infection caused by human papillomavirus (HPV). In
certain embodiments, the disease is an infection caused by
hepatitis C virus (HCV). In certain embodiments, the disease is an
infection caused by a herpes virus (e.g., herpes simplex virus
(HSV)). In certain embodiments, the disease is an infection caused
by Ebola virus. In certain embodiments, the disease is an infection
caused by severe acute respiratory syndrome (SARS). In certain
embodiments, the disease is an infection caused by influenza virus.
In certain embodiments, the disease is an infection caused by an
influenza virus. In certain embodiments, the disease is an
infection caused by an influenza A virus. In certain embodiments,
the disease is human flu (e.g., human flu caused by HIN1, H2N2,
H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, or H10N7 virus). In
certain embodiments, the disease is bird flu (e.g., bird flu caused
by H5N1 or H7N9 virus). In certain embodiments, the disease is
swine influenza (e.g., swine influenza caused by HIN1, H1N2, H2N1,
H3N1, H3N2, H2N3, or influenza C virus). In certain embodiments,
the disease is equine influenza (e.g., equine influenza caused by
H7N7 or H3N8 virus). In certain embodiments, the disease is canine
influenza (e.g., canine influenza caused by H3N8 virus). In certain
embodiments, the disease is an infection caused by an influenza B
virus. In certain embodiments, the disease is an infection caused
by an influenza C virus. In certain embodiments, the disease is
Dengue fever, Dengue hemorrhagic fever (DHF), Dengue shock syndrome
(DSS), hepatitis A, hepatitis B, hepatitis D, hepatitis E,
hepatitis F, infection caused by Coxsackie A virus, infection
caused by Coxsackie B virus, fulminant viral hepatitis, viral
myocarditis, infection caused by parainfluenza virus, infection
caused by an RS virus (RSV) (e.g., RSV bronchiolitis, RSV
pneumonia, especially an infant and childhood infection caused by
RSV and RSV pneumonia in the patients with cardiopulmonary
disorders), infection caused by measles virus, infection caused by
vesicular stomatitis virus, infection caused by rabies virus,
Japanese encephalitis, infection caused by Junin virus, infection
caused by human cytomegalovirus, infection caused by
varicellovirus, infection caused by cytomegalovirus, infection
caused by muromegalovirus, infection caused by proboscivirus,
infection caused by roseolovirus, infection caused by
lymphocryptovirus, infection caused by macavirus, infection caused
by percavirus, infection caused by rhadinovirus, infection caused
by poliovirus, infection caused by Marburg virus, infection caused
by Lassa fever virus, Venezuelan equine encephalitis, infection
caused by Rift Valley Fever virus, infection caused by Korean
hemorrhagic fever virus, infection caused by Crimean-Congo
hemorrhagic fever virus, encephalitis, Saint Louise encephalitis,
Kyasanur Forest disease, Murray Valley encephalitis, tick-borne
encephalitis, West Nile encephalitis, yellow fever, infection
caused by adenovirus, infection caused by poxvirus, or a viral
infection in subjects with immune disorders.
[0370] In certain embodiments, the disease is a fibrotic condition.
In certain embodiments, the disease is selected from the group
consisting of renal fibrosis, post-operative stricture, keloid
formation, hepatic cirrhosis, biliary cirrhosis, and cardiac
fibrosis. In certain embodiments, the disease is scleroderma. In
certain embodiments, the disease is idiopathic pulmonary
fibrosis.
[0371] In certain embodiments, the methods described herein include
contacting a cell with an effective amount of a composition
thereof. In certain embodiments, the cell is in vitro. In certain
embodiments, the cell is in vivo.
EXAMPLES
[0372] In order that the present disclosure may be more fully
understood, the following examples are set forth. The synthetic and
biological examples described in this application are offered to
illustrate the compounds, pharmaceutical compositions, and methods
provided herein and are not to be construed in any way as limiting
their scope.
[0373] In some examples, polylactone diacrylates with different
numbers of lactone units have been synthesized according to FIG. 4
and used in the synthesis of novel polylactone-based PBAEs with the
same procedure shown in FIG. 1. These novel carriers have further
been formulated with oligonucleotides and polynucleotides to form
nanoparticles, which are transfected into cells.
[0374] The present disclosure provides formulations of the polymers
described herein with mRNA to form nanoparticles. Such
nanoparticles can be used to transfect the mRNA into cells,
including, e.g., HeLa cells. The potency of these novel
nanoparticles has been evaluated and is comparable to the potency
of one of the current top performing PBAEs polymers
(DD90-C12-122)..sup.9f The polylactone-based PBAEs with 5 units of
-caprolactone (caprolactone or CL) shows a higher transfection
efficiency than DD90-C12-122. In particular, the PBAE C1 is five
times more effective and 35% less cytotoxic than DD90-C12-122. In
addition, C1 does not release compounds that may induce side
effects that are difficult to evaluate with a cellular assay, such
as those related to a systematic toxicity and genotoxicity.
Experimental Section
Materials
[0375] All chemicals were used as received except when specifically
noted. All the solvents used were of analytical-grade purity and
were purchased from Sigma Aldrich. -caprolactone (CL), acryloyl
chloride, triethylamine, 2-hydroxyethyl acrylate (HEA),
4-methoxyphenol, tin(II) 2-ethylhexanoate, bisphenol A glycerolate
(DD), ethylene glycol diacrylate (A), dodecyl amine (C12),
4-(2-aminomethyl) morpholine (4), (+/-)-3amino-1,2-propanediol (1),
N--N'-dimethyl ethylene diamine (3) were obtained from Sigma
Aldrich (St. Louis, Mo., USA). 14:0 PEG2000 PE (PEG-lipid) was
purchased from Avanti Polar Lipids (Alabaster, Ala., USA).
5-amino-1-pentaol (2) and heparin sodium salt were obtained from
ALFA Aesar (Haverhill, Mass., USA).
[0376] Firefly luciferase (FLuc) mRNA was generously provided by
Shire Pharmaceuticals (Lexington, Mass.). FLuc mRNA contained a 5'
cap (Cap1), a 5' UTR consisting of a partial sequence of the
cytomegalovirus (CMV) immediate early 1 (IE1) gene, a coding region
as described below, a 3' UTR consisting of a partial sequence of
the human growth hormone (hGH) gene, and a 3' polyA tail.
[0377] Firefly luciferase (FLuc) mRNA sequence:
TABLE-US-00003 (SEQ ID NO: 1)
AUGGAAGAUGCCAAAAACAUUAAGAAGGGCCCAGCGCCAUUCUACCCAC
UCGAAGACGGGACCGCCGGCGAGCAGCUGCACAAAGCCAUGAAGCGCUA
CGCCCUGGUGCCCGGCACCAUCGCCUUUACCGACGCACAUAUCGAGGUG
GACAUUACCUACGCCGAGUACUUCGAGAUGAGCGUUCGGCUGGCAGAAG
CUAUGAAGCGCUAUGGGCUGAAUACAAACCAUCGGAUCGUGGUGUGCAG
CGAGAAUAGCUUGCAGUUCUUCAUGCCCGUGUUGGGUGCCCUGUUCAUC
GGUGUGGCUGUGGCCCCAGCUAACGACAUCUACAACGAGCGCGAGCUGC
UGAACAGCAUGGGCAUCAGCCAGCCCACCGUCGUAUUCGUGAGCAAGAA
AGGGCUGCAAAAGAUCCUCAACGUGCAAAAGAAGCUACCGAUCAUACAA
AAGAUCAUCAUCAUGGAUAGCAAGACCGACUACCAGGGCUUCCAAAGCA
UGUACACCUUCGUGACUUCCCAUUUGCCACCCGGCUUCAACGAGUACGA
CUUCGUGCCCGAGAGCUUCGACCGGGACAAAACCAUCGCCCUGAUCAUG
AACAGUAGUGGCAGUACCGGAUUGCCCAAGGGCGUAGCCCUACCGCACC
GCACCGCUUGUGUCCGAUUCAGUCAUGCCCGCGACCCCAUCUUCGGCAA
CCAGAUCAUCCCCGACACCGCUAUCCUCAGCGUGGUGCCAUUUCACCAC
GGCUUCGGCAUGUUCACCACGCUGGGCUACUUGAUCUGCGGCUUUCGGG
UCGUGCUCAUGUACCGCUUCGAGGAGGAGCUAUUCUUGCGCAGCUUGCA
AGACUAUAAGAUUCAAUCUGCCCUGCUGGUGCCCACACUAUUUAGCUUC
UUCGCUAAGAGCACUCUCAUCGACAAGUACGACCUAAGCAACUUGCACG
AGAUCGCCAGCGGCGGGGCGCCGCUCAGCAAGGAGGUAGGUGAGGCCGU
GGCCAAACGCUUCCACCUACCAGGCAUCCGCCAGGGCUACGGCCUGACA
GAAACAACCAGCGCCAUUCUGAUCACCCCCGAAGGGGACGACAAGCCUG
GCGCAGUAGGCAAGGUGGUGCCCUUCUUCGAGGCUAAGGUGGUGGACUU
GGACACCGGUAAGACACUGGGUGUGAACCAGCGCGGCGAGCUGUGCGUC
CGUGGCCCCAUGAUCAUGAGCGGCUACGUUAACAACCCCGAGGCUACAA
ACGCUCUCAUCGACAAGGACGGCUGGCUGCACAGCGGCGACAUCGCCUA
CUGGGACGAGGACGAGCACUUCUUCAUCGUGGACCGGCUGAAGAGCCUG
AUCAAAUACAAGGGCUACCAGGUAGCCCCAGCCGAACUGGAGAGCAUCC
UGCUGCAACACCCCAACAUCUUCGACGCCGGGGUCGCCGGCCUGCCCGA
CGACGAUGCCGGCGAGCUGCCCGCCGCAGUCGUCGUGCUGGAACACGGU
AAAACCAUGACCGAGAAGGAGAUCGUGGACUAUGUGGCCAGCCAGGUUA
CAACCGCCAAGAAGCUGCGCGGUGGUGUUGUGUUCGUGGACGAGGUGCC
UAAAGGACUGACCGGCAAGUUGGACGCCCGCAAGAUCCGCGAGAUUCUC
AUUAAGGCCAAGAAGGGCGGCAAGAUCGCCGUGUAA
General Methods and Instruments
1) Synthesis of the Polylactone-based Diacrylates
[0378] Polylactone-based diacrylates were synthesized in a two-step
procedure: (i) ring opening polymerization of CL with HEA as
initiator and tin(II) 2-ethylhexanoate as catalyst and (ii)
esterification with acryloyl chloride (see FIG. 4). In the first
step, the ring opening polymerization was carried out in bulk with
a CL to HEA ratio and HEA to tin(II) 2-ethylhexanoate ratio equal
to 3, 5 and 7 and 1/200, respectively. As an example for q=3, 1 g
of CL, 17 mg of Na.sub.2SO.sub.4 and 1 mg of 4-methoxyphenol were
weighted in a septa-sealed flask and heated to 130.degree. C. in a
constant temperature oil bath under stirring. 1 g of HEA were mixed
with 17 mg of tin(II) 2-ethylhexanoate in a different vial and
injected into the pre-heated CL containing flask. The
polymerization was allowed to proceed for 3 hours. An aliquot was
taken to perform .sup.1H NMR (in CDCl.sub.3) and GPC (in THF). In
the second step, the esterification was carried out in
dichloromethane with 2 equivalent of triethylamine and acryloyl
chloride. As an example for q=3, 3.95 g of the previous
macro-monomer and 2.4 ml of triethylamine were dissolved in 50 ml
of DCM and poured in a septum sealed round-bottom flask. 1.4 ml of
acryloyl chloride were added dropwise into the reactor under inert
atmosphere at 0.degree. C. and under stirring. The reaction was
left to equilibrate to room temperature and then stopped after 24
h. The final mixture was filtered and washed several times with
water and brine. The mixture was dried over Na.sub.sSO.sub.4 and
the solvent eliminated via rotavapor. The final diacrylate was
dried under vacuum and characterized via NMR and GPC. The PCL-based
custom diacrylates were characterized via .sup.1H NMR (400 MHz,
CDCl.sub.3) on a Bruker spectrometer.
[0379] Polylactone-based diacrylates and PBAE polymers were
dissolved in tetrahydrofuran (THF) at a concentration of 4 mg
ml.sup.-1, filtered over 0.2 um PTFE syringe filter and eluted in
Styragel columns at a 1 ml min.sup.-1 flow rate. The instrument is
equipped with a Malvern Viscotek.TM. TDA 305 triple detector.
Molecular weights and polydispersities were relative to linear
polystyrene standards.
2) PBAE Synthesis
[0380] In certain embodiments, alkyl-side chain containing polymers
were synthesized as shown in FIG. 5. Briefly, the diacrylate
monomer, the C12 amine and the hydrophilic amine were dissolved in
DMSO at a concentration of 0.6 M and added in a 4 ml vials in such
way that their molar ratio was 1.2:0.3:0.7. The hydrophobic C12
amine was heated to 60.degree. C. before addition to the reaction
medium in order to avoid crashing out. The reaction was purged with
nitrogen for 2 minutes and heated to 90.degree. C. After 2 days,
the end capping was added and the reaction re-started at 90.degree.
C. for an additional day. The final concentration was adjusted to
100 mg ml.sup.-1 by adding more DMSO and the samples were divided
into aliquots and stored at -80.degree. C.
3) Nanoparticle Formulation
[0381] Two different procedures were adopted to produce the
nanoparticles (NPs). In the first case, 5 ul of the 100 mg
ml.sup.-1 polymer solution in DMSO were dissolved in 195 ul of 25
mM NaOAc and then mixed by pipetting with 200 ul of a solution of
50 ng/ul of mRNA in 25 mM NaOAc buffer. In the second case, 5 ul of
the 100 mg ml.sup.-1 polymer solution in DMSO were dissolved in 45
ul of ethanol with different amount of PEG-lipid when specifically
noted and mixed by pipetting with 50 ul of a solution of 200 ng/ul
of mRNA in 25 mM NaOAc buffer. The final mixture was finally
diluted with PBS to reach the mRNA final concentration of 5
ng/ul.
[0382] Nanoparticle (NP) size, PDI (polydispersity index), and
(potential (i.e., zeta potential; electrokinetic potential) were
obtained using a Zetasizer (Malvern). For size measurement, NPs
were diluted in PBS at a 1/40 v/v ratio and an intensity average
size was reported. For the .zeta. potential measurements, NPs were
diluted in deionized water at a ratio of 1/40 v/v.
4) Transfection Tests
[0383] 20000 HeLa cells in 100 ul of freshly prepared medium were
seeded into each well of a 96-well white polystyrene tissue culture
plate (Costar.RTM.) and left to grow for a day. In a typical
experiment, for a mRNA dose of 50 ng/well, 50 ul of the 5 ug/ul
mRNA NP formulation were mixed with 450 ul of freshly prepared
medium pre-heated to 37.degree. C. The conditioned medium was
removed by the wells and replaced with 100 ul of the diluted mRNA
NP formulation. The HeLa cells were left to incubate for another
day. The MultiTox-Fluor Multiplex Cytotoxicity Assay (Promega) and
cellular Bright-Glo kits (Promega) were carried out according to
the specifications of the producer in order to evaluate the cell
viability and the cellular luminescence via a Tecan plate reader.
Cellular luminescence was normalized to live cell count that, in
turn, was determined via a standard curve made using the viability
assay.
5) In Vivo Experiments
[0384] 20 ul of PBAE (100 ug/ul in DMSO) and different amount of
PEG-lipid were dissolved in 180 ul of ethanol and then mixed by
repeated pipetting to the aqueous phase consisting of 40 ul of 1
mg/ml mRNA and 160 ul of 25 mM NaOAc buffer. After 10 min, the NPs
were dialyzed against 4 L of PBS at 4.degree. C. in 20000 MWCO
cassettes (Thermo Fisher). The mRNA concentration of the final NPs
were evaluated via a modified Quanti-iT RiboGreen RNA assay (Thermo
Fisher) according to a previous work.sup.24. In vivo jetPEI
(Polyplus) was used according to manufacturer instructions at an
N/P of 8, the maximum recommended polymer:nucleic acid ratio.
[0385] NP formulations were injected via tail vein in female
C57BL/6 mice (Charles River Laboratories, 18-22 g). 130 uL of 30 mg
ml.sup.-1 D-luciferin (PerfkinElmer) in PBS were injected
intraperitoneally 24 hours after the administration of the NP
formulation for luciferase image experiments. Mice were sacrificed
via CO.sub.2 asphyxiation 10 min after D-luciferin injection. The
luminescence of the pancreas, spleen, kidneys, liver, lungs, and
heart was quantified via an IVIS imaging apparatus (PerkinElmer).
24 hours following intravenous nanoparticle injection in mice,
blood samples were collected via the tail vein in serum collection
tubes (Sarstedt). Serum was collected from the blood, and ALT and
AST activities were analyzed using AST and ALT
colorimetric/fluorometric activity assay kits (Sigma). Assays were
performed according to manufacturer instructions, and enzyme
activities were normalized to those of PBS-treated mice.
6) Nanoparticle Stability Test
[0386] After synthesizing NPs for the in vivo tests, the final
concentration was adjusted to 50 ng/ul mRNA. 90 ul of NP solution
was added to each well of a transparent 96 well plate. The
absorbance of each plate was measured initially at 660 nm. After
the addition of 10 ul of fetal bovine serum, the plate was
incubated at 37.degree. C. and the absorbance was measured at the
same wavelength after 15, 30, 45, 60, 90 and 120 minutes.
DISCUSSION
[0387] The polylactone-based diacrylates were synthesized via a
novel two-step procedure that consists of (i) a ring opening
polymerization of caprolactone (CL) with 2-hydroxyethylacrylate
(HEA) as initiator and tin(II)-ethylhexanoate as catalyst and (ii)
acylation with acryloyl chloride (see FIG. 4).
[0388] The ROP is a so-called "living polymerization", a technique
that allows for control over the number of the units of
caprolactone (q) that can be attached to the final diacrylate. In
addition to PCL being inherently more biocompatible than other
diacrylates, the tunability of q by varying the reaction
stoichiometry allows for control over the diacrylate's (and
therefore the PBAE's) lipophilicity and molecular weight. In
addition, the polymerization does not require any solvent or
further purification steps due to the nearly complete conversion
and the absence of by-products.sup.25. For this reason, the
obtained macromonomer can be directly used in the second step of
the synthesis of the custom diacrylates, an esterification with
acryloyl chloride. This latter step was used to attach the
additional double bond required to produce the PBAE polymers via
Michael step-growth polymerization. An ethylenglycol diacrylate
(A), which has a q value equal to 0, has been used in previous
PBAEs..sup.9f Three different PCL-based diacrylates were
synthesized with a low polydispersity ( <1.3) and theoretical q
values very close to the one evaluated via .sup.1H NMR (data in
table of FIG. 8A and representative .sup.1H NMR of a custom
diacrylate in FIG. 8B).
[0389] In certain embodiments, PBAEs incorporating the custom
diacrylates were synthesized in a two-step reaction..sup.9f In the
first step, as shown in FIG. 5, an alkyl amine (dodecylamine) and
different hydrophilic amines (1, 2, 3, 4) were reacted with the
custom diacrylates (A, B, C, D) at a ratio equal to 1.2:0.7:0.3
(diacrylate:hydrophilic amine:dodecyl amine) to produce a library
of acrylate-terminated PBAE polymers. The choice to incorporate a
lipophilic amine in the PBAE is justified by the superior stability
and efficiency of the polymers to deliver DNA compared to classic
PBAE polymers..sup.9f The second step is carried out without any
intermediate purification and consists in another Michael addition
with an excess of a PEGylated diamine in order to completely
consume the remaining double bonds in the mixture. In fact, the
end-capping of the PBAE polymers has shown to increase the
transfection efficiency and to reduce their toxicity..sup.26,27
[0390] The PBAE polymers synthesized show a high (see FIG. 9) as
expected from a step-growth polymerization, but in addition they
show a linear behavior of M.sub.w within the adoption of the same
hydrophilic amine in a way similar to the custom diacrylate (FIG.
10A).
[0391] In fact, the M.sub.w obtained via GPC is a linear function
of the number of CL units attached with the intercept equal to the
M.sub.w of the diacrylate A due to the control given by the ring
opening polymerization. Thus, despite the fact that Michael
addition polymerization is known to require high conversion and the
complete absence of impurities in the mixture, this novel strategy
allowed us to improve the control over the M.sub.w and the
lipophilicity of the final material. However, it is important to
note that as long as the number of amines per each polymer chain is
theoretically the same for a pre-assigned stoichiometry,.sup.28 the
increase of the M.sub.w results in a reduction by weight of the
overall ionizable charges (i.e. charge density).
[0392] The lipophilicity of the polymer also plays an important
role in the production of the NPs since it can affect its
solubility in the medium that is used for the ionic complexation of
the oligonucleotides. For this reason, two different procedures
were adopted in order to evaluate the effect of the formulation
method on the NPs size and, in turn, on their transfection
efficiency in vitro. In the first case, so called direct mixing,
the polymer solution (polymer in DMSO) was directly dissolved in 25
mM NaOAc and then mixed with the mRNA. However, not all the
polymers are freely soluble in these aqueous phase and small
nanoparticles were produced. The addition of the oligonucleotide
led to a partial coagulation of these primary NPs into larger
nanoaggregrates, as visible in FIG. 11. In the second case, the
polymer solution was dissolved in ethanol before mixing with mRNA.
In this case, referred to as pre-mixing protocol, the NPs were
formed during the mixing of the two phases resulting into a higher
size compared to the ones obtained with the previous method (see
FIG. 11).
[0393] However, as shown in FIG. 10B, all the NPs generated with
the pre-mixing protocol show a higher transfection efficiency
compared to the ones obtained via direct mixing. This effect is
more enhanced where the lipophilicity of the polymers is higher,
and underscores the importance of formulation conditions, in
addition to material synthesis, when conducting material screens.
Thus, in order to find the best performing materials in the
screening of the PBAE library, the pre-mixing procedure was applied
to all the polymers, which were then used to transfect HeLa cells
(see FIG. 10C). A dependence on the lipophilicity of the polymer on
the transfection efficiency can be seen in all the tested
formulations. In particular, the less lipophilic PBAEs that are
based only on the A diacrylate show little efficacy in mRNA
delivery while the initial increase in the number of the CL units
(q) leads to a higher transfection. However, as mentioned
previously, the beneficial impact of the increased lipophilicity is
counterbalanced by the reduction in the density of ionizable amines
that are necessary to correctly condense the mRNA. When this
reduction is too high, it affects the transfection, as clearly
visible in the polymers made with the D. In addition, as visible in
the cell viability test in FIG. 10D, almost all the tested polymers
are non-toxic despite the lack of a wash step following
transfection.
[0394] The high transfection efficacy of most of these polymers can
also be ascribed to their ability to form relative small and
mono-disperse nanoparticles in PBS, as visible in FIG. 12.
[0395] However, the stability of the NPs in biologically relevant
fluid is a more crucial property for applications in which a
systemic delivery of the mRNA is required. For this reason, the top
performing polymers were co-formulated with 7 wt. % of a
polyethylene glycol-modified lipid (PEG-lipid) and the stability of
the resulting NPs were tested in a mixture of 10% fetal bovine
serum (FBS) according to a previous protocol..sup.29 Briefly, the
NPs were incubated at 37.degree. C. and the optical clarity of the
solution was evaluated at different time points (see FIG. 13A).
Among the C derived polymers, the C1 showed the best stability and
was therefore optimized in order to find the minimum amount of
PEG-lipid that led to no change in the absorbance once incubated
with the FBS (see FIG. 13B).
[0396] The increase in PEG-lipid led to a higher stability, but at
the same time it reduced the transfection efficacy of the NP
formulation due to the charge shielding effect of the PEG tails, as
already reported in literature.sup.29 and also demonstrated in
FIGS. 14A and 14B.
[0397] However, as serum stability is critical for effective
systemic delivery of PBAE polymers,.sup.29 C1 was formulated with
15 wt % PEG-lipid for in vivo testing with an mRNA coding for
firefly luciferase. The stable C1 was injected in mice at three
different doses (0.5, 0.25 and 0.125 mg/kg mRNA) and their efficacy
and toxicity compared with PEI. Interestingly, this PCL-based
polymer has been found to work selectively into the spleen (see
FIG. 13C) in contrast with other members of the PBAE family.sup.29
that also show activity into the lungs, as well as lipid
nanoparticles that are typically effective in the liver..sup.30,31
In addition, even at the highest tested concentration, there is no
significant difference in body weight (see FIG. 15) or in levels of
the liver enzymes ALT and AST compared to PBS (p>0.05)
indicating little systemic toxicity caused by the polymer (see FIG.
13D). The efficacy of the C1 is also higher in the spleen, as well
as more specifically targeted, compared to PEI at all the tested
concentrations, and also possesses a much wider therapeutic window
overall (see FIGS. 13E and 13F).
[0398] Given its spleen-targeting capability, this novel class of
PBAE polymers may be used as novel biodegradable and biocompatible
carriers for the intravenous delivery of antigen-encoding RNA for
cancer immunotherapy and vaccination, as recently shown with a
non-biodegradable lipid formulation..sup.32
[0399] A new synthesis for the production of well controlled
poly-caprolactone based diacrylates has been developed. The
versatility of this method has been demonstrated by varying the
number of caprolactone units attached to each diacrylate and is to
some extent reflected in the characteristics of the PBAE polymers
synthesized from them via step-growth polymerization. The ability
of the novel PCL-based PBAE materials to deliver mRNA has been
shown to depend on the physiochemical characteristics of the
material, such as lipophilicity, as well as the formulation method
used to complex the polymer with the oligonucleotide. This latter
variable represents a previously unstudied aspect of PBAE library
screens that could play an important role in identifying true top
candidates for nucleic acid delivery. The most stable polymer, the
C1, was injected via IV in mice and showed a transfection efficacy
several times higher than the PEI and selectively to the spleen,
opening the possibility to use a completely biodegradable and
biocompatible carrier in the intravenously delivery of
antigen-encoding mRNA for cancer immunotherapy and vaccination. The
adoption of a controlled living polymerization for the synthesis of
more biocompatible and more biodegradable custom diacrylates from
other lactones will lead to the synthesis of more versatile PBAE
polymers with more controlled properties, higher efficacy and lower
toxicity for a variety of applications.
EQUIVALENTS AND SCOPE
[0400] In the claims articles such as "a," "an," and "the" may mean
one or more than one unless indicated to the contrary or otherwise
evident from the context. Claims or descriptions that include "or"
between one or more members of a group are considered satisfied if
one, more than one, or all of the group members are present in,
employed in, or otherwise relevant to a given product or process
unless indicated to the contrary or otherwise evident from the
context. The invention includes embodiments in which exactly one
member of the group is present in, employed in, or otherwise
relevant to a given product or process. The invention includes
embodiments in which more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product
or process.
[0401] Furthermore, the invention encompasses all variations,
combinations, and permutations in which one or more limitations,
elements, clauses, and descriptive terms from one or more of the
listed claims is introduced into another claim. For example, any
claim that is dependent on another claim can be modified to include
one or more limitations found in any other claim that is dependent
on the same base claim. Where elements are presented as lists,
e.g., in Markush group format, each subgroup of the elements is
also disclosed, and any element(s) can be removed from the group.
It should it be understood that, in general, where the invention,
or aspects of the invention, is/are referred to as comprising
particular elements and/or features, certain embodiments of the
invention or aspects of the invention consist, or consist
essentially of, such elements and/or features. For purposes of
simplicity, those embodiments have not been specifically set forth
in haec verba herein. It is also noted that the terms "comprising"
and "containing" are intended to be open and permits the inclusion
of additional elements or steps. Where ranges are given, endpoints
are included. Furthermore, unless otherwise indicated or otherwise
evident from the context and understanding of one of ordinary skill
in the art, values that are expressed as ranges can assume any
specific value or sub-range within the stated ranges in different
embodiments of the invention, to the tenth of the unit of the lower
limit of the range, unless the context clearly dictates
otherwise.
[0402] This application refers to various issued patents, published
patent applications, journal articles, and other publications, all
of which are incorporated herein by reference. If there is a
conflict between any of the incorporated references and the instant
specification, the specification shall control. In addition, any
particular embodiment of the present invention that falls within
the prior art may be explicitly excluded from any one or more of
the claims. Because such embodiments are deemed to be known to one
of ordinary skill in the art, they may be excluded even if the
exclusion is not set forth explicitly herein. Any particular
embodiment of the invention can be excluded from any claim, for any
reason, whether or not related to the existence of prior art.
[0403] Those skilled in the art will recognize or be able to
ascertain using no more than routine experimentation many
equivalents to the specific embodiments described herein. The scope
of the present embodiments described herein is not intended to be
limited to the above Description, but rather is as set forth in the
appended claims. Those of ordinary skill in the art will appreciate
that various changes and modifications to this description may be
made without departing from the spirit or scope of the present
invention, as defined in the following claims.
REFERENCES
[0404] 1. Jin, L.; Zeng, X.; Liu, M.; Deng, Y.; He, N.: Current
Progress in Gene Delivery Technology Based on Chemical Methods and
Nano-carriers. Theranostics 2014, 4, 240-255. [0405] 2. Sergeeva,
O.; Koteliansky, V.; Zatsepin, T.: mRNA-based therapeutics-Advances
and perspectives. Biochemistry (Moscow) 2016, 81, 709-722. [0406]
3. Mulligan, R. C.: The Basic Science of Gene Therapy. Science,
1993, 260, 926-932. [0407] 4. [No authors listed]: HIV Vaccine
Failure Prompts Merck to Halt Trial. Nature, 2007, 449, 390. [0408]
5. Robinson, H. L.; Pertmer, T. M.: Nucleic acid immunizations.
Curr. Protoc. Immunol. 2001, Chapter 2: Unit 2.14. [0409] 6. Vu,
L.; Ramos, J.; Potta, T.; Rege, K.: Generation of a Focused Poly
(amino ether) Library: Polymer-mediated Transgene Delivery and
Gold-nanorod Based Theranostic Systems. Theranostics. 2012, 2,
1160-1173. [0410] 7. Khosravi-Darani, K.; Mozafari, M. R.; Rashidi,
L.; Mohammadi, M.: Calcium Based Non-viral Gene Delivery: An
Overview of Methodology and Applications. Acta Med Iranica, 2010,
48, 133-141. [0411] 8. Luten, J.; van Nostrum, C. F.; De Smedt, S.
C.; Hennink, W. E.: Biodegradable Polymers as Non-viral Carriers
for Plasmid DNA Delivery. J Control Release, 2008, 126, 97-110.
[0412] 9. (a) Zhou, D.; Gao, Y.; Aied, A.; Cutlar, L.; Igoucheva,
O.; Newland, B.; Alexeeve, V.; Greiser, U.; Uitto, J.; Wang, W.:
Highly Branched Poly (.beta.-amino ester)s for Skin Gene Therapy.
Journal of Controlled Release, 2016, 244, 336-346; (b) Sunshine,
J.; Green, J. J.; Mahon, K. P.; Yang, F.; Eltoukhy, A. A.; Nguyen,
D. N.; Langer, R.; Anderson, D. G.: Small-Molecule End-Groups of
Linear Polymer Determin Cell-type Gene-Delivery Efficacy. Advanced
Materials, 2009, 21, 4947-4951; (c) Tzeng, S. Y.; Hung, B. P.;
Grayson, W. L.; Green, J. J.: Cystamine-terminated Poly (beta-amino
ester)s for siRNA Delivery to Human Mesenchymal Stem Cells and
Enhancement of Osteogenic Differentiation. Biomaterials, 2012, 33,
8142-8151; (d) Kim, J.; Sunshine, J. C.; Green, J. J.: Differential
polymer Strucute Tunes Mechanism of Cellular Upatke and
Transfection Routes of Poly (.beta.-amino ester) Polyplexes in
Human Breast Cancer Cells. Bioconjugate Chemistry, 2013, 25, 43-51;
(e) Guerrero-Cizares, H.; Tzeng, S. Y.; Young, N. P.; Abutaleb, A.
O.; Quinones-Hinojosa, A.; Green, J. J.: Biodegradable Polymeric
Nanoparticles Show High Efficacy and Specificity at DNA Delivery to
Human Glioblastoma in Vitro and in Vivo. ACS Nano, 2014, 8,
5141-5153; (f) Eltoukhy, A. A.; Chen, D.; Alabi, C. A.; Langer, R.;
Anderson, D. G.: Degradable Terpolymers with Alkyl Side Chains
Demonstrate Enhanced Gene Delivery Potency and Nanoparticle
Stability. Advanced Materials, 2013, 25, 1487-1493. [0413] 10. (a)
Zhao, J.; Huang, P.; Wang, Z.; Tan, Y.; Hou, X.; Zhang, L.; He,
C.-Y.; Chen, Z.-Y.: Synthesis of Amphiphilic Poly (.beta.-amino
ester) for Efficiently Minicircle DNA Delivery in Vivo. ACS Applied
Materials & Interfaces, 2016, 8, 19284-19290; (b) Sunshine, J.
C.; Sunshine, S. B.; Bhutto, I.; Handa, J. T.; Green, J. J.: Poly
(.beta.-amino ester)-nanoparticle Mediated Transfection of Retinal
Pigment Epithelial Cells in Vitro and in Vivo. PloS one, 2012, 7,
e37543; (c) Mangraviti, A.; Tzeng, S. Y.; Kozielski, K. L.; Wang,
Y.; Jin, Y.; Gullotti, D.; Pedone, M.; Buaron, N.; Liu, A.; Wilson,
D. R.: Polymeric Nanoparticles for Nonviral Gene Therapy Extend
Brain Tumor Survival in Vivo. ACS Nano, 2015, 9, 1236-1249; (d)
Kamat, C. D.; Shmueli, R. B.; Connis, N.; Rudin, C. M.: Lung Cancer
in Vitro and in Vivo. Molecular Cancer Therapeutics, 2013, 12,
405-415. [0414] 11. (a) Carai, M. A. M.; Colombo, G.; Reali, R.;
Serra, S.; Mocci, I.; Castelli, M. P.; Cignarella, G.; Gessa, G.
L.: Central Effects of 1,4-Butanediol are Mediated by GABA(B)
Receptors via its Conversion into .gamma.-Hydroxybutyric Acid.
European Journal of Pharmacology, 2002, 441, 157-163; (b) Satta,
R.; Dimitrijevic, N.; Manev, H.: Drosophila Metabolize
1,4-Butanediol into .gamma.-Hydroxybutyric Acid in Vivo. European
Journal of Pharmacology, 2003, 473, 149-152. [0415] 12. (a) Gore,
A. C.; Chappell, V. A.; Fenton, S. E.; Flaws, J. A.; Nadal, A.;
Prins, G. S.; Toppari, J.; Zoeller, R. T.: Executive Summary to
EDC-2: The Endocrine Society's Second Scientific Statement on
Endocrine-Disrupting Chemicals. Endocrine Reviews, 2015, 36,
593-602; (b) Mirmira, P.; Evans-Molina, C.: Bisphenol A, Obesity,
and Type 2 Diabetes Mellitus: Genuine Concern or Unnecessary
Preoccupation? Translational Research, 2014, 164, 13-21. [0416] 13.
Chen, J.; Guo, Z.; Tian, H.; Chen, X.: Production and Clinical
Development of Nanoparticles for Gene Delivery. Mol. Ther. Methods
Clin. Dev., 2016, 3, 16023. [0417] 14. (a) Kumari, A.; Yadav, S.
K.; Yadav, S. C.: Biodegradable Polymeric Nanoparticles Based Drug
Delivery Systems. Colloids and Surfaces B: Biointerfaces, 2010, 75,
1-18; (b) Bobo, D.; Robinson, K. J.; Islam, J.; Thurecht, K. J.;
Corrie, S. R.: Nanoparticle-Based Medicines: A Review of
FDA-Approved Materials and Clinical Trials to Date. Pharmaceutical
Research, 2016, 33, 2373-2387. [0418] 15. Dash, T. K.; Konkimalla,
V. B.: Poly- -caprolactone Based Formulations for Drug Delivery and
Tissue Engineering: A Review. Journal of Controlled Release, 2012,
158, 15-33. [0419] 16. Gilboa, E.; Vieweg, J.: Cancer Immunotherapy
with mRNA-transfected Dendritic Cells. Immunological Reviews, 2004,
199, 251-263. [0420] 17. McNamara, M. A.; Nair, S. K.; Holl, E. K.:
RNA-based Vaccines in Cancer Immunotherapy. Journal of Immunology
Research, 2015, 2015. [0421] 18. Matsui, A.; Uchida, S.; Ishii, T.;
Itaka, K.; Kataoka, K.: Messenger RNA-based Therapeutics for the
Treatment of Apoptosis-associated Diseases. Scientific Reports
2015, 5. [0422] 19. Weiss, R.; Scheiblhofer, S.; Roesler, E.;
Weinberger, E.; Thalhamer, J.: mRNA Vaccination as a Safe Approach
for Specific Protection from Type I Allergy. Expert Review of
Vaccines, 2012, 11, 55-67. [0423] 20. Pollard, C.; De Koker, S.;
Saelens, X.; Vanham, G.; Grooten, J.: Challenges and Advances
Towards the Rational Design of mRNA Vaccines. Trends in Molecular
Medicine, 2013, 19, 705-713. [0424] 21. Wang, H.; Yang, H.;
Shivalila, C. S.; Dawlaty, M. M.; Cheng, A. W.; Zhang, F.;
Jaenisch, R.: One-step Generation of Mice Carrying Mutations in
Multiple Genes by CRISPR/Cas-mediated Genome Engineering. Cell,
2013, 153, 910-918. [0425] 22. Hashimoto, M.; Takemoto, T.:
Electroporation Enables the Efficient mRNA Delivery into the Mouse
Zygotes and Facilitates CRISPR/Cas9-based Genome Editing.
Scientific Reports, 2015, 5. [0426] 23. Gori, J. L.; Hsu, P. D.;
Maeder, M. L.; Shen, S.; Welstead, G. G.; Bumcrot, D.: Delivery and
Specificity of CRISPR/Cas9 Genome Editing Technologies for Human
Gene Therapy. Human Gene Therapy, 2015, 26, 443-451. [0427] 24.
Kaczmarek, J. C.; Patel, A. K.; Kauffman, K. J.; Fenton, O. S.;
Webber, M. J.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G.:
Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the
Lungs. Angewandte Chemie, 2016, 55, 13808-13812. [0428] 25.
Ferrari, R.; Yu, Y.; Morbidelli, M.; Hutchinson, R. A.; Moscatelli,
D.: F-Caprolactone-based Macromonomers Suitable for Biodegradable
Nanoparticles Synthesis Through Free Radical Polymerization.
Macromolecules, 2011, 44, 9205-9212. [0429] 26. Sunshine, J.;
Green, J. J.; Mahon, K. P.; Yang, F.; Eltoukhy, A. A.; Nguyen, D.
N.; Langer, R.; Anderson, D. G.: Small-Molecule End-Groups of
Linear Polymer Determine Cell-type Gene-Delivery Efficacy. Advanced
Materials, 2009, 21, 4947-4951. [0430] 27. Eltoukhy, A. A.;
Siegwart, D. J.; Alabi, C. A.; Rajan, J. S.; Langer, R.; Anderson,
D. G., Effect of Molecular Weight of Amine End-modified Poly
(.beta.-amino ester) s on Gene Delivery Efficiency and Toxicity.
Biomaterials. 2012, 33, 3594-3603. [0431] 28. Carothers, W. H.:
Polymers and Polyfunctionality. Transactions of the Faraday
Society, 1936, 32, 39-49. [0432] 29. Kaczmarek, J. C.; Patel, A.
K.; Kauffman, K. J.; Fenton, O. S.; Webber, M. J.; Heartlein, M.
W.; DeRosa, F.; Anderson, D. G.: Polymer-Lipid Nanoparticles for
Systemic Delivery of mRNA to the Lungs. Angewandte Chemie, 2016,
55, 13808-13812. [0433] 30. Kauffman, K. J.; Dorkin, J. R.; Yang,
J. H.; Heartlein, M. W.; DeRosa, F.; Mir, F. F.; Fenton, O. S.;
Anderson, D. G.: Optimization of Lipid Nanoparticle Formulations
for mRNA Delivery in Vivo with Fractional Factorial and Definitive
Screening Designs. Nano letters, 2015, 15, 7300-7306. [0434] 31.
Fenton, O. S.; Kauffman, K. J.; McClellan, R. L.; Appel, E. A.;
Dorkin, J. R.; Tibbitt, M. W.; Heartlein, M. W.; DeRosa, F.;
Langer, R.; Anderson, D. G.: Bioinspired Alkenyl Amino Alcohol
Ionizable Lipid Materials for Highly Potent in Vivo mRNA Delivery.
Advanced Materials, 2016, 28, 2939-2943. [0435] 32. Kranz, L. M.;
Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng,
M.; Fritz, D.; Vascotto, F.; Hefesha, H.: Systemic RNA Delivery to
Dendritic Cells Exploits Antiviral Defence for Cancer
Immunotherapy. Nature, 2016, 534, 396-401.
Sequence CWU 1
1
111653RNAArtificial SequenceSynthetic polynucleotide 1auggaagaug
ccaaaaacau uaagaagggc ccagcgccau ucuacccacu cgaagacggg 60accgccggcg
agcagcugca caaagccaug aagcgcuacg cccuggugcc cggcaccauc
120gccuuuaccg acgcacauau cgagguggac auuaccuacg ccgaguacuu
cgagaugagc 180guucggcugg cagaagcuau gaagcgcuau gggcugaaua
caaaccaucg gaucguggug 240ugcagcgaga auagcuugca guucuucaug
cccguguugg gugcccuguu caucggugug 300gcuguggccc cagcuaacga
caucuacaac gagcgcgagc ugcugaacag caugggcauc 360agccagccca
ccgucguauu cgugagcaag aaagggcugc aaaagauccu caacgugcaa
420aagaagcuac cgaucauaca aaagaucauc aucauggaua gcaagaccga
cuaccagggc 480uuccaaagca uguacaccuu cgugacuucc cauuugccac
ccggcuucaa cgaguacgac 540uucgugcccg agagcuucga ccgggacaaa
accaucgccc ugaucaugaa caguaguggc 600aguaccggau ugcccaaggg
cguagcccua ccgcaccgca ccgcuugugu ccgauucagu 660caugcccgcg
accccaucuu cggcaaccag aucauccccg acaccgcuau ccucagcgug
720gugccauuuc accacggcuu cggcauguuc accacgcugg gcuacuugau
cugcggcuuu 780cgggucgugc ucauguaccg cuucgaggag gagcuauucu
ugcgcagcuu gcaagacuau 840aagauucaau cugcccugcu ggugcccaca
cuauuuagcu ucuucgcuaa gagcacucuc 900aucgacaagu acgaccuaag
caacuugcac gagaucgcca gcggcggggc gccgcucagc 960aaggagguag
gugaggccgu ggccaaacgc uuccaccuac caggcauccg ccagggcuac
1020ggccugacag aaacaaccag cgccauucug aucacccccg aaggggacga
caagccuggc 1080gcaguaggca agguggugcc cuucuucgag gcuaaggugg
uggacuugga caccgguaag 1140acacugggug ugaaccagcg cggcgagcug
ugcguccgug gccccaugau caugagcggc 1200uacguuaaca accccgaggc
uacaaacgcu cucaucgaca aggacggcug gcugcacagc 1260ggcgacaucg
ccuacuggga cgaggacgag cacuucuuca ucguggaccg gcugaagagc
1320cugaucaaau acaagggcua ccagguagcc ccagccgaac uggagagcau
ccugcugcaa 1380caccccaaca ucuucgacgc cggggucgcc ggccugcccg
acgacgaugc cggcgagcug 1440cccgccgcag ucgucgugcu ggaacacggu
aaaaccauga ccgagaagga gaucguggac 1500uauguggcca gccagguuac
aaccgccaag aagcugcgcg gugguguugu guucguggac 1560gaggugccua
aaggacugac cggcaaguug gacgcccgca agauccgcga gauucucauu
1620aaggccaaga agggcggcaa gaucgccgug uaa 1653
* * * * *